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ABSTRACT OF DISSERTATION

ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN BIOSYNTHETIC
GENE CLUSTER AND ALTERING THE GLYCOSYLATION PATTERNS
OF TETRACENOMYCINS AND MITHRAMYCIN-PATHWAY MOLECULES

Natural products occupy a central role as the majority of currently used antibiotic
and anticancer agents. Among these are type-II polyketide synthase (PKS)-derived
molecules, or polyketides, which are produced by many representatives of the genus
Streptomyces. Some type-II polyketides, such as the tetracyclines and the anthracycline
doxorubicin, are currently employed as therapeutics. However, several polyketide
molecules exhibit promising biological activity, but due to toxic side effects or solubility
concerns, remain undeveloped as drugs.
Gilvocarcin V (GV) (topoisomerase II inhibitor) has a novel mechanism of
action: [2+2] cycloaddition to thymine residues by the 8-vinyl side chain and crosslinking of histone H. Mithramycin blocks transcription of proto-oncogenes c-myc and csrc by forming an Mg2+-coordinated homodimer in the GC-rich minor groove of DNA.
The purpose of this research was to investigate the biosynthesis of several type II
polyketide compounds (e.g. chrysomycin, elloramycin, and mithramycin) with the goal of
improving the bioactivities of these drugs through combinatorial biosynthesis. Alteration
of the glycosylation pattern of these molecules is one promising way to improve or alter
the bioactivities of these molecules. To this end, an understanding of the
glycosyltransferases and post-polyketide tailoring enzymatic steps involved in these
biosynthetic pathways must be established. Four specific aims were established to meet
these goals.
In specific aim 1, the biosynthetic locus of chrysomycin A was successfully
cloned and elucidated, which afforded novel biosynthetic tools. Chrysomycin
monooxygenases were found to catalyze identical roles to their gilvocarcin counterparts.
Cloning of deoxysugar constructs (plasmids) which could direct biosynthesis of
ketosugars, NDP-D-virenose, and NDP-D-fucofuranose in foreign pathways was
undertaken in specific aim 2. Finally, these “sugar” plasmids were introduced into
producer organisms of elloramycin and mithramycin pathways in specific aims 3 and 4 to
interrogate the endogenous glycosyltransferases in order to alter their glycosylation
patterns. These experiments resulted in the successful generation of a newly glycosylated
tetracenomycin, as well as premithramycin, and mithramycin analogues. In specific aim
4, a new mithramycin analogue with an altered sugar pattern rationally designed and
improved structural features was generated and structurally elucidated.

KEYWORDS: Polyketides, Combinatorial Biosynthesis, Gene Cluster,
Glycosyltransferases, Glycodiversification
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CHAPTER 1: BACKGROUND AND INTRODUCTION
INTRODUCTION
General Overview and Pharmaceutical Relevance of Polyketides
Since the earliest development of scientific thought, natural products have occupied
a central role as pharmaceutical agents in the treatment of human disease. The
etymology for pharmaceutic stems from the Greek word, pharmakon, meaning “a remedy
or poison.” This distinction keenly demonstrates that the earliest Hippocratic physicians
understood drugs to have beneficial or harmful effects on human physiology. With the
advent of modern pharmacognosy, natural products have served an integral role as firstresort therapeutic agents, models for elucidating biosynthetic pathways, and as targets for
chemical total synthesis (1).
Within the greater context of natural products, polyketides are a family of bacterialand fungi-derived natural products that serve in many pharmaceutically relevant
capacities (2). Polyketides are produced by polyketide synthases (PKS) through a series
of linear condensation steps between a starter unit (e.g. acetyl-CoA, propionyl-CoA) and
several extender units (e.g. malonyl-CoA) to yield in type II PKS systems an enzymetethered poly-β-ketoester. Many polyketides are biosynthesized by gram positive, soildwelling bacteria of the Actinomycetes family, with most of these compounds being
produced by the genus Streptomyces (3).
Polyketide-derived molecules are unmatched in structural diversity and many of
them possess anticancer and other biological activities (Figure 1) (4). These activities
include immunosuppressant, antimicrobial, antineoplastic, and cholesterol-reducing
drugs, to name a few; the sales of polyketide-derived pharmaceutics are in excess of
fifteen billion dollars per annum (2). So far, three types of polyketide synthases have
been described with respect to the nature of their biosynthesis: type I, type II, and type
III. As such, these families of polyketide synthases are capable of generating very
diverse chemical structures. Resveratrol (1) is a type III stilbene-type compound that has
received considerable interest for its anti-inflammatory and cancer-preventive activities,
while tetrangulol (2) is the first such characterized type II PKS-derived angucycline
antibiotic (5). Methymycin (3) and especially erythromycin A (7) are 12-membered and
1

14-membered macrolides, respectively, studied for their antimicrobial activities (6-7).
Amphotericin B (4) is a clinically important type I PKS-derived antifungal agent (8).
Lovastatin (6) is a highly reduced iterative type I PKS-derived product that possesses
nanomolar inhibition of HMG-CoA reductase, and as such, is representative of the
blockbuster statin drugs (9-10). Oxytetracycline (5) is a type II PKS-derived antibiotic,
whereas tetracenomycin C (8) was important in initial studies for aromatization and
cyclization of nascent polyketide intermediates in context with type-2 PKSs (11).
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Figure 1 Representative examples of clinically-relevant type I, type II, and type IIIderived polyketides.
The pharmaceutical importance of polyketide-derived molecules has generated
tremendous interest in elucidating the biosynthetic machinery responsible for generating
their chemical diversity (4). The advent of molecular biology has allowed for cloning of
2

entire biosynthetic loci of polyketide-type compounds. Ever since the cloning and
heterologous expression of the entire actinorhodin biosynthetic locus (12), recombinant
techniques have become indispensable for understanding the role of individual enzymes
(e.g. gene inactivation) or groups of enzymes (e.g. heterologous expression of minimal
polyketide synthase) in generation of polyketide scaffolds. As a result, these preliminary
studies can allow for manipulation of these pathways to generate novel derivatives with
more advantageous pharmaceutical properties.
Type I Polyketide Synthase-Derived (PKS) Molecules
The Type I polyketide synthases are “megasynthases” composed of many modules,
which are roughly analogous to the fatty acid synthase from primary metabolism (13).
As such, both the highly functionalized type I “megasynthase” domains and fatty acid
synthases share similar biosynthetic routes (Figure 2), with two major differences: 1)
type I polyketide synthases utilize more diverse extender units and starter units than
simply malonyl-CoA and acetyl-CoA, respectively (e.g. methylmalonyl-CoA for
extender units, propionyl-CoA starter unit, etc.), and 2) type I polyketide synthases often
have incomplete reduction cycles (13). Type I polyketide synthases are unlike their fatty
acid counterparts that produce exclusively a saturated chain, and type I PKSes require
subsequent desaturases to introduce double bonds. In fatty acid biosynthesis, priming of
acetyl-CoA onto the acyl carrier protein (ACP) by ACAT is followed by its binding to a
sulfhydryl group on a nearby enzymatic site. Malonyl-CoA is loaded onto the ACP via
MCAT, then malonyl -ACP undergoes decarboxylation, and then the resulting carbanion
condenses with acetyl-S-Enz. The β-ketone is then stepwise reduced to a fully saturated
sp3 bond. Subsequent elongations give a fully reduced fatty acid. In the type I PKS, the
reduction cycle is abrogated at one of several steps, often the result of missing or
inactivated modules along the megasynthase, which functionalizes the resulting C2
extender units with ketone, hydroxyl, olefinic, or fully saturated moieties (6-7, 14).
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Figure 2 Comparison of fatty acid biosynthesis with the incomplete reduction cycle of a
prototypical type I PKS.
The products of type I PKS megasynthases polyketides are 12-, 14-, and 16membered macrolides, polyenes, and polyethers (14). The loading domains may consist
of solely an ACP (e.g. in the case of avermectin and erythromycin type I PKS) or may
also contain a ketoacyl synthase domain with a glutamine substitution for cysteine (14).
These synthases are subdivided into modules consisting of acyltransferase (AT), acyl
carrier protein (ACP), ketoreductase (KR), dehydratase (DH), enoyl reductase (ER),
ketosynthase (KS). The last module possesses an additional thioesterase domain (TE) for
hydrolysis and lactonization of the linear polyketide chain (Figure 3). The type I PKS
has a co-linearity between its modules, and as such, a nascent polyketide chain is passed
along from the sulfhydryl group of the ACP of one domain to the next ACP until the TE
domain hydrolyzes it (14).
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In the early 1990’s, the sequence and linearity of erythromycin A biosynthesis was
firmly established as representative of type I PKS molecules with the cloning of the entire
6-deoxyerythronolide B (6-dEBS) PKS cluster (7). The PKS region (eryA) is coded on
three ORFs spanning ~35kb of chromosomal DNA, and its enzymatic domains are
encoded within 6 PKS modules (7) (Figure 3).
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Figure 3 Elucidation of the EryA polyketide megasynthase.
Domains are color-coded by function. AT=Green, ACP=Pink, KS=Blue, KR=Red,
DH=Yellow, ER=Orange, TE=Black.
The elucidation of the linear organization of EryA suggested possible domain functions
in which inactivation of specific domains could result in predictable structures. Indeed,
inactivation of the ketoreductase in module five resulted in a corresponding 5,6-deoxy-3α –L-mycarosyl-5-oxoerythronolide B compound (not shown), lacking the desosamine
residue due to the establishment of a 5-keto group instead of the alcohol, to which the
sugar could have been attached (14). The use of genetic data to predict domain function,
and consequently, to hypothesize about structures resulting from inactivation of specific
domains was somewhat successfully employed also for other type I PKS systems (14).
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Type II Polyketide Synthase (PKS) Molecules
Type II polyketides consist primarily of the polyaromatic/cyclized classes of
polyketide-derived molecules (13, 15). The poly-β-ketothioester is installed iteratively
by a type-II PKS, also called the “minimal PKS” (16), consisting of β-ketoacyl synthase
(KSα), chain length determinant enzyme (CLF/KSβ) (KSα and KSβ form a close
heterodimer), and an acyl carrier protein (ACP) for successive transfer of malonate to the
growing polyketide chain, in addition to the necessary enzymes for chain initiation (4).
This “minimal” polyketide synthase has the minimal number of enzymes necessary to
produce the first visualized intermediates in type II pathways. MCAT transfers malonylCoA to the ACP as in other PKS pathways for use as the extender units; however,
different starting units can also be utilized in type II PKS pathways (e.g. malonamylCoA, propionyl-CoA, crotonyl-CoA, butyryl-CoA). Specialized enzymes have been
evolved to biosynthesize and load these starter units (17-19). Chain initiation begins
when the starter unit is loaded onto the KSα-KSβ. Malonyl-ACP is decarboxylated in βketoacyl synthase and is condensed with the starter unit, and the extended polyketide
chain is transferred to the β-KS to release the ACP, which is now free to accept another
malonyl-CoA (4, 20). X-ray crystallography studies on the actinorhodin KSα-KSβ
complex revealed its heterodimeric nature; as a rule, these two enzymes are almost
always translationally coupled (16). A tunnel in the heterodimer allows for expansion of
the growing nascent (and highly reactive) poly-β-ketothioester, thereby shielding it from
nucleophilic water molecules (16). In the actinorhodin KSα- KSβ heterodimer, cysteine
169 is the catalytic amino acid residue required for formation of the thioester, and
phenylalanine 116 a gating residue, which prevents further condensations of acetate units
beyond a heptaketide (16).
The cyclization strategies employed in type II polyketide pathways give rise to the
structural diversity observed among the anthracycline, angucycline, tetracycline, and
tetracenomycin-type molecules (Figure 4a) (4). The poly-β-ketothioester is highly
reactive, and therefore every type II PKS cluster has a functional set of closely-associated
cyclases/aromatases/oxoacyl-ketoreductases necessary to steer the cyclization(s) of the
polyketide core towards a certain skeletal framework (4).
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Figure 4 Spontaneous cyclization of polyketides.
a) Cyclization events yielding skeletal frameworks for families of type II polyketides. b)
Example of spontaneous cyclization event in the absence of cyclase enzyme and
examples of spontaneously cyclized shunt products.
The minimal PKS directs the folding pattern to the nascent polyketide chain, and the
cyclases and aromatase enzymes are responsible for “locking-in” the skeleton, or in the
case of angucycline polyketides, installing the angular shape by initiating C4-C17
cyclization (4, 14). In the case of tetracycline and aureolic acid polyketide cyclization,
C7-C12 are linked in the first ring cyclization, followed by C5-C14 linking in the second
ring cyclization, C3-C16 linking in the third ring cyclization, and finally C1-C19 linking
in the fourth ring cyclization in the case of the tetracyclines (16) (21-22) (Figure 4a). In
the case of premithramycin type molecules (e.g. 17), it is possible that tandem
oxygenations by MtmOI (?)/MtmOII act on a tricyclic intermediate, which establishes an
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epoxide. The epoxide is reductively opened, thereby allowing fourth ring cyclization
(23-24). These four ring cyclizations yield a linear molecule. In the case of the
angucyclines, the first two ring cyclizations are similar to the tetracycline/aureolic acid
cyclizations, C7-C12 and C5-C14, but a specialized C4-C17 third ring cyclase is
responsible for creating the angular appearance of these molecules, followed by C2-C19
fourth ring cyclization, resulting in intermediate UWM6 (18) (Figure 4a).
In the absence of the polyketide-associated ketoreductase or cyclase/aromatase
enzymes, spontaneous cyclization processes occur involving the highly reactive poly-βketothioester. These aberrant cyclizations result in “shunt products,” which are
polyketide metabolites that accumulate in the pathway that are not intermediates for
downstream pathway enzymes. In general, shunt products are biosynthetically
unproductive but they reveal some information about the preceding biosynthesis (Figure
4b).
Type III PKS Molecules
Type III PKS molecules are produced predominantly in plants, but some are also
biosynthesized in bacteria. Type III polyketides are biosynthesized by a single βketoacyl synthase enzyme without the assistance of an ACP (25), and the enzyme makes
use of a variety of starter units (e.g. coumaroyl-CoA, etc.). Resveratrol, 1, is an example
of a stilbene-type polyketide from this pathway.

Post-PKS Tailoring steps
After the core skeleton has been assembled, the post-PKS tailoring steps
functionalize the molecule, thereby supplying it with the chemical moieties that
contribute to its biological activity (26). The oxygenations, methylation, glycosylations,
aminotransfer reactions, halogenations, reductions that tailor these polyketide skeletons
are catalyzed by highly specialized sets of enzymes (26). Post-PKS tailoring enzymes
have evolved to bind restrictively to a particular substrate and many have stringent
cofactor requirements for catalysis. The genetic and biochemical characterization of
specific tailoring enzymes and their substrates is often the first objective for
combinatorial biosynthesis (27). Combinatorial biosynthesis, the modification and
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recombining of heterologous genes in a biosynthetic pathway to achieve novel natural
products, is practically often concerned with the characterization and interchange of these
post-PKS tailoring enzymes (27). As such, an introduction to some of these post-PKS
enzymes is merited.
Oxygenases
Oxygenases are some of the most common and diverse enzymes employed in
secondary metabolic pathways (27). In general, oxygenases install oxygen moieties as
aldehydes, ketones, or hydroxyl groups. These oxygen moieties are handles for
important chemical transformations and can serve as mediators of biological activity. For
example, the installation of a hydroxyl or a ketone moiety creates an additional hydrogen
bond donor or acceptor. Ketones reduce the pKa of α-hydrogens, which allows for more
facile abstraction by a base. In addition, oxygenases mediate carbon-carbon bond
cleavage, and some oxygenases may install highly reactive epoxides, for example (27).
Oxidoreductases also add or remove hydrogens (dehydrogenases, ketoreductases) and
oxidize C-O bonds (e.g. oxidases, secondary alcohol to ketone), and dehydratases
catalyze the elimination of water to install double bonds.
Oxygenases are easily characterized by their cofactor requirements, conserved
amino acid moieties, and the number of oxygens that are installed on a substrate.
Cofactor free monooxygenases have no cofactor involved in their mechanism; rather, the
substrate assists in the installation of molecular diatomic oxygen. These oxygenases are
also referred to as anthrone oxygenases or also “internal monooxygenases” (27). The
HypC anthrone oxygenase from Aspergillus parasiticus was overexpressed in E. coli and
purified for in vitro conversion of norsolorinic acid anthrone to norsolorinic acid (Figure
5). HypC possesses two catalytic domains that are conserved across emodinanthrone
oxygenases- QLXXQWSRIFY and RXLXXPL (the active site residues are underlined)
(28). Tryptophan 43, tyrosine 48, and arginine 140 are involved in coordinating an
enzyme-stabilized zwitterion of norsolorinic acid anthrone (19) that allows for molecular
oxygen to attack para to the anthrone oxygen (Figure 5). Glutamine 38 stabilizes the
reaction product by hydrogen bonding with the newly-formed quinone oxygen in
norsolorinic acid (20) (28).
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Flavin-dependent monooxygenases possess an N-terminal domain (GXGXXG)
which is involved in binding of FAD (27). These oxygenases also bind NAD(P)H for
reduction of FAD to FADH2, which then binds diatomic oxygen to form the key
peroxyflavin intermediate (27). A nucleophile present on the substrate then attacks the
peroxide, thereby forming a new bond with oxygen and forming water (27). Cytochrome
P-450 oxygenases possess a prosthetic heme group, which coordinates a Fe3+ cation.
These CYP-450 oxygenases often require an accessory ferredoxin protein to regenerate
NADPH (27). One FAD- and NADPH-dependent oxygenase (DnrF) and a P450
monooxygenase from the doxorubicin biosynthetic pathway (DoxA) are depicted with
cofactor requirements in Figure 5.
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Figure 5 Mechanisms of cofactorless and FAD-dependent monooxygenases.
a) Mechanism of cofactor-free oxygenase HypC. b) FAD- and NADPH- dependent
monooxygenase DnrF and P450 oxygenase DoxA from doxorubicin pathway.
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DnrF is involved in 11-hydroxylation of aklavinone to afford ε-rhodomycinone in an
FAD and NADPH-dependent manner, whereas DoxA is a CYP-450 that catalyzes both
13-hydroxylation and hydroxymethyl formation at C-14 (27, 29).

Methyltransferases, Aminotransferases, and glycosyltransferases
Methyltransferases and aminotransferases are important enzyme classes for postPKS decoration. These enzymes modify the reactivity and lipophilicity/ hydrophilicity of
natural products through the addition of methyl groups and amino functionalities,
respectively. Methyltransferases add an additional C1 unit by means of a nucleophilic
attack by an electron-rich donor moiety on S-adenosyl methionine to afford S-adenosyl
homocysteine and a methylated compound. One pertinent example of O-methylation is
catalyzed by MtmMI from the mithramycin biosynthetic pathway of Streptomyces
argillaceus (23). MtmMI catalyzes the removal of a proton from the 4-OH group, and
the resulting oxygen nucleophile attacks the methyl group of S-adenosyl methionine that
is positioned in the methyltransferase active site to give premithramycinone (27) (Figure
6) (30). N-methylation or O-methylation increases the hydrophobicity of a compound by
removing a hydrogen bond donor (27). N-methylations can form tertiary amines, which
give very important pharmaceutical properties to a drug (27). C-methylations are
employed biosynthetically to introduce a “branch” into a deoxysugar or onto a polyketide
skeleton.
Aminotransferases catalyze the transfer of an amine group to a corresponding
carbonyl. The amino group donor is usually pyridoxamine phosphate (PMP), which
forms an imine with the carbonyl carbon, which is then hydrolyzed to yield the newly
transaminated substrate and pyridoxal phosphate (PLP) (31). Aminotransfer reactions
require a carbonyl handle. The transformation of a carbonyl into an amine converts a
hydrogen bond acceptor into a hydrogen bond donor, which is often important for
biological activity. As such, this greatly enhances the hydrophilicity of a compound. In
the oxytetracycline pathway, the PMP-dependent aminotransferase OxyQ is used to
transaminate the 4-keto position of 4-ketoanhydrotetracycline (28), a very unstable
pathway intermediate, to afford 4-aminoanhydrotetracycline (29) (Figure 6). OxyQ
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tailors one of the canonical tetracycline reactions (amine group at 4 position), and
effectively “captures” the labile 28 (21, 31).
Glycosyltransferases (GTs) are among the most numerous and utilitarian enzymes
in all of nature. As such, glycosylations are invaluable to the biological activity of
polyketides. Indeed, many polyketides are inactive without their appended sugars (32).
Glycosylation increases biological activity and hydrophilicity of a compound by virtue of
installing several –OH hydrogen bond donors present on a sugar. Glycosyltransferases
require a pool of “donor substrates,” nucleotide diphosphate-bound (NDP) sugars that
often are deoxygenated at one or more positions, and an “acceptor substrate,” which in
most cases is an aglycone or suitable polyketide core that will receive the sugar donor
(33). Glycosyltransferases have evolved into two predominant families characterized by
the nature of their Rossman folds, GT-A and GT-B superfamilies (34). Most polyketide
glycosyltransferases are members of the GT-B superfamily of glycosyltransferases, and
they possess two domains with an α/β Rossman fold involved in the binding of the sugar
donor substrate in the C-terminus and the acceptor substrate in the N-terminus (34-35).
Glycosyltransferases can either catalyze glycosylation with inversion or retention of
configuration; in most cases with the GT-B superfamily of glycosyltransferases,
glycosylation involves inversion of configuration, which is the underlying reason for the
earliest discovery of Klyne’s Rule (36) (Figure 6).
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Figure 6 Depictions of methyltransfer, aminotransfer, and glycosyltransfer reactions.
a) 17 is methylated at 4-OH by MtmMI to give 27. b) aminotransfer reaction catalyzed
by OxyQ. c) Depictions of both retaining and inverting glycosyltransfer reactions.
In addition to glycosyltransferases, nature has evolved many different deoxysugar
tailoring enzymes involved in the modificiation of sugar donors (37). These deoxysugar
pathways begin with D-glucose-6-phosphate, which is interconverted to D-glucose-1phosphate (30) by phosphoglucomutase (Figure 7). D-glucose-1-phosphate (30) is
captured by NDP-glucose synthase, a specialized enzyme that catalyzes the coupling of
NMP from a corresponding NTP with the phosphate group of 30. A second enzyme that
is usually clustered near NDP-glucose synthase is NDP-D-glucose-4,6-oxidoreductase
(38) (or simply NDP-4,6-dehydratase). This enzyme catalyzes the NAD-dependent
removal of two electrons and two protons from C-4 and 4-OH, and dehydrates across the
5,6 bond of 31 to afford a double bond, which is then reduced by 4,6 dehydratase to
generate NDP-4-keto-6-deoxy-D-glucose (32) (Figure 7) (32).
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Figure 7 Deoxysugar biosynthesis from D-glucose-1-phosphate (30).
D-glucose-1-phosphate (30) coupled with NMP via NDP-glucose synthase to give NDPD-glucose (31) in an NTP-dependent manner. 31 is dehydrated and reduced across the 5,
6 bond and oxidized at C-4 to afford NDP-4-keto-6-deoxy-D-glucose (32), which is a
universal intermediate for downstream deoxysugar tailoring enzymes, which can generate
tremendous chemical diversity as witnessed in sugars 33-38.
A series of downstream tailoring enzymes can catalyze further deoxygenations,
epimerizations, and other reactions to generate chemical diversity in sugar donors. The
cloning of these deoxysugar pathways and their subsequent heterologous introduction
into foreign hosts has become a very important strategy for altering the glycosylation
pattern of polyketides (39).

Introduction to Gilvocarcin (GV) Biosynthesis
Gilvocarcin V (GV) (39) (toromycin A, anandimycin A) is the most important
representative compound of the benzo[d]naphtho[1,2-b]pyran-6-one C-glycoside
antibiotics (40). It was first isolated in 1981 in Japan from a fermentation of
Streptomyces gilvotanereus (NRRL 11382) along with its congeners gilvocarcin M (40)
and gilvocarcin E (41) (from S. anandii), and the antibiotic gets its name from the grayish
yellow color of this strain after it has aged (40) (Figure 8). It was also isolated from
fermentations of Streptomyces arenae, Streptomyces anandii, and Streptomyces
griseoflavus Gö 3592 (41-42). Gilvocarcin V was determined to have excellent
biological activity against Staphylococcus aureus and Bacillus subtilis, and weak activity
against gram negative bacteria. However, it demonstrated remarkable antitumor activity
against sarcoma 180 solid tumors and Ehrlich ascites carcinoma in murine cell lines
(Increased Life Span of 126%) (40, 43). Interestingly, 39 maintained a very low in vivo
cytotoxicity profile despite its considerable antitumoral effects (43). Experiments by
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Elespuru et al. confirmed that treatment of 39 with visible light photoactivated a [2+2]
cycloaddition of 39 with thymine residues of DNA. This contrasts with the mostly
inactive gilvocarcin M (40), which possesses an 8-methyl side chain. Gilvocarcin M
lacks the photosensitizing effect exhibited by gilvocarcin V, most likely because it lacks
the 8-vinyl sidechain (44). Further studies confirmed that 39 binds to histone H3 and
cross-links DNA, which the C-glycosidically-linked D-fucofuranose may play an
essential role in its binding to the histone H3 protein (45-47).
Additional C-glycosidically linked gilvocarcin-type analogues, the chrysomycins
(42-44) and the ravidomycins (45-48) were soon isolated from fermentations of S.
albaduncus AD0819 and S. ravidus (48-50) (Figure 8). Chrysomycin was originally
isolated in 1955 by Strelitz et al., however, the structure elucidation of these compounds
was not conducted until the 1980s (51). Structure elucidation using 1H-NMR and 13CNMR experiments revealed that 42 and 43 shared the same benzo[d]naphtho[1,2b]pyran-6-one chromophore as 39, yet differed with respect to the 8-side chain (vinyl in
the case of chrysomycin A and methyl in the case of chrysomycin B) (50). Furthermore,
the chrysomycins possess a C-glycosidically-linked branched sugar called D-virenose
(named for virenomycin, which was the name given to these compounds by the Russian
group who elucidated the structure of the sugar moiety of 42-44) (52). The ravidomycins
were elucidated to possess the same chromophore. However, they possessed an
aminosugar, D-ravidosamine, C-glycosidically linked at 4-position, with 4’-O-acetyl
groups present in some of the isolated compounds (48, 53). Ravidomycin V (RV, 45)
and chrysomycin A (CV, 42) demonstrated promising antitumor activities, with RV (45)
and 4’-O-desacetyl RV demonstrating the most potent biological activities against cancer
cell lines (48) (47).
The isolation of other related natural products: L-rhamnosylated O-glycosides BE12406A and B (not shown), polycarcin V (53), and C-glycosidically-linked ketopyranose
and ketofuranose compounds (Mer- 1020 dA-dD, 49-52, respectively) greatly expanded
the library of known gilvocarcin-type compounds (54-57) (Figure 8).
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Figure 8 Structures of gilvocarcin-class antitumor antibiotics.
Structures of the gilvocarcins (39-41), the chrysomycins (42-44), the ravidomycins (4548), and other gilvocarcin-type C-glycosides (49-53).
Feeding experiments of gilvocarcin V and chrysomycin A with [1-13C] and [213

C]acetate by Takahashi et al.(58) and Carter et al.(59) revealed that 9 aromatic carbons

were enriched, and feeding with [3-13C] and [2-13C]-labeled propionate revealed that the
vinyl side chain of gilvocarcin V was the result of incorporation of a propionate starter
unit. Labeling with [1,2-13C2]acetate produced the labeling pattern seen in (Figure 9).
Feeding with [1-13C, 18O2]-labeled acetate by Liu et al. demonstrated that the oxygens at
C-1, C-10, and C-12 derived from acetate units (Figure 9) (60). The labeling of C-6 with
one carbon from labeled acetate presupposes a C-C bond cleavage at carbons C-5 and C6 of an angucycline intermediate, in addition to the oxygens at 5 and 6 positions that must
derive from atmospheric oxygen (60).
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Figure 9 Gilvocarcin labeling pattern, after incorporation experiments using [1,2-13C2]
acetate and [1-13C, 18O2]-acetate of gilvocarcin, respectively.
Subsequently, the entire gilvocarcin biosynthetic gene cluster was cloned from
genomic DNA of gilvocarcin-producing Streptomyces griseoflavus Gö 3592 onto a
single pOJ446-derived E. coli-Streptomyces shuttle cosmid, named cosG9B3 (61). When
cosG9B3 was heterologously expressed in host Streptomyces lividans TK 24, 39 and 40
were produced with yields comparable to wildtype S. griseoflavus Gö 3592 (61). With
the entire gilvocarcin gene cluster in hand, gene inactivation experiments of the
gilvocarcin oxygenases, glycosyltransferase, oxidoreductases, and methyltransferases
shed considerable light on the order of biosynthetic events for 39 (60, 62-64). Of
considerable interest in this biosynthetic pathway are the enzymatic steps necessary to
generate the oxidative cleavage of the 5,6 bond, the genes encoding NDP-D-fucofuranose
biosynthesis and attachment, and the enzymes responsible for the installation of the 8vinyl side chain (60, 62-64).
The biosynthetic pathway of 39 was laid out through bioinformatic analysis of the
gil gene cluster and inactivation experiments. GilP and GilQ were identified as
functional malonyl-CoA and propionyl-CoA acyltransferases for the transfer of starter
units to the minimal PKS, which consists of GilABC (Figure 10) (65). Oxoacyl
ketoreductase GilF presumably reduces the resulting C-9 carbonyl, which is then
dehydrated to aromatize ring D, then cyclases GilG and GilK aromatize ring C and
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cyclize rings A and B to afford the first postulated angucycline intermediate of this
pathway, homo-UWM6 (18) (66). GilOIV and GilOI were found to encode dual-function
FAD-dependent monooxygenases/dehydratases, presumably involved in the oxygenation
cascade (60, 63).
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Figure 10 Hypothesis for GV (39) biosynthetic pathway.
Enzymatic transformations are indicated in blue. Shunt products accumulated in
indicated G9B3 gene-deletion mutants are depicted in red.
Inactivation of gilOIV in G9B3 resulted in accumulation of rabelomycin (54) and
homorabelomycin (55) as shunt products, which are not capable of being processed by
downstream oxygenases (Figure 10). Rabelomycin (54) and homorabelomycin (55) are
likely spontaneously oxidized at C-12 to afford the quinone (66). Inactivation of gilOI
yielded intermediates 58 and 59, prejadomycins, which are dehydrated across C-2 and C3. This demonstrated that GilOIV likely acts first, dehydrating across the 2-3 bond,
followed by dehydration by GilOI across the 4a-12b bond to aromatize ring A.
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CH3

Shunt products 56 and 57 suggest a C-5 oxygenation by GilOIV or GilOII, but the
exact order of oxygenation events is not well understood. Inactivation of the jadomycin
A FAD-monooxygenase/dehydratases JadF (GilOIV homologue) and JadH (GilOI
homologue) gave similar results as the respective GV oxygenase inactivations (63, 67)
(Figure 10). JadH was found to complement the cosG9B3-gilOI- strain, and JadF was
found to complement the cosG9B3-gilOIV- strain to reconstitute 39 production (68).
These experiments demonstrated that GilOI/GilOIV/GilOII act in a co-dependent, multioxygenase complex as do the jadomycin counterparts JadF/JadH/JadG. Further evidence
of JadH/GilOI function was recently provided by Yang et al. to demonstrate that JadH is
an FAD, NADPH-dependent dehydratase/ oxygenase that dehydrates C-4a, C-12b of 58,
then acts as a C-12 oxygenase to afford the C-3 methyl homologue of 60 as a shunt
product (69). Therefore, it is proposed that GilOI dehydrates C-4a, C-12b 59, then
oxygenates C-12 to yield the hydroquinone. Shortly after the first ring is aromatized, it is
likely that GilOIII hydroxylates at the benzylic position of the 3-propionyl side chain,
which resultantly undergoes dehydration to afford the vinyl moiety (this is evinced in the
shunt product vinyl-dehydrorabelomycin, 61) (70). Subsequent oxygenations by GilOIV
and/or GilOII result in a Baeyer-Villiger intermediate, which subsequently cleaves the
5,6 C-C bond, affording an acid and an aldehyde intermediate (as determined by
pregilvocarcin V, a hemiacetal isolated from the GilR-deleted cosG9B3 strain) (71). It
should be noted that an analogous ring-cleaved intermediate is also hypothesized to be an
intermediate of the jadomycin pathway just before L-isoleucine incorporation (Figure
11). In the gilvocarcin pathway, GilM theoretically captures this intermediate and
methylates at the 7-hydroxyl, effectively steering this pathway away from an
angucycline-framework towards the gilvocarcin chromophore (Unpublished Results,
Madan Kharel, Tao Liu). Further 10-O-methylation by GilMT, C-glycosylation using
NDP-D-fucofuranose at C-4 by GilGT, and dehydrogenation of the 6-OH by GilR to
afford the lactone completes biosynthesis of 39 (70-71).
Gene disruption experiments of the gilvocarcin biosynthetic pathway have been
important not only for shedding some light into the sequence of enzymatic steps, but they
have also resulted in generation of novel gilvocarcin analogues (70-72). Disruption of
gilGT led
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Figure 11 Depiction of oxygenase cascade between UWM6 (18) and Jadomycin A (69).
to the accumulation of defucogilvocarcins E and M (62 and 63), which clearly revealed
GilGT’s role in C-4 glycosylation with the structurally distinct D-fucofuranose (70).
Furthermore, the S. lividans (cosG9B3-GilGT-) is an important strain for combinatorial
biosynthesis involving heterologously expressed C-glycosyltransferases from related
pathways, such as the chrysomycin pathway. Also, disruption of 4-ketoreductase GilU
from NDP-D-fucofuranose biosynthesis resulted in 4’-hydroxy-gilvocarcins, with
improved bioactivity against cancer cell lines as compared to 39, as well as improved
solubility due to the additional 4’-OH group (72). Such a finding reveals unexpected
substrate flexibility by the sugar ring contraction enzyme and by GilGT towards an
unnatural NDP-furanose donor substrate. As a result, the elucidation of biosynthetic gene
clusters of related gilvocarcin-type antibiotics, e.g. chrysomycin and ravidomycin, is not
only an important exercise for understanding the role of uncharacterized gil genes
(gilLMN), but it can yield valuable tools for recombining genes to generate novel
gilvocarcins.

Introduction to Mithramycin (MTM) Biosynthesis
Mithramycin (MTM) (70) is a representative member of the aureolic acid family
of antineoplastic antibiotics (Figure 12). It is accumulated in strains of Streptomyces
plicatus and Streptomyces argillaceus. Aureolic acid antibiotics are named after their
yellow color (Latin, aurum= gold), and they are distinguished by their many saccharidal
chains O-glycosidically linked at 2-position and 6-position, as well as the highly oxidized
pentyl side chain at 3-position (Figure 12) (73-74). The other representative members,
chromomycin A3, UCH9, durhamycin A, olivomycin A all possess the highly oxidized 3aliphatic side chain, but differ with respect to the nature of the sugars, the nature of their
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linkage, and the degree of O-methylation or O-acetylation of the various sugar residues,
or in the case of durhamycin A, C-acylation at C-7 position (75-77).
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Figure 12 Mithramycin A (70) and structures of related aureolic acid antibiotics (71-75).
Mithramycin was discovered by Grundy et al. in 1953, and its structure was subsequently
revised several times with regard to the linkage of the trisaccharide chain and the
stereochemistry of the sugars; ultimately, Rohr et al. confirmed the structure as being 70
using 2D NMR spectroscopic methods (78). Mithramycin has been employed in the
treatment of Paget’s bone disease, testicular carcinomas, and hypercalcemia (79-85).
Mithramycin’s mode of action is that it binds to the GC-rich minor groove of
protooncogenic regions, such as c-myc, c-src, and other Sp1-dependent pathways in a
homodimer, coordinated head to tail with another molecule of 70 by an Mg2+ cation (8688). However, despite its promising activity, prolonged mithramycin treatment is not

21

well-tolerated. It has major cytotoxic side effects, including bone marrow, hepatic, and
kidney cytotoxicities (89). Additional biological activities for the aureolic acid family
include nanomolar HIV Tat protein inhibition by durhamycin A, and mithramycin has
potential Sp1-dependent therapeutic value in treating Alzheimer’s disease and
Huntington’s disease (90-94).
The biosynthesis of mithramycin (70) has been studied extensively by the Salas
and Rohr groups during the 2000s, and the functions of most of the candidate enzymes
were identified through gene disruption experiments (23-24, 89, 95-108) (Figure 13).
Inactivation of the mtmPKS genes led to a nonproducing mithramycin mutant, and
inactivation of monooxygenase MtmOII lead to an improperly cyclized shunt product,
premithramycinone G (87, Figure 14) (24, 106, 108). This latter observation caused reenvisioning of the early mithramycin cyclization steps as going through a putative
tricyclic intermediate, which would be oxygenated by MtmOI and/or MtmOII, then
cyclized to yield the first tetracyclic premithramycin compound in the pathway, 4demethylpremithramycinone (17) (23-24, 101). Subsequent 4-O-methylation by MtmMI
leads to premithramycinone (27), which was accumulated by the S. argillaceus
(MtmGIV-) (100). Subsequent glycosylation of the first D-olivose by MtmGIV
(premithramycin A1, 76), and the second sugar of the trisaccharide D-oliose by MtmGIII
(premithramycin A2, 77) were revealed through inactivation of both mtmGIV and
mtmGIII in S. argillaceus, respectively (100). However, as there are five deoxysugars in
biosynthesis of 70, and only four glycosyltransferases, either MtmGIV or MtmGIII were
anticipated to be responsible for transfer of the third sugar of the trisaccharide chain, Dmycarose, with MtmGIV being the preferred candidate for this dual action (100).
Individual inactivation experiments of mtmGI and mtmGII , and cross-feeding of 79 into
both the S. argillaceus (MtmGI-) and S. argillaceus (MtmGII-) revealed that MtmGI is
responsible for attaching the first D-olivose to the 6-O position and then MtmGII Oglycosidically links the last D-olivose to the 3A-O position of 79 to yield the fullyglycosylated premithramycin B 80 (96, 105). Premithramycin B was determined to be
the substrate for a novel Baeyer-Villiger monooxygenase, MtmOIV, and this enzyme has
been crystallized and modeled to identify the active site residues necessary for catalyzing
ring cleavage of 80 to 81 (95, 103, 109-110) . This is perhaps the single most important
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unifying step for this biosynthesis, because MtmOIV acts as a “gatekeeper” that
necessarily allows for generation of active mithramycin molecules (tricyclic with highly
functionalized aliphatic side chain branching from C-3) from inactive premithramycin
molecules (tetracyclic) (95). Finally, MtmW captures the labile mithramycin β-diketone
intermediate, and reduces the 4’-ketone to afford 70.
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Figure 13 Biosynthetic pathway of Mithramycin (70).
Highlights include individual glycosylation steps catalyzed by MtmGI, MtmGII,
MtmGIII, and MtmGIV, and Baeyer-Villiger-oxidative cleavage by MtmOIV, and final
reduction by associated ketoreductase MtmW.
Combinatorial biosynthesis of the mithramycin pathway has been an invaluable
tool for generating novel premithramycin and mithramycin analogues shown in Figure
14 (23, 89, 96-98, 100, 103, 105, 109, 111-113). Inactivation experiments of the various
glycosyltransferases have generated premithramycins with different lengths of
saccharidal chains (76-80). Inactivation experiments of the various methyltransferase
genes (mtmMII, mtmMI, mtmC) have resulted in a 7-demethylmithramycin analogue (82),
4-demethylpremithramycinone (17), and inactivation of the mtmC and mtmTIII genes has
resulted in isolation and characterization of novel ketopremithramycins and
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ketomithramycins (83-86), respectively. Recombination with glycosyltransferase
urdGT2 and lanGT4 from the urdamycin and landomycin pathways, respectively,
resulted in novel premithramycin 7-C-glycosides (88-92) (113). Furthermore,
recombination with deoxysugar biosynthetic genes from heterologous hosts has resulted
in many novel mithramycin-type molecules with altered saccharidal moieties (e.g. 93)
(111-112) (Figure 14). Therefore, combinatorial biosynthesis remains the best
methodology for generating novel mithramycins. Synthetic approaches towards total
synthesis of aureolic acids have proven to be step-intensive and difficult with respect to
maintaining stereochemical control. For example, Roush et al. have synthesized the
tetrasaccharide and the chromophore of durhamycin A, the latter being composed of >13
synthetic steps (77, 114). In contrast, the problems of stereochemical control and poor
step economy are more readily overcome with combinatorial biosynthesis.
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Figure 14 Premithramycins and mithramycins previously generated by combinatorial
biosynthesis.

SPECIFIC AIMS
Combinatorial biosynthesis has emerged as a key strategy for generating novel
derivatives of complex natural products, particularly with regards to modification of postpolyketide tailoring steps. Over the last few years, significant illumination into the
biosynthesis of the gilvocarcins and jadomycins has been accomplished through the
cloning and genetic investigation of these pathways, yet some enzymes of these pathways
remain enigmatic. In the spirit of furthering knowledge about the biosynthesis of these
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clinically promising molecules, this present research is conducted to clone the gene
cluster for the related benzo[d]naphtho[1,2-b]pyran-6-one C-glycoside antibiotic
chrysomycin A. Furthermore, characterization of this gene cluster is conducted with an
emphasis on the monooxygenase enzymes and the deoxysugar tailoring enzymes for
generation of NDP-D-virenose. Another purpose of this work is to generate novel
tetracenomycin and aureolic acid derivatives with altered glycosylation patterns using
combinatorial biosynthesis. For this, cloning of novel deoxysugar-biosynthesizing
cassettes and introduction of these plasmids into producing strains was conducted.
Resulting metabolites were isolated, and their structures were determined in order to
draw conclusions about the substrate flexibility of the endogenous glycosyltransferases.

Specific Aim 1: To clone and analyze the entire chrysomycin A biosynthetic gene
cluster. To prove its functional role in chrysomycin biosynthesis experiments by crosscomplementing chrysomycin monooxygenases in gilvocarcin-oxygenase deficient
mutants.

The cloning of entire Streptomyces sp. biosynthetic gene clusters was possible using
cosmid vectors, which can often contain 30-40kb of genomic DNA. Using the cloning of
the gilvocarcin biosynthetic gene cluster as a template for this study, the complete
chrysomycin gene cluster was cloned on one or more cosmids, probed, and sequenced.
The sequencing of this cluster gave valuable information about the shared enzymes
between these pathways and their shared roles in 39 and 42-43 biosynthesis.
Furthermore, the identification of novel enzymes responsible for biosynthesis and
attachment of NDP-D-virenose will be useful for heterologous expression of these
enzymatic components in other producing organisms. Cross-complementation of the
oxygenases from this cluster into the respective blocked mutants of the gilvocarcin
pathway can prove the role of this biosynthetic locus in production of chrysomycin. This
aim will be discussed in chapter 2.

Specific Aim 2: To investigate the potential role of enzymes in D-fucofuranose ring
contraction in biosynthesis of gilvocarcin V. Structure elucidation of the metabolites
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accumulated in this strain will give valuable analysis about its role. Furthermore, this
information will be used to clone constructs for the biosynthesis of NDP-D-virenose and
NDP-D-fucofuranose in vivo.

Recombination of deoxysugar biosynthetic genes is one effective means of exploiting
endogenous glycosyltransferase donor substrate flexibility. Inactivation of the putative
glycosyltransferase GilN proved that it plays no role in NDP-D-fucofuranose
biosynthesis. This finding was an important step towards identifying the enzyme
responsible for furanose ring contraction. Furthermore, plasmids directing the
biosynthesis of NDP-D-virenose and NDP-D-fucofuranose and their biosynthetic
intermediates were cloned for heterologous expression and interrogation of endogenous
glycosyltransferases from other pathways. These aims will be discussed in chapter 3.

Specific Aim 3: To interrogate the substrate flexibility of the glycosyltransferase,
ElmGT, towards a variety of deoxysugar donor substrates. Various constructs directing
the biosynthesis of novel deoxysugars will be transformed into a recombinant strain
harboring the genes for 8-demethyl-tetracenomycin C biosynthesis and the sugar donor
flexible glycosyltransferase, ElmGT.

The substrate flexibility of glycosyltransferases is one important factor in generating
novel derivatives with altered glycosylation patterns. Another factor is the introduction
of recombinant plasmids that direct biosynthesis of novel deoxysugars, which are not
present in a producing organism. For this, a recombinant strain, namely S. lividans
(cos16F4), which harbors the biosynthetic genes for the production of 8-demethyltetracenomycin C and the sugar flexible glycosyltransferase, ElmGT, will be used as an
expression host. Glycodiversification studies will further clarify the substrate flexibility
of ElmGT and the role of these cassettes in biosynthesizing various NDP-deoxysugars.
These aims will be discussed in Chapter 4.

Specific Aim 4: To generate novel mithramycin derivatives with altered glyosylation
patterns.
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The mithramycin biosynthetic pathway of Streptomyces argillaceus has five
glycosyltransfer steps and four glycosyltransferases, which presents an excellent system
for glycodiversification experiments involving novel deoxysugar plasmids. For this,
plasmids directing the biosynthesis of various deoxysugar cassettes will be
heterologously introduced into Streptomyces argillaceus and several blocked mutants
using protoplast transformation. Any accumulated novel mithramycin derivatives were
structurally elucidated to yield important compounds for biological testing. These
objectives will be discussed in Chapter 5.

Copyright © S. Eric Nybo 2011
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CHAPTER 2: ISOLATION AND ELUCIDATION OF THE CHRYSOMYCIN
BIOSYNTHETIC GENE CLUSTER
INTRODUCTION
Previous isolation of benzo[d]naphtho[1,2-b]pyran-6-one C-glycoside antibiotics
The chrysomycins (42 and 43) were historically the first gilvocarcin-type Cglycosides isolated, by Strelitz and Flonne in 1955 (51), though their structures were not
determined, and only published in the 1980s by Weiss et al. (50). The initial structure
determination of the sugar moiety of 42 and 43 by Weiss et al. was suggested to have a
1

C4 configuration. However, their assignments were based on relative stereochemistry

assigned by coupling constants. Brazhnikova et al. isolated the sugar component of 42
and 43 (their group had referred to it as virenomycin) through methanolysis and 1D- and
2D-NMR analysis of the sugar moiety identified it to be methyl-β-D-virenoside, thereby
disproving the 1C4 configuration suggested by Weiss et al. (52)
Biological activity of chrysomycin A
The antitumor activity of chrysomycin A was established in a murine P 388
lymphocytic leukemia cell line (50). Chrysomycin A protected the mice with an
increased lifespan of 54% compared to control mice. As such, the antitumor activity of
chrysomycin A was established as being very similar to gilvocarcin V in this cell line
(57% increased life span and LD50 at doses greater than 1 g/kg), while exhibiting no
lethal effects at the dose administered (50). Photoactivation studies confirmed the role of
the 8-vinyl side-chain of 42 DNA-binding using a [2+2] cycloaddition to thymine
residues (115-116). Studies on the crosslinking of histone H3(116) suggest an important
role for the binding of the C-glycoside moiety to this densely positively-charged protein
(117). Matson et al. reached the same conclusions about the activity of chrysomycin A,
while suggesting that another factor of its binding, other than photoactivation of the 8vinyl side, was responsible for the binding of chrysomycin A to DNA (118). Structureactivity relationships by the Mercian company on the 4-keto-D-virenose derivative 51
showed that this derivative has improved activity in solid tumor cell lines over 42, an
observation only attributable to the presence of a ketosugar.
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Rationale for cloning chrysomycin A biosynthetic gene cluster
Previous work on the gilvocarcin biosynthetic gene cluster was paramount for
development of a coherent biosynthetic pathway and for generation of novel derivatives
through inactivation experiments and glycodiversification experiments (72, 119).
Therefore, cloning of the chrysomycin A gene cluster will be important for expanding the
combinatorial biosynthetic toolbox with NDP-D-virenose biosynthetic genes.
Furthermore, because chrysomycin A possesses a pyranose C-glycosidic moiety
compared to the furanose moiety of gilvocarcin, the C-glycosyltransferase responsible for
attachment of NDP-D-virenose to the polyketide acceptor substrate is valuable for
interrogation of other pyranose substrates. As it is anticipated that 39 and 42 share
identical biosynthetic steps towards the generation of the gilvocarcin-type chromophore,
the chry cluster should possess a homologous set of genes to the characterized gil gene
cluster. Additionally, direct comparison of the genes present in the chrysomycin A gene
cluster with those that are present in the gilvocarcin gene cluster as well as the gene
cluster of the ravidomycins, will possibly illuminate the roles of some still unknown
gilvocarcin biosynthetic enzymes, among these are gilLMNV.

RESULTS AND DISCUSSION
Construction of cosmid library for S. albaduncus AD819
A library screening approach was envisioned for the isolation and sequencing of
cosmid DNA pertinent to the biosynthesis of chrysomycin. Cosmid vector pOJ446 was
selected as the cosmid cloning vector for this (previously used for cloning of the
gilvocarcin gene cluster) (61). The vector pOJ446 possesses several useful features: its
cos sites allow for packaging 35-40 kilobase pair fragments of genomic DNA; it
possesses origins of replication for cloning in both E. coli and Streptomyces sp. (SCP2*).
It also has an oriT site for conjugal transfer into Streptomyces sp. hosts. For this, a
cosmid library of Streptomyces albaduncus AD819 was generated by ligating partiallydigested Sau3AI fragments of genomic DNA into pOJ446, prepared with HpaI/BamHI
(3). The evaluation of the amount of the genome that is covered in the cosmid library
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can be modeled using a mathematical equation. This equation factors the average size of
genomic DNA inserted into a single plasmid, the number of E. coli colonies transformed
with cosmids harboring genomic DNA, and the size of the genome. To calculate the total
coverage of the cosmid library, the following equation was used:
N=log(1-fc) / log(1-L/G)
Where N= the total number of clones, fc is the fractional coverage of the genome, L is the
length of genomic DNA present in each cosmid clone, and G is equal to the total length
of the genome (3). G for the total genomic length of Streptomyces albaduncus is
approximated by comparing the lengths of the characterized Streptomyces lividans TK 66
(NCBI data) (8,318,010 bp) and Streptomyces coelicolor A3(2) (8,667,507 bp) genomes,
or about 8,500,000 bp (120). Fc is usually calculated to be >95% coverage of a genome,
and L was determined by restriction analysis of ten random cosmids from the titering
reaction (Figure 15). This analysis indicated that an average insert size of ~38 kb was
present in the cosmids so digested. Therefore, approximately 670 unique colonies from a
titering reaction would be required for >95% coverage. The resulting number of colonies
from titering was 2300 colonies, which is roughly ~4x the theoretical coverage of the
entire S. albaduncus genome.

Positive hybridization of probes of NDP-glucose-4,6-dehydratase, 3-oxoacyl-acyl
carrier protein-reductase (chryF), and Ketoacyl synthase (KSα) cosmid DNA
For the isolation of cosmids pertinent to chrysomycin biosynthesis, two DNA
fragments were designed for probing the genomic library corresponding to genes that
were theorized to be a part of the gene cluster of 42. Two degenerate fragments
corresponding to conserved regions of β-ketoacyl synthase (KSα) and NDP-4,6dehydratase were synthesized (38, 61, 121). KSα is an essential component of the
“minimal polyketide synthase” responsible for polymerizing additional acetate units to a
growing poly-β-ketothioester (Figure 10). NDP-4,6-dehydratase is an essential earlyacting deoxysugar enzyme (Figure 7). Such an approach of using two probes increases
the chances of finding clusters that are pertinent to chrysomycin biosynthesis, because
deoxysugar biosynthetic genes and polyketide synthase genes were expected to be
clustered together. Furthermore, polyketide gene clusters are fairly ubiquitous among
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streptomycetes, and screening with a single KSα probe may uncover multiple polyketide
gene clusters from S. albaduncus. For example, in the chartreusin biosynthetic pathway,
cosmids positively hybridizing to PKS probes were isolated from at least 3 different
PKS-encoding pathways (122).
It was necessary to design a second NDP-4,6-dehydratase probe than the one used
by Bechthold et al. upon discovering a conserved downstream region (e.g. reverse primer
synthesized from BEWLHVDDHC region) that is absolutely conserved among 4,6dehydratases. Colony hybridization with the two digoxigenin (DIG)- labeled probes
(~650 basepair KSα probe and ~600 basepair 4,6 dehyratase probe) resulted in colonies
that hybridized with both the KSα and the NDP-4,6-dehydratase probe (Figure 15). One
of these cosmids, namely cosChry1-1, was chosen for Southern Blot analysis and shotgun
sequencing.
After sequencing revealed that cosChry1-1 was lacking a polyketide-associated
ketoreductase, a “gilF” candidate gene essential for biosynthesis of the polyketide, a third
DIG-labeled-probe based on conserved amino acid residues for 3-oxoacyl-ACPreductases was generated. A second round of colony hybridization resulted in 3 more
colonies that positively hybridized to the chryF probe. The cosmids isolated from these
colonies were called cosChryF1, cosChryF2, and cosChryF3, because they each harbored
the putative chryF gene.

Southern blot studies of cosChry1-1, cosChryF1, cosChryF2, cosChryF3
CosChry1-1 was digested with BamHI and was hybridized with both DIG-labeled
KSα and NDP-4,6-dehydratase probes (Figure 16). The Southern Blot of BamHIdigested cosChry1-1 indicated positive binding of the KSα probe to a 7.0 kilobase pair
region, and the NDP-4,6-dehydratase probe was confirmed to bind to a ~7.8 kilobase pair
fragment. Therefore, cosChry1-1 was confirmed to contain both the putative KSα and
4,6-dehydratase genes necessary for chrysomycin biosynthesis clustered together on the
same cosmid. As a result, cosChry1-1 was used for further “shotgun” sequencing
experiments.
It was necessary to confirm the presence of chryF in each of the three cosmids
identified by colony hybridization. Therefore, each of the three cosmids were digested
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with BamHI and were hybridized with the DIG-labeled chryF probe (Figure 16). In all
three cases, chryF was found to strongly hybridize with a ~4 kilobase pair region on the
cosmids. An additional PCR experiment using the KSα primers amplified the expected
KSα fragment from each cosmid, confirming that the chryF and the putative β-ketoacyl
synthase genes were clustered together on each of cosChryF1, cosChryF2, cosChryF3.

Figure 15 Amplification of probes and colony hybridization.
(Upper Left) 0.7% agarose gel of KSα probe and NDP-4,6-dehydratase probe (Upper
Middle). (Upper Right) BamHI digest of 7 randomly selected cosmids to determine size
of inserts from restriction analysis. (Bottom) Plaques from colony hybridizations with
DIG-labeled KSα and 4,6-dehydratase probes. Darkest colonies are clones that are
positively hybridizing.
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Figure 16 Southern blot studies of chry cosmids.
(Upper Row) Southern blots of selected BamHI digested cosmids with DIG-labeled KSα
and NDP-4,6-dehydratase probes, respectively. (Lower Left) Southern blot of DIGlabeled chryF with BamHI-digested cosChryF1, cosChryF2, cosChryF3 on left and
cosChryF1, cosChryF2, cosChryF3 digested with PstI on the right. (Lower Right)
Amplification of chryA (0.65 kb) from cosChryF1, cosChryF2, cosChryF3.
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Shotgun sequencing of cosChry1-1, primer walking of cosChryF1-cosChryF3,
subcloning of chryF fragment
CosChry1-1 was shotgun sequenced using a Mu transposon-based insert to allow
for generation of short (800 bp-1000 bp) reads by a sequencer (HyperMu Transposase,
Materials and Methods) (123-124). The resulting short reads were combined by the
Phred/Phraps/Consed software package, which was used to generate contiguous sequence
reads (contigs). From this sequencing, three contiguous regions of ~8 kilobases, ~12
kilobases, and ~13 kilobases were generated. To sequence the overlapping regions of
these contigs, subcloning experiments of cosChry1-1 were undertaken. CosChry1-1 was
digested with BamHI, and two resulting fragments of ~7.8 kilobases and 3 kilobases were
rescued and cloned into the same sites of pBluescript II K/S+, and these resulting
constructs (pBS7PQ and pBS3U, respectively) were used for primer walking. An 80
basepair overlap of pBS7PQ between chryQ and chryX1 revealed one connection, and the
other came from sequencing pBS3U from the 5’-end of chryU to the 3’-end of chryRM.
To sequence chryF, a ~4kb BamHI fragment was subcloned into the same
restriction sites of pBluescript II K/S+ to give pBS4F, which was primer walked outward
from the center of chryF (this sequence being provided by sequencing the chryF probe in
a pGEM-T vector) until arriving at known sequence from cosChry1-1. A combination of
primer walking and subcloning revealed the upstream chryF-containing region and
connected it with known chryOI ORF from the cosChry1-1 shotgun sequencing
experiments. The sequencing of the upstream region was stopped when all genes
necessary for biosynthesis of 42 were determined (based on direct comparison with the
GV gene cluster). A further sequencing of 1000 base pairs revealed ORFs whose
encoded proteins seemed to be irrelevant for biosynthesis of 42, and were likely involved
in primary metabolism, which effectively bounded the upstream region of the cluster.
Bioinformatics analysis of DNA
The resulting sequence reads were analyzed via the FramePlot and NCBI BLAST
databases for the determination of discrete open reading frames (ORFs) and assignment
of putative functions to chry genes from similarity searches (Materials and Methods).
ORFs were also judged to possess a relatively high percentage of GC bases in the wobble
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base position of their codons. Streptomyces sp. genes are characterized by a relatively
high percentage of guanines and cytosines (high GC %) residing in the third base pair, or
wobble base pair, of codons. As a result, analysis of the 34,654 nucleotide sequence
resulted in 35 open reading frames that were identified for genes putatively responsible
for biosynthesis of 42, self-defense from chrysomycin, regulation of the pathway, or
constituted genes whose encoded protein products were of unknown function (chryLV).
Prospective gene candidates were named according to their gil cluster homologues.
Therefore, the nomenclature of the chry cluster reflects the precedence of the gilvocarcin
gene cluster and the similarities between their biosynthetic components. A table of ORFs
and proposed functions of encoded enzymes is included in Figure 20. The complete chry
cluster nucleotide sequence is assigned the NCBI Accession No. FN565166.
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Figure 17 Map of the chry cluster using arrows to indicate direction of candidate ORFs.
Polyketide biosynthesis enzymes depicted in Black, deoxysugar biosynthetic and
glycosyltransferase enzymes are Green, monooxygenases are Red, enzymes involved in
regulation or export of CV are Grey, polyketide O-methyltransferase in Light Blue, and
putative ORFs encoding proteins of unknown function are White.
Minimal ‘PKS’ genes and genes implicated in polyketide cyclization,
ketoreduction, aromatization
The minimal polyketide synthase, consisting of chryABC, is clustered towards the
upstream region of the chry cluster, near the polyketide cyclases chryGK and the PKSassociated ketoreductase, chryF (Figure 17). ChryABC are translationally-coupled with
one another, which is a common feature of type-II polyketide synthase genes. ChryA
encodes the ketoacyl synthase for chrysomycin biosynthesis; its protein product consists
of 422 amino acids, and demonstrates strong sequence identity and similarity to other
known ketoacyl synthases (KSα). It particularly exhibits strong sequence similarity to
the Streptomyces ravidus RavA KSα protein (423 amino acids, 90% identity/94%
similarity) and the S. fradiae UrdA KSα protein (426 aa, 80% identity, 88% similarity).
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It has a KAS type I-II domain, a FabF domain, a putative dimer interface for interaction
with ChryB, and a putative conserved catalytic cysteine residue, C169 (16). ChryB, the
chain length determinant-encoding gene (KSβ), encodes a 402 amino acid chain length
determinant, which forms a heteromeric complex with ChryA. ChryB demonstrates
similarity to known type II KSβ proteins (71%/83% with UrdB, 51%/67% GilB,
77%/85% RavB). ChryC encodes the PKS-associated acyl carrier protein (ACP) of the
“minimal” PKS. The 87 amino acid product bears similarity to the ACPs of the
jadomycin and ravidomycin pathways (JadC 61%/71%, RavC 79/84%).
Amazingly, the chry cluster possesses another ACP homologue, namely chryC1,
which is transcribed in the same direction as and is between the cyclases chryGK.
ChryC1 possesses strongest sequence similarity with acyl carrier proteins RavC1
(71%/81%) and SimA3 from S. antibioticus (59%/72%). It is unclear what role a second
ACP has in the chry cluster, however, it may be used for extending the polyketide chain
with either the malonate or propionate starter unit selectively. Because chrysomycin
biosynthesis involves both malonate and propionate starter units, the presence of two
ACPs might help steer the pathway towards production of either 42 or 43. However,
Shepherd et al. have shown that sister protein RavC1 loads both propionyl-CoA and
malonyl-CoA comparably (65). The chry and rav gene clusters represent an anomaly in
type II polyketide biosynthesis encoding two functional acyl carrier proteins in the same
gene cluster (65). Only in a couple other type II PKS gene clusters have two encoded
ACPs been found clustered together- the frenolicin and R1128 clusters (65). Therefore, it
is possible that ChryC1 is an ancillary ACP that assists in extending the growing
polyketide chain along with ChryC. ChryP (protein product is 322 amino acids) and
chryQ (protein product is 327 amino acids) encode a malonyl-CoA acyltransferase
(MCAT) and a propionyl-CoA acyltransferase, respectively. The gil biosynthetic
machinery also possesses a homologous pair of MCAT and propionyl-CoA
acyltransferase enzymes, GilP and GilQ, respectively, however, MCATs can also be
recruited from the fatty acid biosynthesis (18). A BLAST database search of ChryP
reveals sequence similarity to MCATs from other type II PKS pathways (PgaH
50%/64%). ChryQ resembles the closely related RavQ propionyl-CoA acyltransferase
from the rav gene cluster (65%/72%).
37

ChryF encodes the putative polyketide-associated ketoreductase (261 aa)
necessary for ketoreduction at the C-9 carbonyl of the polyketide chain (Figure 18). It
has significant similarity to known oxoacyl-ACP-ketoreductases RavF (86%/92%) and
Orf7 from S. echinatus (72%/84%). Interestingly, chryF is in stand alone at the
beginning of the chry cluster (Figure 17), whereas in the gil cluster gilF is transcribed
directly after the gilvocarcin minimal polyketide synthase, gilABC, reflecting the intimate
nature of its interaction with GilABC. However, clustering of chryF with the minimal
PKS genes is not an absolute requirement. The cyclases-encoding genes chryGK are
immediately upstream of chryOIV and chryABC (Figure 17). ChryG (109 aa) and chryK
(314 aa) encode the cyclases responsible for installing the angucycline framework of CV.
ChryG (OvmC- 71%/84%, UrdF 74%/84%) exhibits strong similarity to other
angucycline-type C4-C17 cyclases, and ChryK exhibits similarity to bifunctional
dehydratases/cyclases (RavK 72%/81%, SaqL 61%/72%). In theory, ChryK acts first,
dehydrating the C-9 position, which results in spontaneous aromatization of the first ring
and cyclization of the second ring, and cyclase ChryG acts next, cyclizing the third ring
and performing C4-C17 angular cyclization of ring A of homo-UWM6 (18) (Figure 18).
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Oxygenases, oxidoreductase, and methyltransferase genes
The oxygenases of the chry cluster are integral for the transformations that result
in 18 being rearranged into the distinctive gilvocarcin-chromophore (Figure 18). Four
oxygenase encoding genes were identified in the chry cluster, which is in agreement with
a complement of four oxygenases being required for biosynthesis of GV (Figure 10) (60,
62, 68-69). ChryOI, chryOII, chryOIII, and chryOIV encode the four monooxygenase
homologues so identified in this gene cluster. ChryOIV and chryOI encode putative
FAD-dependent oxygenases. Furthermore, their products ChryOIV (491 aa) and ChryOI
(513 aa) demonstrate sequence similarity with one another (46%/55%), which is also the
case with FAD-dependent monooxygenase pairs JadF/H and GilOIV/OI from the
jadomycin and gilvocarcin pathways, respectively. The product of chryOIV demonstrates
sequence similarity to GilOIV (36%/48%) and JadF (55%/63%), which are known to
catalyze the 2,3-dehydration step of homo-UWM6 (Figure 18). ChryOIV is also
believed to play a vital role in the installation of a 5-OH, which in a presently unclear and
perhaps concerted manner with ChryOII, undergoes a Baeyer-Villiger oxidative cleavage
of a hypothetical intermediate to afford a ring-opened acid/aldehyde compound (Figure
18). The encoded product of chryOI demonstrates sequence similarity to JadH
(60%/69%) and GilOI (43%/55%), which has been shown to catalyze the 4a, 12bdehydration of 2,3-dehydro-homo-UWM6 (59). Furthermore, it is proposed that ChryOI
installs a 12-hydroxyl moiety to afford a hydroquinone, which Chen et al. refer to as CR1
(69). However, this compound rapidly oxidizes to the dehydrorabelomycins (60 and 61,
Figure 10).
ChryOIII encodes a P450 monooxygenase responsible for installation of the 8vinyl side chain of 42. The encoded product (394 aa) has considerable sequence
similarity to P450 monooxygenases from other pathways, including GilOIII (72%/81%).
It is believed that as soon as the A ring is fully aromatized and either just before or after
12-hydroxylation that ChryOIII acts as to install the 3-vinyl side chain (Figure 18).
ChryY encodes a ferredoxin accessory protein just downstream of chryOIII: P450
monooxygenases utilize either their own ferredoxin accessory protein, or recruit
ferredoxin from the electron transport chain. It is unclear by what mechanism the 3-vinyl
side chain is installed. However, by employing chemical logic, ChryOIII could install a
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hydroxyl group on the 1” benzylic position of the 3-ethyl group. This hydroxyl group
could be potentially installed via a radical mechanism, for example. Once the hydroxyl
moiety has been installed, a facile dehydration would afford the vinyl side chain that
serves as the warhead for chrysomycin’s biological activity.
ChryOII encodes a putative anthrone monooxygenase that initially was
hypothesized to catalyze 12-hydroxylation. It demonstrates similarity to other putative
anthrone monooxygenases (JadG 53%/71%, GilOII 65%/76%). However, JadH has been
shown to catalyze this 12-hydroxylation, and furthermore, the absence of 12hydroxylated shunt products in the GilOI- and JadH-deleted strains indicate that ChryOI
probably catalyzes a similar step in the biosynthesis of 42 (60, 69). However, C-12
hydroxylation could also occur spontaneously as a shunt process, as in the case of
rabelomycin. This assignment is purely suppositional, and the assignment of GilOII-type
cofactorless monooxygenases as anthrone monooxygenases may just reflect that little is
known about this intriguing class of oxygenases.

It is more likely that C-12

hydroxylation occurs during an oxygenase cascade in a concerted and mechanisticallycontrolled fashion after ring A aromatization, thereby affording a hydroquinone
intermediate (Figure 18). Therefore, ChryOII might be responsible for the C5-C6
carbon-carbon bond cleavage reaction, perhaps as a novel Baeyer-Villiger (BVMO) type
reaction (Figure 19). It may act in a concerted fashion with ChryOIV to generate the
acid-aldehyde ring-opened intermediate. Furthermore, BLAST analysis suggests that
ChryOII has a conserved histidine, H185 that is in common with the larger antibiotic
monooxygenase superfamily. It is possible that this residue may be involved in the ring
cleavage reaction; this H185 is absolutely conserved in JadG/GilOII/RavOII as well. To
prove this hypothesis, in theory a simple mutagenesis experiment of ChryOII H185 to
alanine could confirm this catalytic role. For example, the vancomycin dioxygenase
DpgC involves conversion of 3,5-dihydroxyphenylacetyl coenzyme A to 3,5dihydroxyphenylglyoxylate using a single-electron transfer mechanism from the substrate
to one oxygen of diatomic oxygen (125). Therefore, it could be proposed that H185
serves as a conserved base in ChryOII for abstraction of a proton from C5, which allows
for subsequent attack of the substrate onto diatomic oxygen (Figure 19). The following
mechanism can either follow a BVMO route (A) or proceed via a dioxetane route (B)
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(Figure 19), as was suggested by the DpgC crystal structure (125). The BVMO route
(A) proposes oxygenation at C5 by ChryOII, reduction catalyzed by an unknown enzyme,
and oxygenation by ChryOIV. One of the mechanistic limitations of this route is the
requirement for another reduction event. The dioxetane route (B), however, generates a
dioxetane intermediate and subsequent rearrangement affords the acid and aldehyde.
However, one limitation of this route (B) is that ChryOIV only serves as the 2,3dehydratase in this pathway and has no oxygenase function. This route may be supported
by inactivation experiments, however, because in the S. lividans (cosG9B3-GilOIV-)
mutant production spectrum, a small amount of gilvocarcin M is produced along with the
major products of rabelomycin and homorabelomycin (Madan Kharel, unpublished
results), only using GilOI and GilOII. Therefore, in the absence of GilOIV, GilOI may
possess slight flexibility towards UWM6 (18) enough to catalyze both the 2,3dehydrations and 4a-12b dehydrations, which then allows for GilOII to perform the
dioxygenase reaction in the absence of GilOIV, resulting in the accumulation of small
amounts of GM. Additionally, it is interesting to note that upon feeding
dehydrorabelomycin (3-methyl congener of 60) to a PKS-deficient mutant strain of S.
venezuelae that both CR1 and dehydrorabelomycin were both fully-converted to
jadomycin A, whereas feeding of 60 to the S. lividans (cosG9B3-gilOIV-) strain did not
result in conversion to 39 (68). Cross-complementation of the jadG gene into the GilOIIdeleted mutant failed to complement the pathway and restore production of 39. As a
result, GilOII/ChryOII and JadG may bind different pathway molecules, in the case of the
gilvocarcins and chrysomycins, a hydroquinone.
ChryMT encodes a putative 340 amino acid protein that serves in O-methylation
of the chromophore of chrysomycin (Figure 18). ChryMT exhibits strong sequence
similarity to O-methyltransferases from other pathways (e.g. MetLA1 50%/64%).
ChryMT is hypothesized to be a SAM-dependent O-methyltransferase that O-methylates
either the 12-hydroxyl or 10-hydroxyl moieties. ChryMT is proposed to O-methylate the
10-hydroxyl position due to the suspected involvement of ChryRM in catalyzing an
unusual methylation immediately after the C5-C6 cleavage step, which becomes 12-Omethyl. The substrates for these reactions are completely unknown, however.
Furthermore, it is uncertain if 10-O-methylation occurs before or after glycosylation with
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D-virenose.

It seems plausible that the presence of the 4-C-virenoside moiety is not an

essential requirement for ChryMT methylation, as defucogilvocarcins (62-64), which are
O-methylated at 10- and 12-positions, are accumulated in the S. lividans (cosG9B3gilGT-) strain and other producing organisms.
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Figure 19 Theoretical routes to C5-C6 carbon carbon bond cleavage of the
chrysomycins.
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H

H185 of ChryOII is portrayed as a predicted catalytic base. A) Baeyer Villiger-catalyzed
route towards the ring-cleaved acid/aldehyde intermediate. B) Dioxygenase and
dioxetane formation by ChryOII route to acid/aldehyde intermediate.
ChryRM encodes a putative two-domain protein that involves both a GilM-type
methylation step and a GilR-type dehydrogenation step of prechrysomycin V (96).
ChryRM (N-terminal domain=518 aa, C-terminal=243 aa) demonstrates sequence
similarity to GilM (41%/58%) and GilR (50%/63%). Initially, the putative chryR was
suspected to be sequenced wrong, in that an extra nucleotide insertion appeared to have
happened in the initial sequencing file. Upon re-sequencing and confirmation that the
chryR sequence was indeed correct, it was determined that chryRM composed a single
ORF whose product would be a dual domain protein, ChryRM. Sequence comparison
with ravRM confirmed that both the rav and chry clusters encode such a predicted two
domain protein. The 761 aa predicted ChryRM could potentially have important
ramifications for elucidation of the late-acting chrysomycin biosynthetic steps from the
ring-cleaved acid-aldehyde intermediate to the final dehydrogenation step of
prechrysomycin V 94 to chrysomycin V 42. It is interesting that in the case of the
ravidomycin and chrysomycin clusters, these two proteins are fused versus in the
gilvocarcin cluster where GilM and GilR are separate entities. The rav and chry clusters
very likely share a common ancestor, given that their genetic organization is almost
identical, and this may account for the presence of a fused protein. This protein very
likely was originally fused in an ancestor, and then over time genetic mutation may have
caused the chryRM/ravRM to become two functional ORFs gilR and gilM in the gil
cluster. However, both the rav and chry clusters encode deoxyhexose tailoring enzymes,
in essence the only major difference between these clusters, and the presence of a
deoxyhexose of the prechrysomycin/preravidomycin intermediates may require a very
specialized RavR or ChryR domain to catalyze dehydrogenation of the hemiacetal to the
lactone (as compared to the fucofuranose-containing pregilvocarcin). Kharel et al.
demonstrated that GilR catalyzes the turnover of pregilvocarcin V (kcat =2.29±0.03 min1

), but also the unglycosylated predefucogilvocarcin V less effectively (kcat=0.65±0.086

min-1). Interestingly, prechrysomycin V (94) turned over poorly by GilR (71). This
observation clearly demonstrates the preference and substrate specificity for these
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dehydrogenases towards a very particular type of glycosylated molecule, a deoxyfuranose
for GilR, and deoxypyranoses for RavRM and ChryRM. Therefore, ChryRM is unusual
in that it is anticipated to accept two separate substrates- the acid/aldehyde intermediate,
and a fully-glycosylated prechrysomycin compound (94). Its overexpression would be
useful in studies aimed at determining the nature of collaboration between the R and M
enzyme-activities. This could be used to interrogate turnover of various pyranosyl
pregilvocarcins that could be generated with “sugar plasmid” recombination experiments
in vivo.
ChryH encodes a putative NAD(P)H-dependent FAD reductase with significant
sequence similarity to other similar reductases (e.g. Kfla_5747, 64%/75%). It is thought
that ChryH binds NAD(P)H and provides reduced FADH2 to the FAD-dependent
oxygenases ChryOIV/ChryOI. Disruption of GilH did not abrogate biosynthesis of 39,
and heterologously-expressed GilH evinced a yellow color indicative of FAD binding,
thereby confirming its role as an accessory protein (64).
Genes involved in self-defense, regulation, and other functions
The chry cluster has several ORFs which are predicted to encode proteins
essential for regulation and export of chrysomycin. ChryX demonstrates sequence
similarity to spore-associated protein precursors (SapA, 73%/84%), which may have
some role in regulating sporulation of S. albaduncus. Upstream of chryX is an ORF
encoding a Zinc-finger SWIM protein >700 bp long, therefore this region demarcates one
boundary of the cluster with genes whose encoded functions are not necessary for
biosynthesis of chrysomycin. ChryX1 and chryX2 encode an apparent two-component
response regulation system that is also encoded by ORFs ravJ (54%/70%) and ravX5
(67%/82%) that are likely involved in regulating expression of chry biosynthetic genes.
ChryX3, X5, X6, X7,X8 represent various regulators putatively involved in chrysomycin
biosynthesis, with chryX3 encoding a putative MarR type regulator, and chryX5, X7, and
X8 pertaining to putative TetR family regulators. ChryJ encodes a drug efflux permease,
and would be similar in this respect to gilJ. It is believed that ChryJ is essential for
export and self-defense for S. albaduncus from chrysomycin. ChryX9 encodes a putative
Acyl-CoA dehydrogenase (SSDG_02680, 84%/89%), which is an enzyme from fatty acid
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β-oxidation from primary metabolism. ChryX4 putatively encodes hexokinase
(Tfu_1012 61%/75%), which catalyzes the transfer of a phosphate to the 6-position of Dglucose in the first step of glycolysis. Interestingly, chryL (GilL, 37%/50%) is also
present, and it encodes a putative NAD-dependent epimerase/dehydratase, but its role in
the biosynthesis of 42 can only be speculated about. This gene demonstrates similarity to
gilL, an ORF encoding a protein of unknown function in gilvocarcin biosynthesis. ChryV
is another gene of unknown function related to gilV; BLAST analysis indicates that
ChryV has a domain that is related to the chlorite dismutase family of enzymes.
Enzymes of this family are largely hypothetical proteins, however, chlorite dismutase is
responsible for dissociation of chlorite into its composite chlorine and oxygen species.
Genes involved in biosynthesis and attachment of NDP-D-virenose
NDP-D-virenose is a key structural feature of 42, and the genes involved in
deoxysugar biosynthesis are a unique feature of the chry cluster. ChryDE are
translationally-coupled and encode an NDP-glucose synthase (ChryD, 355 aa,
SSEG_09374, 78%/90%) and an NDP-4,6-dehydratase (ChryE, 328 aa; SSDG_01263
77%/84%), respectively. It is believed that these two enzymes are responsible for the
first two transformation steps from D-glucose-1-phosphate (30) to NDP-D-glucose (31) to
NDP-4-keto-6-deoxy-D-glucose (32) (Figure 20). Very often, the genes encoding these
two enzymes are translationally coupled; however, in some clusters, these genes are
located in another chromosomal locus, far-removed from the antibiotic biosynthetic
genes. For example, the elloramycin producer Streptomyces olivaceus clusters the 8demethyl tetracenomycin C antibiotic genes in a separate chromosomal locus from the
rhaABCD genes necessary to supply NDP-L-rhamnose (126). ChryCMT (411 aa,
PCZA361 61%/72%) and chryU (Acel_0416 46%/55%) are clustered together and
encode a putative C-methyltransferase and a truncated 4-ketoreductase, respectively.
ChryCMT is predicted to use a SAM cofactor, and ChryU could be an NAD(P)Hdependent ketoreductase enzyme. ChryCMT and ChryU could potentially catalyze the
last two transformations of 32 to a 3-C-methylated ketosugar, 95, and ChryU could
potentially reduce 95 to an axial 4-OH, to yield NDP-D-virenose. The assignments of the
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enzyme functions encoded by these genes and their cloning into overexpression vectors
will be covered in Chapter 3.
ChryGT (379 aa, GilGT, 44%/62%) encodes the only candidate
glycosyltransferase in the chry cluster. It is hypothesized to use 96 as the donor substrate
to transfer D-virenose the polyketide acceptor substrate, which at this point remains a
hypothesized intermediate. The mechanism for direct C-glycosylation of the
chrysomycin chromophore is anticipated to involve the phenolic 1-OH group, but an
additional Fries-like rearrangement has also been postulated (56). However, chryGT
potentially encodes a valuable C-GT for pathway engineering. For example, chryGT
could be placed under the strong ermE* promotion and subsequently integrated into the
chromosome of the S. lividans (cosG9B3-gilGT-) genome for interrogation with foreign
deoxysugar donor substrates. These could easily be supplied as plasmid-borne sugar
“cassettes” over-expressing deoxysugar biosynthetic enzymes from exogenous hosts.
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Figure 20 Hypothesized biosynthetic route to NDP-D-virenose (96).
ChryD catalyzes 1-phosphonucleotide transfer to D-glucose-1-phosphate (30). ChryE
catalyzes 4-oxidation and 6-reduction of NDP-D-glucose (31) to afford NDP-4-keto-6deoxy-D-glucose (32). ChryCMT catalyzes 3-C-methyltransfer to 32 to afford NDP-4keto-D-virenose (95), and ChryU catalyzes 4-ketoreduction of 95 to afford NDP-Dvirenose (96).
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ORFs

Size[a]

ID/SM
(%)[b]

Origin

Nucleotide
accession no.

Proposed function

chryX

149

84/89

S. griseoflavus Tu 4000

ZP_05536903

Spore-associated
protein precursor

chryF

261

71/83

fabG, S. echinatus

ABL09955

Ketoreductase

chryV

110

31/52

GilV, S. griseoflavus

ABE03981

Hypothetical Protein

chryH

189

62/73

Kribbella flavida DSM
17836

ZP_03859638

Oxidoreductase/NADHdependent FMN
Reductase

chryOI

513

59/70

PgaE, Streptomyces sp.
PGA64

2QA1_A

FAD-Dependent
Monooxygenase

chryG

109

70/83

OvmC, S. antibioticus

CAG14964

Cyclase

chryC1

83

58/71

SimA3, S. antibioticus

AAL15582

Acyl Carrier Protein

chryK

314

61/71

Tfu_1222, Thermobifida
fusca YX

YP_289283

Bifunctional
Cyclase/Dehydratase

chryOIV

491

55/63

OvmOII, S. antibioticus

CAG14970

FAD-Dependent
Monooxygenase

chryA

422

79/87

AAO65362

chryB

402

70/82

Pd2A, Streptomyces sp.
WP 4669
UrdB, S. fradiae

Ketoacyl Synthase
(KSα)
Chain Length Factor
(KSβ)

chryC

120

60/70

Acp, S. venezuelae

AAB36564

Acyl Carrier Protein

chryOIII

394

71/80

GilOIII, S. griseoflavus

AAP69584

Cytochrome P-450
Monooxygenase

chryY

62

44/62

NP_218020

Ferredoxin

chryP

322

49/63

FdxD, Mycobacterium
tuberculosis H37rv
PgaH, Streptomyces sp.
PGA64

AAK57533

Malonyl-CoA Carrier
Protein Transacylase

chryQ

327

49/58

AknF, S. galileus

AAF70110

Propionyl-CoA Carrier
Protein Transacylase

chryX1

265

38/50

AurIO, S. aureofaciens

AAK59995

Regulator

chryX2

201

56/72

Gra-orf10, S.
violaceoruber

CAA09631

Two-Component
Response Regulator

chryE

328

77/84

YP_002200633

TDP-glucose-4,6dehydratase

chryD

355

78/90

SSDG_01263, S.
pristinaespiralis ATCC
25486
SSEG_09374, S. sviceus
ATCC 29083

YP_002205669

Glucose-1-phosphate
thymidylyltransferase
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CAA60570

chryJ

623

78/87

YP_001826335

Major facilitator
superfamily permease

YP_001826336

MarR family
transcriptional regulator

44/62

SGR_4823, S. griseus
subsp. griseus NBRC
13350
SGR_4824, S. griseus
subsp. griseus NBRC
13350
GilGT, S. griseoflavus

chryX3

293

71/82

chryGT

379

AAP69578

C-glycosyltransferase

chryMT

340

49/63

MetLA1, S. tubercidicus

AAT45282

O-methyltransferase

chryOII

236

65/76

GilOII, S. griseoflavus

AAP69583

Anthrone
Monooxygenase

chryRM

761

52/67;
41/58

ABL09969/
AAP69591

Oxidoreductase/
Methyltransferase

chryU

302

46/55

ORF 22, S.
echinatus/GilM, S.
griseoflavus
Acel_0416,
Acidothermus
cellulolyticus 11B

YP_872176

TDP-4dehydrorhamnose
ketoreductase

chryCMT

411

61/72

CAA11777

C-methyltransferase

chryHK

309

61/75

YP_289073

Hexokinase

chryL

210

37/50

PCZA361,
Amycolatopsis orientalis
Tfu_1012, Thermobifida
fusca YX
GilL, S. Griseoflavus

AAP69590

NAD-dependent
epimerase/dehydratase

chryX4

135

70/82

YP_001824391

TetR Family
transcriptional regulator

NP_631661

Hypothetical Protein

YP_001821941

TetR Family
transcriptional regulator

YP_002198950

Acyl-CoA
Dehydrogenase

SGR_2879, S. griseus
subsp.
griseus NBRC 13350
chryX5
120
61/74
SC2H2.18, S. coelicolor
A3(2)
chryX6
202
78/83
SGR_429, S. griseus
subsp.
griseus NBRC 13350
chryX7
545
83/89
SSDG_02680, S.
pristinaespiralis ATCC
chryX8
129
61/68
25486
SCD31.02c, S.
coelicolor A3(2)
chryX9
155
62/79
Caul_2306, Caulobacter
sp. K31
[a]
: number of amino acids; [b]: identity/similarity

NP_628836
Regulatory Protein
YP_001683931

TetR Family
transcriptional regulator

Figure 21 Table of proposed chrysomycin ORFs, predicted functions of their producers,
and identity/similarity scores among closest homologues.
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Attempts at heterologous expression and inactivation of chrysomycin biosynthetic
genes
In order to prove the role of the chry cluster in production of chrysomycin,
heterologous expression experiments of the various cosmids encoding chrysomycin
biosynthetic genes were undertaken. Chry1-1 and CosChryF2 were chosen for
heterologous expression in Streptomyces lividans, because they contained the greatest
portion of the chry cluster genes as determined by restriction analysis. Streptomyces
lividans TK 24 is a preferred transformation host because of its genetic pliability, and
because under normal conditions it fails to express antibiotic biosynthetic genes, making
it effectively “background neutral” (3). The cosmids were transformed into S. lividans
TK 24 by a well-characterized conjugation protocol between a special E. coli host and
Streptomyces lividans (See Materials and Methods) (3). Exconjugants were fermented
for 4-5 days, and methanolic extracts were chromatographed via HPLC/MS to evaluate
the production of chrysomycin-related metabolites (See Materials and Methods).
Expression of cosChry1-1 or cosChryF2 in S. lividans failed to result in the production of
metabolites with the characteristic chromophore of angucycline or gilvocarcin-related
compounds when compared to extracts of S. lividans (pOJ446) as a negative control.
Because chryABCFGKP were present on cosChryF2, at least rabelomycin or UWM6
should have been accumulated in the S. lividans (cosChryF2) strain. The lack of
accumulated metabolites likely resulted from poor cosmid expression or
missing/dysfunctional regulators necessary for chrysomycin biosynthesis.
As an alternative, classical inactivation experiments were envisioned for
disruption of the chryA and chryCMT genes. Inactivation of chryA would result in a nonproducing mutant and inactivation of chryCMT was anticipated to disrupt NDP-Dvirenose biosynthesis, and depending on the substrate flexibility of ChryGT, would result
in a novel gilvocarcin with a C-glycosidically linked pyranose moiety. ChryA and
chryCMT were cloned into pKC1139, which is an RK2-derived vector that is used for
gene deletion experiments in Streptomyces. pKC1139 features a temperature-sensitive
replicon that prevents it from replicating autonomously, so any surviving AprR
transformants must be single-crossover mutants (3). A thiostrepton resistance cassette
was cloned and inserted into unique restriction sites in the middle of chryA and chryCMT
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(XmaI for chryA and BglII in chryCMT) (See Materials and Methods). The resulting
constructs, pKC1139-chryCMT and pKC1139-chryA, were unable to be transformed into
S. albaduncus via protoplast transformation, electroporation, and conjugation procedures.
S. albaduncus may simply be recalcitrant to genetic manipulation due to a severe
restriction system.
Cross complementations using chrysomycin oxygenases
In order to prove the chrysomycin biosynthetic gene cluster was responsible for
biosynthesis of 42, when inactivation experiments and heterologous expression of the
chrysomycin cluster were not feasible, in vivo cross-complementation experiments were
envisioned using chry biosynthetic genes and gilvocarcin blocked mutants. For this, the
four chry monooxygenases were selected for overexpression, because they are crucial for
the 12-position hydroxylation, C5-C6 bond cleavage, and installation of the 8-vinyl side
chain, steps that are unmistakably characteristic for the biosynthesis of the chrysomycin
chromophore. ChryOI, chryOII, chryOIII, and chryOIV were cloned into pEM4 under
the strong, constitutive ermE* promoter (see Materials and Methods). The resulting
constructs, pChryOI, pChryOII, pChryOIII, pChryOIV were transformed into gilvocarcin
mutants deficient in the oxygenases GilOI, GilOII, GilOIII, and GilOIV respectively.
When pChryOI was transformed into S. lividans TK 24 (cosG9B3/GilOI-), for
unexplained reasons, the resulting transformant neither produced gilvocarcin (39), as
expected, nor even prejadomycins (58) or (59), as are typically accumulated in the gilOIdeleted strain. This is likely explained by poor host utilization of the cosG9B3-GilOIcosmid. The S. lividans TK 24 (cosG9B3/GilOIV-)/pChryOIV strain successfully
restored production of gilvocarcin biosynthesis, producing 39 and 40 (see Figure 22).
Because chryOIV and chryOI both encode FAD-dependent monooxygenases and are
quite similar to each other, it could be possible that ChryOIV might actually be the
GilOI-homologue, or it may be able to catalyze both 2,3-dehydration and 4a,12bdehydration steps. Therefore, pChryOIV was cross-complemented into the S. lividans
TK 24 (cosG9B3/GilOI-) mutant. The resulting transformant failed to recapitulate
gilvocarcin biosynthesis, indicating that ChryOIV is responsible for 2,3-dehydration in
chrysomycin biosynthesis (see Figure 22).
50

Figure 22 HPLC chromatograms of pChryOIV complementations
A) S. lividans (cosG9B3-GilOIV-) extract- rabelomycin (54) (Rt=13.0 min-1) and
homorabelomycin (55) (Rt=14.9 min-1). B) S. lividans (cosG9B3-GilOIV-)/pChryOIV
extract- gilvocarcin M (40) (Rt=14.2 min- 1) and gilvocarcin V (39) (Rt=14.7 min-1). C)
S. lividans (cosG9B3-GilOI-) extract-prejadomycin (58) (Rt=14.5 min-1) and homoprejadomycin (Rt=15.8 min -1)D) S. lividans (cosG9B3-GilOI-)/pChryOIV extract.
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Figure 23 HPLC chromatograms of pChryOII and pChryOIII chromatograms.
A) S. lividans (cosG9B3-GilOII-) extract-dehydrorabelomycin V (61) (Rt=24.3 min-1) and
dehydrorabelomycin E (60) (Rt= 25.3 min-1). B) S. lividans (cosG9B3-GilOII-)/pChryOII
extract- gilvocarcin M (40) (Rt=14.2 min- 1), gilvocarcin V (39) (Rt=14.7 min-1),
gilvocarcin E (41) (Rt= 15.0 min.-1), rabelomycin (54) (Rt=13.0 min-1) C) S. lividans
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(cosG9B3-GilOIII-) extract- gilvocarcin M (40) (Rt=14.2 min- 1) gilvocarcin E (41) (Rt=
15.0 min.-1) D) S. lividans (cosG9B3-GilOIII-)/pChryOIII extract- gilvocarcin M (40)
(Rt=14.2 min- 1), gilvocarcin V (39) (Rt=14.7 min-1), and gilvocarcin E (41) (Rt= 15.0 min.1
).
The failure of pChryOIV to completely restore gilvocarcin production probably indicates
that ChryOIV is not a perfect fit with GilOI and/or GilOII in the hypothetical multioxygenase complex, and therefore, some of the pathway continues towards unproductive
accumulation of shunt rabelomycins.
Both pChryOIII and pChryOII completely restored production of 39 and 40
(Figure 23), which indicates that ChryOIII is responsible for installation of the 8-vinyl
side chain, likely through hydroxylation and spontaneous dehydration at 1”-position of
the ethyl side chain of a still undetermined pathway intermediate. Simultaneously, this
experiment also indicates that ChryOII is capable of functioning in a surrogate capacity
when GilOII is not present in the oxygenase cascade. However, the presence of
rabelomycin indicates that some UWM6 is incompletely converted in this
complementation strain. Furthermore, the presence of gilvocarcin E, 41, may be
explained by an incomplete activity of GilOIII in this strain. In the GilOII-deleted strain,
both dehydrorabelomycin E and V are accumulated, which may indicate that GilOIII acts
on a hydroquinone intermediate. This result suggests that ChryOII is involved in the C5C6 carbon-carbon bond cleavage reaction, however, the mechanism by which it acts is
elusive.

SUMMARY
The chrysomycin biosynthetic gene cluster was cloned successfully onto four
cosmids that spanned 34,654 nucleotides and possessed 35 open reading frames pertinent
to biosynthesis of chrysomycin A. The involvement of the chrysomycin biosynthetic
gene cluster in biosynthesis of chrysomycin was successfully demonstrated by
heterologous complementation of the GilOII-, GilOIII-, and GilOIV-deleted mutants of
the gilvocarcin pathway by expression constructs pChryOII, pChryOIII, and pChryOIV
in these pathways. As a result, the chry cluster affords novel genes for expression in
other pathways, such as chryGT, which is likely responsible for the 4-C-glycosylation of

53

the chrysomycin chromophore. Furthermore, the identification of NDP-D-virenose
biosynthetic genes is intriguing for further heterologous expression experiments to
characterize the encoded products of chryD, chryE, chryCMT, chryU, and possibly chryL.
EXPERIMENTAL
DNA Isolation, Subcloning, and cloning of plasmids
For general cloning conditions, the protocols in Sambrook and Russel were
followed with regards to introduction of DNA into E. coli. For isolation of plasmid
DNA, the Fermentas GeneJET MiniPrep spin columns were used as per the
manufacturer’s protocol. For isolation of DNA fragments from electrophoresis gels, the
QIA QG buffer (Qiagen, California) was used for extracting DNA from gel fragments.
High fidelity pfu DNA polymerase was used to generate PCR fragments via the following
program (Hot start, 1 cycle @ 96 °C for 3 minutes, 30 cycles- 94 °C for 30 seconds,
lowest Tm-5 °C for 1 minute, 72 °C @ 1 min/1kb amplified DNA, 1 cycle 3 minutes @
72 °C). PCR fragments were ligated into PCR-Blunt-IITOPO vector (Invitrogen). For
cloning pChryOI, pChryOII, pChryOIII, pChryOIV the corresponding oxygenase genes
chryOI, chryOII, chryOIII, and chryOIV were amplified from cosChry1-1 cosmid DNA,
cloned into TOPO vector, then cut with XbaI/EcoRI and ligated into the exact sites of
pEM4 to give the expression vectors. For cloning pKC1139-chryA and pKC1139chryCMT, a ~3kb chryA or chryCMT fragment was ligated into the EcoRI/HindIII sites of
pKC1139 vector. A thiostrepton resistance gene, tsr, was amplified from pEM4 and
ligated into into a unique restriction marker in the middle of the target gene for
inactivation (chryA- XmaI, chryCMT- BglII). Plasmids used in this study are summarized
in Table 2.1. Primers used in this study are summarized in Table 2.3.

54

Table 1 Plasmids used in Chapter 2
Plasmid Name
pOJ446

cosChry1-1
cosChryF1
cosChryF2
cosChryF3
pEM4

pChryOI
pChryOII
pChryOIII
pChryOIV
PCR-Blunt-TOPO-II

Relevant Characteristics
Streptomyces-E. coli shuttle
vector for cosmid library
generation
Partial chrysomycin cluster
cloned into pOJ446
Partial chrysomycin cluster
cloned into pOJ446
Partial chrysomycin cluster
cloned into pOJ446
Partial chrysomycin cluster
cloned into pOJ446
E. coli-Streptomyces shuttle
plasmid that contains
ermE* for the expression of
genes in Streptomyces
chryOI cloned into pEM4
chryOII cloned into pEM4
chryOIII cloned into pEM4
chryOIV cloned into pEM4
Clone blunt PCR products

Reference
(127)

This work
This work
This work
This work
(128)

This work
This work
This work
This work
Invitrogen

Bacterial strains and culture conditions
Streptomyces albaduncus AD819 and Streptomyces lividans TK 24, and S.
lividans TK 24 (cosG9B3) and derivative strains were routinely cultivated and
maintained on M2 agarose plates (1.5% agar, 0.4% glucose, 1% malt extract, 0.4% yeast
extract, and 0.1% CaCO3). For production of spores, S. lividans TK 24 was grown on
M2 agar for 5-6 days until the production of white-grey spores was visible on top of the
mycelia, which were harvested by scraping with a toothpick then deposited in a sterile 1.5
mL Eppendorf-style tube, which were then immediately used for conjugation (see
Introduction of chry cosmids into Streptomyces lividans via Conjugation). For
production of metabolites, S. albaduncus or recombinant S. lividans (cosG9B3) and
derivative strains were grown in liquid SG medium (See Production and Isolation of
Gilvocarcin-related metabolites).
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For growth in liquid medium to prepare protoplasts or for genomic DNA, S.
albaduncus or S. lividans TK 24 were grown in 100 mL YEME media (0.3% yeast
extract, 0.5% bacto-peptone, 0.3% malt extract, 1% glucose, 10.3% sucrose, 1L) for 3-4
days at 28 °C in an orbital shaker (250 RPM). For protoplasts, 200μL MgCl2 (2.5M) and
2.5 mL Glycine (20%) were added to each 100 mL flask. Protoplasts were regenerated
on R2YE agar (10.3% sucrose, K2SO4 0.25 g/L, MgCl2 10.12 g/L, Glucose 1%,
Casaminoacids 0.1 g/L, Yeast extract 5 g/L, agar 15 g) (added to the solution after
autoclaving: KH2PO4 10 mL (0.5%), CaCl2 80 mL (3.68%), L-proline 15 mL (20%),
TES Buffer 100 mL (5.73%, adjusted to pH 7.2), Trace elements 2 mL, NaOH 5 mL
(1N)). All solutions were sterilized by autoclaving before usage.
Escherichia coli XL1 blue MRF cells (Stratagene) were used for routine cloning
procedures and propagation of plasmids and cosmid DNA. E. coli strains were grown in
lysogeny broth (LB) or LB agar containing appropriate antibiotics to select for
recombinant plasmids: (kanamycin 50 μg/mL; chloramphenicol 25 μg/mL; apramycin 50
μg/mL, and ampicillin 100 μg/mL) whenever necessary at 37 °C (in an orbital shaker,
250 RPM for liquid cultures). E. coli ET12567/pUZ8002 was used as a demethylating
strain for conjugation with Streptomyces sp.. S. albaduncus was used as a source of
genomic DNA. Strains generated and used in this study are summarized in Table 2.2.

Table 2 Bacterial strains used in Chapter 2

Strain Name
E. coli XL1-Blue-MRF

E. coli ET12567/pUZ8002
Streptomyces albaduncus
Streptomyces lividans TK
24
S. lividans (cosG9B3GilOI-)
S. lividans (cosG9B3-

Relevant Characteristics
Host for routine cloning
work and genomic library
construction
Host for conjugal transfer of
plasmids into Streptomyces
Chrysomycin wildtype
producer
Streptomyces host

Reference
Stratagene

Produces 56-59. S. lividans
with cosG9B3-GilOI
deleted cosmid.
Produces 56-59. pChryOIV

(130)
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(129)
(59)
(3)

This work

GilOI-)/pChryOIV
S. lividans (cosG9B3GilOII-)
S. lividans (cosG9B3GilOII-)/pChryOII
S. lividans (cosG9B3GilOIII-)
S. lividans (cosG9B3GilOIII-)/pChryOIII
S. lividans (cosG9B3GilOIV-)
S. lividans (cosG9B3GilOIV-)/pChryOIV

transformed into previous
strain
Produces 60, 61. S. lividans
with cosG9B3-GilOII
deleted cosmid.
Produces 39-41, 55.
pChryOII transformed into
previous strain.
Produces 39, 41. S. lividans
with cosG9B3-GilOIIIdeleted cosmid.
Produces 39, 40. pChryOIII
transformed into previous
strain.
Produces 54, 55. S. lividans
with cosG9B3-GilOIVdeleted cosmid.
Produces 39, 40.
pChryOIV transformed into
previous strain.

(68)

This work

(70)

This work

(130)

This work.

Table 3 Oligonucleotide Primers used in Chapter 2

Primer Name
chryOI_for
chryOI_rev
chryOII_for
chryOII_rev
chryOIII_for
chryOIII_rev
chryOIV_for
chryOIV_rev
chryA_ina_for
chryA_ina_rev
chryCMT_in_for
chryCMT_in_rev
Tsr_for
Tsr_rev
chryF_probe_for
chryF_probe_rev
KS_probe_for

Oligonucleotide Sequence
5’- CTGGTCTCTAGAGCTGGAGCCGGTCCGCCG
AGGAGGGCG -3’
5’- ATGTGCGAATTCGTCGGCCGGGACCGCACG-3’
5’-ATTCTAGACCACCCGTACCGAGCCAC-3’
5’-ATGAATTCCCCGTCGTCCGCCGCGCG-3’
5’-ATTCTAGAGACCCGTTCCCGCAGCTC-3’
5’-ATGAATTCGAACACGAAGGCTGTCGT-3’
5’-GCGGTTCTAGACCGCGCGCACCGGCTGCCCGGG-3’
5’-CCGGTGAATTCACAGGAATCCGATGGCGGT-3’
5’-CGCGAATTCCGACGCCGTACGGGAGCTGCT-3’
5’-CCAAAGCTTCCGTCCCGGCCGCCGGCCTGC -3’
5’-CGGAAGCTTTCGTCAACGCCGCCGT-3’
5’-GGCGCGAATTCGGGCGGCGAGGTC-3’
5’- CAGCCCGGGAGATCTTGATAAGGCGAATACTT
CATATG -3’
5’- TCGCCCGGGAGATCTGTGATCATCACTGACGAA
TCGAGGTCGAGGAAC -3’
5’-GCCCTVGTSACSGGNGGNACCAGY-3’
5’-GTTGCCVAGNCCGCCGCASACGTT-3’
5’-GTSTCSACSGGSTGYACSTCSGGS-3’
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KS_probe_rev
DH_probe_for
DH_probe_rev

5’-SCCGATSGCSCCSAGSGARTGSCC-3’
5’-CSGGSGSSGCSGGSTTCATSGG-3’
5’-CAGTGGTCSACGTGSAGCCACTCSCG-3’

Construction and Screening of S. albaduncus Genomic Library
Genomic DNA of S. albaduncus was isolated following standard protocol (3).
The genomic DNA was partially digested with Sau3AI, dephosphorylated with calf
intestinal phosphatase (CIP) and ligated to pOJ446 vector digested with BamHI and
HpaI. The ligation sample was transduced into E. coli XL1-Blue MRF using Gigapack III
XL packaging extract (Stratagene). A titering of 2300 colonies was obtained for the
library. Two sets of degenerate primers (a standard KS-probe-for and KS-probe-rev, and
a newly designed DH-probe-for and DH-probe-rev) were used to amplify the internal
nucleotide sequences of ketoacyl synthase (KSα) and NDP-D-glucose-4,6-dehydratase
from the genomic DNA of S. albaduncus. The amplified KSα fragment was labeled with
DIG and used to screen positive colonies. The positive colonies were further screened
with the NDP-D-glucose-4,6-dehydratase probe. Colony hybridization and southern blot
analyses revealed three cosmid clones for S. albaduncus genomic libraries. A probe
suited to detect a type II PKS-associated ketoreductase gene (gilF homologue) was also
constructed (chryF_probe_for and chryF_probe_rev) to probe for cosmids that contained
chryF. Three positively hybridizing colonies yielded cosmids cosChryF1, cosChryF2, and
cosChryF3. CosChryF2 demonstrated the most overlap with cosChry1–1 according to
the restriction analysis map. Thus, cosmids cosChry1–1 and cosChryF2 were selected for
sequencing.

Sequencing and annotation of the chry cluster
Sequencing of the cosmids was carried out involving a standard shotgun approach
using the HyperMu™ MuA Transposase kit (Epicentre) following the reported protocol
used by the sequencing facilities of the Advanced Genetic Technologies Center (AGTC)
located in the College of Agricultural Sciences of the University of Kentucky
(http://www.uky.edu/Centers/AGTC/). Phred/Phrap/Consed software package
(http://www.phrap.org.) was used to process and assemble raw sequence data into larger
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contigs. The small gaps between contigs were filled by primer walking. Frame plot
(http://www.nih.go.jp/~jun/cgi-bin/frameplot.pl) and ORF finder
(http://www.ncbi.nlm.nih.gov/projects/gorf/) were used to assign the open reading
frames. Functional assignments of ORFs were performed through database comparison
using BLASTX and BLASTN search tools on the server of the National Center for
Biotechnology Information, Bethesda, Maryland, USA (http://www.ncbi.nlm.nih.gov).
Introduction of chry cosmids into Streptomyces lividans via Conjugation
Cosmid DNA was introduced into S. lividans TK 24 via conjugation with E. coli
ET12567/pUZ8002 containing cosmids cosChry1-1and cosChryF2. The E. coli donor
was grown overnight supplemented with kanamycin 50 μg/mL; chloramphenicol 25
μg/mL; apramycin 50 μg/mL in a 7 mL culture tube. The cells were centrifuged, washed
twice with sterile LB, and resuspended in 500 μL of 2 x YT broth (1.6% tryptone, 1%
yeast extract, and 0.5% NaCl (pH 7.0)). S. lividans TK 24 spores were taken from a 5-6
day old M2 agar plate, scraped into 500 μL 2 x YT broth, heat shocked at 50 °C, placed
on ice for 5 minutes, and finally mixed with the E. coli donor cells. 200 μL aliquots were
plated on MS agar plates (mannitol 20 g/L, soya flour 20g/L, agar 20g/L, 10mM final
conc. MgCl2) and incubated at 28 °C for 24 hours before being overlaid with apramycin
(50 μg/mL) and nalidixic acid (100 μg/mL). Exconjugants were picked after 3-5 days of
incubation at 28 °C.

Production and Isolation of Gilvocarcin-related metabolites
For production of gilvocarcin-related metabolites, a small chunk of spores from a
3-5 day old M2 agar plate of S. albaduncus or S. lividans TK 24 (cosG9B3)-derived
strains was grown in 100 mL of Soytone-Glucose medium (Glucose 20 g/L, soy peptone
10g/L, CaCO3 2 g/L, CoCl2 1 mg/L) in a 250 mL baffled flask at 28 °C in an orbital
shaker (250 RPM) . This culture was supplemented with apramycin (50 μg/mL) and/or
thiostrepton (25 μg/mL) when appropriate. After 4-5 days, 25 mL of the culture was
collected in a 50 mL Falcon-style centrifuge tube, extracted with 25 mL ethyl acetate, and
centrifuged for 5 minutes at 3000 RPM. The EtOAc layer was pipetted off and collected
in a round bottom flask (RBF) and the organic solvent was dried in vacuo under reduced
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pressure conditions. The remaining yellow oil was dissolved in a small amount of
methanol, filtered through a 0.2 μm syringe-driven filter, and subjected to HPLC/MS and
UV-analyses. A linear gradient of acetonitrile and acidified water (solvent A = 0.1%
formic acid in H2O; solvent B = acetonitrile; 0–15 min 25% B to 100% B; 16–24 min
100% B; 25–26 min 100% to 25% B; 27–29 min 25% B) was used to separate
compounds. A Symmetry C18 (4.6 250 mm, 5 μm) column was used for analytical scale
separations. A flow rate of 0.5 mL/min was used for analytical scale separations.
Micromass ZQ 2000 (Waters) equipped with HPLC (Waters alliance 2695 model) and
photodiode array detector (Waters 2996) were used to analyze the compounds.
Atmospheric pressure chemical ionization (APCI) and Electrospray ionization (ESI)
probes were used to detect molecular ions.
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CHAPTER 3: IN VIVO STUDIES AND CLONING OF DEOXYSUGAR
CASSETTES DIRECTING BIOSYNTHESIS OF NDP-D-FUCOFURANOSE AND
NDP-D-VIRENOSE
INTRODUCTION
NDP-D-fucofuranose and NDP-D-virenose serve as integral structural moieties in
the activity of both gilvocarcin V (39) and chrysomycin A (42), respectively. Both are
characterized by being 6-deoxygenated sugars distinctive tailoring steps: ring contraction
to a furanose for NDP-D-fucofuranose and C-methylation for NDP-D-virenose (see
Figure 28). These sugars are relatively scarce in nature: NDP-D-fucofuranose is a
requisite component of E. coli O52 antigen, and NDP-D-virenose is present as a residue
of Coxiella burnetii phase I lipopolysaccharide (131-133). As such, both NDP-Dvirenose and NDP-D-fucofuranose both enhance the biological activity of these antigenic
polysaccharides through their interactions with host immune systems. Beyond this, the Lconfigurated fucofuranose is a key component of hygromycin B, and the structure
elucidation gilvocarcin V was the first example of a D-configurated fucofuranose (Figure
24). NDP-D-virenose is fairly unique among branched sugars, as most are 2’deoxygenated, e.g. NDP-L-mycarose, NDP-D-mycarose, NDP-L-axenose, and NDP-Lchromose B (134-136) (Figure 24).
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Figure 24 Structures of NDP-D-fucofuranose (97) and NDP-D-virenose (96).
Compared to NDP-activated furanose (NDP-L-fucofuranose 98) and branched pyranose
(NDP-L-axenose (99), NDP-D-mycarose (100), NDP-L-mycarose (101), and NDP-Lchromose B (102)) sugars.
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Common examples of branched sugar biosynthesis
The biosynthesis of branched-chain sugars involves specialized enzymes that
attach one or two carbon unit extensions using S-adenosyl methionine or pyruvate as
cofactors (137). Deoxysugars with single carbon extensions use C-methyltransferases
that catalyze nucleophilic attack of a corresponding NDP-activated deoxysugar enolate to
a +CH3 moiety of an enzymatically-bound S-adenosyl methionine cofactor (Figure 25).
This S-adenosyl methionine can be positioned above or below the NDP-4’-keto species
(si-face or re-face) which imparts the stereochemistry of the methyl group (Figure 25)
(137). An example of C-methylation catalyzed by the product of chryCMT is indicated in
Figure 25.
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Figure 25 SAM-dependent C-methylation by ChryCMT of NDP-4-keto-6-deoxy-Dglucose to afford 95.
Nature’s strategies for catalyzing pyranose-furanose transformations
Furanoses are scarce in polyketide pathways, but along with pyranoses, the
furanose conformation is energetically favored (64). The C-glycosidically linked Dfucofuranose of gilvocarcin V possesses all of the stereocenters of gilvocarcin, and it is
believed to be essential for binding to histone H3 (46, 64). As such, identification of the
enzymatic strategies that nature uses to contract pyranoses to furanose sugars, such as Dfucofuranose, merits some discussion. Primarily, most of the enzymes that are known to
catalyze furanose ring contraction are mutases, such as UDP-galactose mutase. This
enzyme catalyzes pyranose to furanose ring contraction of UDP-D-galactose in an FADdependent manner. (The crystal structure of K. pneumoniae UDP-galactose mutase was
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crystallized with 2.25 Ǻ resolution and bound flavin (FAD) by Beis et al.) (138) (Figure
26). The UDP-galactose mutase from Deinococcus radiodurans was crystallized to 2.36
Ǻ resolution with bound UDP-D-galactose by Partha et al. (139). The UDP-D-galactose
substrate is stabilized through interactions of the FAD 4-position oxygen with the C4hydroxyl of UDP-D-galactose, and several water molecules bond with conserved active
site residues to correctly position the sugar substrate: His88, Arg364, Tyr371, Asn372,
and His109 (139) (Figure 26).
These mutases are very similar with the recently characterized Fcf2, which
catalyzes the identical pyranose to furanose ring contraction for NDP-D-fucopyranose to
97 (131). Fcf2, unlike the UDP-galactose mutase enzymes, catalyzes ring contraction in
a cofactor-free manner (131). Furthermore, the 4-C-D-fucofuranose moiety of
gilvocarcin has been shown to rearrange from a furanose to pyranose ring in an acidcatalyzed manner, without the presence of a specific enzyme (140). However, this results
in a mixture of β- and α-connected fucopyranose moieties. The D-fucofuranose moiety of
For Streptomyces griseoflavus, it might be plausible that the NDP-D-fucose to NDP-Dfucofuranose ring contraction might occur in an enzymatically controlled fashion. For
the analogous reaction in Escherichia coli, it can be theorized that an internal basic amino
acid in Fcf2 performs the same catalytic role that the enzymatically-bound FADH- plays
in the galactose mutases. An amino acid residue could attack the anomeric carbon of
NDP-D-fucose, thereby causing opening of the ring oxygen. An internal base could
catalyze removal of the proton of 4-OH, therby allowing for a facile intramolecular attack
of the 4-alkoxide onto the enzymatically bound anomeric center, affording 97 (Figure
27).
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RESULTS AND DISCUSSION
Identification of gilL and gilN candidate genes for NDP-D-fucofuranose
biosynthesis
In the gilvocarcin pathway, several candidate enzymes for biosynthesis of 97 were
previously identified through bioinformatics analyses and inactivation experiments. GilD
and gilE were identified as encoding the enzymes NDP-glucose synthase and NDP-4,6dehydratase to catalyze transformation from D-glucose-1-phosphate (30) to NDP-Dglucose (31) and NDP-4-keto-6-deoxy-D-glucose (32), respectively (see Figure 28).
GilU was demonstrated to be a truncated ketoreductase involved in 4’-ketoreduction of
32 to afford NDP-D-fucose 103 (See Figure 28). GilU was previously inactivated in
cosG9B3 by Liu et al., and heterologous expression of the mutagenized cosmid resulted
in accumulation of 4’-hydroxygilvocarcins and defucogilvocarcins (72). Hydration of
NDP-4-keto-6-deoxy-D-glucose (32) resulted in a substrate that closely resembled the
putative NDP-D-fucose substrate of the ring contraction enzyme, and amazingly, both the
ring contraction and the glycosyltransfer of the surrogate NDP-4-hydroxy-D-fucose sugar
are carried out in vivo. The gilU-deleted mutant strain, S. lividans (cosG9B3-GilU-),
evinced important considerations about the deoxysugar biosynthesis of the Dfucofuranose moiety. The ring contraction enzyme and GilGT both demonstrate some
substrate flexibility towards a foreign donor substrate. However, disruption of gilU
caused detrimental downstream effects, in that unglycosylated defucogilvocarcins were
predominantly accumulated in this strain. Also, this strain was successfully used by
Shepherd, Liu et al. as a transformation host for flooding of the gilvocarcin pathway with
foreign deoxysugars, effectively resulting in polycarcin (53) and 4-C-β-D-olivosyl
gilvocarcin analogues (119).
The identity of the enzyme involved in ring contraction is currently unknown. The
gil cluster does not contain any Fcf2/UDP-galactose mutase-type candidates for the
contraction of NDP-D-fucose (98) to NDP-D-fucofuranose (97) (131). However, gilL and
gilN are two candidate ORFs whose encoded products could potentially be involved in
ring contraction of the sugar. Figure 27 illustrates that gilN encodes a hypothetical 297
amino acid glycosyltransferase that could catalyze ring contraction of the sugar in the
enzymatic pocket, then attach it to the 1-OH of the acceptor substrate. A subsequent
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Fries-like rearrangement by GilGT might result in the anticipated C-4 glycosylation. Or,
alternatively, the product of gilL, a putative 212 amino acid NAD-dependent
epimerase/dehydratase (similar BLAST description to gilU), may represent a novel sugar
ring-contraction enzyme. To clarify this question, both gilN and gilL had been previously
inactivated, but the resulting cosmids cosG9B3-GilN- and cosG9B3-GilL- have not been
successfully characterized through heterologous expression.
Generation of a G9B3-gilN- and G9B3-gilL- deletion cosmids and heterologous
expression
Previous work by Carsten Fischer and Lili Zhu had resulted in cosG9B3-derived
cosmids in which individual gil genes had been deleted via the PCR Redirect technology
(see Materials and Methods, Chapter 3). The resulting cosmids cosG9B3-GilN- and
cosG9B3-GilL- were introduced into Streptomyces lividans via a conjugation procedure
between S. lividans and E. coli ET12567/pUZ8002 (see Materials and Methods, Chapter
2). Despite screening several
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Figure 28 Biosynthetic pathways to NDP-D-fucofuranose and NDP-D-virenose.
transformants, S. lividans TK 24 (cosG9B3-GilL-) exconjugants were fermented in SG
media after 4-5 days and the methanolic extracts were chromatographed via HPLC/MS,
there was no difference in the production spectrum as compared to extracts of control
strain S. lividans TK 24 (pOJ446) with empty plasmid (See Materials and Methods,
Chapter 2). Conjugation was repeated with S. albus, which has been noted to be an
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optimal strain for heterologous production of antibiotic gene clusters as compared to S.
lividans, so the conjugation protocol was repeated using S. albus as transformation host.
Still, no heterologous expression of cosG9B3-GilL- could be achieved, likely owing to
poor cosmid utilization by the Streptomyces spp. hosts.
S. lividans TK 24 (cosG9B3-GilN-) was confirmed to lack a complete gilN gene
by amplification of the ~200 base pair FLP scar via colony PCR (Figure 29).
Exconjugants were fermented in 100 mL SG medium for 4-5 days, and methanolic
extracts were chromatographed via HPLC/MS to visualize the production pattern. This
strain was determined to be producing metabolites with a gilvocarcin chromophore. As a
result, this strain was cultured in 5 liters of SG media to isolate enough of the metabolites
for structural elucidation.
Structure determination of metabolites accumulated by S. lividans TK 24
(cosG9B3-gilN-) strain
Culturing of the gilN-deleted disruption strain encoding a putative
glycosyltransferase revealed metabolites with gilvocarcin chromophores (See Materials
and Methods, Chapter 3). Two metabolites with a gilvocarcin-type chromophore were
identified at Rt= 14.65 min-1 and Rt= 15.30 min-1, respectively. Low resolution ESI/MS
revealed a peak of 481 amu (-)ESI-MS mode for the metabolite with Rt= 14.65 min-1 and
a peak of 493 amu (-)ESI-MS mode for the metabolite with Rt= 15.30 min-1. A minor
product was identified with Rt=16.18 min-1, and it was identified as homorabelomycin
(55) via UV, mass, and identical retention time upon co-injection with standard
homorabelomycin. The identities of these metabolites were assigned via mass, UV, and
1

H-NMR spectral analysis. Because the anticipated metabolites of the gilN-deleted

mutant could have been structural isomers of 38 and 39 with C-glycosidically-linked
pyranose sugars instead of D-fucofuranose, it was necessary to isolate enough of the
compounds for structural elucidation.
The major compound was identified to be gilvocarcin V (39) based on identical
retention time to 39 as determined by co-injection with standard gilovcarcin V, identical
low resolution mass (493 amu [M-H] (-ve) mode), and analysis of the 1H NMR-coupling
constants of the sugar moiety (Figure 30 and Table 3.2). The 1’-H signal appeared as a
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doublet at δ 6.19 with J=5.5 Hz. The 2’-H (δ 4.67) and 3’-H (δ 3.86) both indicated an
integration of one proton and a multiplet splitting pattern. This resembles the trans-axial
splitting of the 2’-H and 3’-H signals of D-fucofuranose. Furthermore, the 4’-H appeared
at δ 3.51 as a doublet of doublets with J= 4.2, 5.9 Hz, and 5’-H was at δ 3.86 with a
multiplet splitting pattern. The 6’-CH3 was at δ 1.24 as a doublet with J= 6.5 Hz.
Because furanoses have a compact, “envelope” conformation, the coupling constants
between their protons are less than 7 Hz. The rest of the 1H-NMR signals corresponded
to the chromophore of gilvocarcin V when compared to published spectral data.
Furthermore, the yield of this metabolite was comparable to that of wildtype S.
griseoflavus and S. lividans (cosG9B3) (yield ~11.0 mg/L), therefore GilN appears to be
not involved in GV biosynthesis. Therefore, by process of elimination, it seems possible
that gilL could encode a novel NAD-dependent epimerase/dehydratase enzyme involved
in ring contraction of 103 to yield 97.
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Figure 29 1H-NMR spectrum of gilvocarcin V isolated from S. lividans (cosG9B3gilN-) (500 MHz).
Electrophoresis gel detailing colony PCR of ~200 base pair FLP scar from the gilNmutant.
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Figure 30 Structures of metabolites isolated from S. lividans (cosG9B3-gilN-).
The presence of chryL in the chry cluster might be more clear upon this hypothesis that
gilL might encode a putative ring contraction enzyme. Obviously, S. albaduncus does
not produce a C-glycosidically-linked furanose, but the Mercian strain that produces
furanose compounds, Mer-1020 dA (49) and Mer-1020 dD (52), may employ a
GilL/ChryL-like enzyme to ring contract the 4-keto-D-virenose moiety of the Mer-1020
dC and Mer-1020 dB compounds. Or, possibly, this occurs nonenzymatically and
spontaneously.
Construction of NDP-D-fucofuranose and NDP-D-virenose and intermediate-synthesizing
cassettes for in vivo interrogation of GTs
Previously, Salas et al. have demonstrated the ubiquity of cloning entire
deoxysugar operons onto single plasmids for in vivo overexpression experiments (39).
This approach has resulted in generation of novel tetracenomycins and steffimycins with
altered glycosylation patterns (141). However, this approach has mostly focused on 2,6dideoxygenated and 2,3,6-trideoxysugars, while only one construct exists with a 2’hydroxysugar encoding L-rhamnose (pRHAM) (39). Therefore, constructs which can
direct biosynthesis of NDP-D-virenose and NDP-D-fucofuranose might be useful for in
vivo glycodiversification. To investigate the role of the various NDP-D-virenose
biosynthetic genes in encoding biosynthesis of 96, and to evaluate the role of gilL in ring
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contraction of 97, constructs were generated directing the biosynthesis of these sugars
and their intermediates. For this, pUWL201PW and pEM4 were used for expression of
entire or combinations of the deoxysugar biosynthetic pathways. Both pEM4 and
pUWL201PW are Streptomyces spp. expression vectors that use the constitutive, strong
ermE* promoter to overexpress cloned genes (128, 142). For this, chryCMT was
amplified upstream of its putative ribosomal binding site and cloned into pEM4, to yield
pEN1. ChryGT was cloned into pEN1 to yield pEN2, and both of these constructs were
introduced into the S. lividans TK 24 (cosG9B3-GilU-) and S. lividans TK 24 (cosG9B3GilGT-) via protoplast transformation. The resulting transformants were screened for
their production of novel gilvocarcin-related compounds, however, unfortunately no new
metabolites were accumulated in these strains. This can be explained by the failure of
GilGT to accept a branched sugar donor, or the failure of the pEN1 construct to encode a
functional C-methyltransferase. Simultaneously, the failure of pEN2 may account for
ChryGT’s inability to accept five-membered sugar donors.
ChryGT was replaced by chryU in pEN2 to afford pEN3 for heterologous
expression in other pathways with NDP-glucose synthase and NDP-4,6-dehydratase.
Furthermore, a series of pUWL201PW constructs were prepared with an entire NDP-Dvirenose pathway. pUWL201PW affords a couple advantages: several unique cloning
sites for introduction of genes or combinations of genes, the aforementioned ermE*
promoter, and an optimized ribosomal binding site. First, ravDE were cloned into
pUWL201PW in the PstI/BamHI sites to provide NDP-glucose synthase and NDP-4,6dehydratase (construct pUWL-DE). RavDE have been proven to be functional through in
vivo heterologous expression of the ravidomycin gene cluster and through in vitro
characterization of their ability to produce NDP-4-keto-6-deoxy-D-glucose (30, 143).
Cloning of chryCMT afforded pKVIR and addition of chryU afforded pVIR*II. pKVIR
is intended to biosynthesize NDP-4-keto-D-virenose (95), while pVIR*II is intended to
biosynthesize NDP-D-virenose (96).
A series of constructs intended to encode NDP-D-fucofuranose biosynthetic genes
were prepared. GilU was cloned into a unique site of pUWL-DE to afford pFUCO,
which should biosynthesize NDP-D-fucose (103) in vivo. GilL was cloned into this
construct to afford pFUCOII, which should encode NDP-D-fucofuranose biosynthesis
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(97). All together, these constructs potentially biosynthesize rather unique 2-hydroxy-6deoxysugars that are not encoded in many biosynthetic pathways. Furthermore, they
might prove useful in interrogating the substrate flexibility of glycosyltransferases in
other polyketide-producing organisms.

SUMMARY
In this chapter, gilL and gilN were both studied as potential candidates for the ring
contraction step of D-fucofuranose, gilL encoding an NAD-dependent
epimerase/dehydratase and gilN encoding a putative glycosyltransferase. Subsequent
inactivation of gilN in cosG9B3, and expression of this deleted cosmid, resulted in
production of gilvocarcin V and M, which were verified by co-injection with standard 39
and 40, mass, UV, and 1H-NMR spectral characterization. Furthermore, production of
gilvocarcin V in this strain was close to wildtype yields (~11.0 mg/L), which indicates
that gilN plays no role in gilvocarcin biosynthesis. GilL, then, appears to be a likely
candidate for ring contraction. Like gilU, gilL demonstrates similarity to NADHdependent epimerases/dehydratases, and its similarity to chryL might indicate a common
ring contraction enzyme in both S. griseoflavus and the Mercian strain. As heterologous
expression of cosG9B3-gilL- was not possible, A number of different constructs were
prepared with genes implicated in biosynthesis of NDP-D-fucofuranose and NDP-Dvirenose.
EXPERIMENTAL
Table 4 Bacterial strains and plasmids used in Chapter 3
Strain/Plasmid Name
Strains
S. lividans TK 24
(cosG9B3-GilN-)
Plasmids
pET-28a(+)

pUC19

Relevant Characteristics

Reference

Produces 39 and 40. S.
lividans with cosG9B3GilN-deleted cosmid.

This work.

KmR. E. coli protein
expression vector. Used for
subcloning.
AmpR. E. coli cloning
vector.

Novagen.
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Stratagene.

pUWL201PW

pEM4

pEN1

pEN2

pEN3

pFUCO

pFUCOII

pKVIR

pVIR*II

AmpR, TsrR. E. coliStreptomyces shuttle vector.
Used to overexpress genes
under ermE* promotion.
AmpR, TsrR. E. coliStreptomyces shuttle vector.
Used to overexpress genes
under ermE* promotion.
AmpR, TsrR. chryCMT
cloned under ermE* in
pEM4. Intended to produce
NDP-4-keto-D-virenose in
strain with endogenous
NDP-glucose synthase &
4,6-DH.
AmpR, TsrR. chryCMT and
chryGT cloned under
ermE* in pEM4. Intended
to produce NDP-4-keto-Dvirenose and ChryGT in
strain with endogenous
NDP-glucose synthase &
4,6-DH.
AmpR, TsrR. chryCMT and
chryU cloned under ermE*
in pEM4. Intended to
produce NDP-D-virenose in
strain with endogenous
NDP-glucose synthase &
4,6-DH.
AmpR, TsrR. gilU, ravDE
cloned under ermE* in
pUWL201PW. Intended to
produce NDP-D-fucose.
AmpR, TsrR. gilLU, ravDE,
cloned under ermE* in
pUWL201PW. Intended to
produce NDP-Dfucofuranose.
AmpR, TsrR. chryCMT,
chryDE cloned under
ermE* in pUWL201PW.
Intended to produce NDP4-keto-D-virenose.
AmpR, TsrR. chryCMT,
chryU, ravDE cloned under
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(144)

(145)

This work.

This work.

This work.

This work.

This work.

This work.

This work.

ermE* in pUWL201PW.
Intended to produce NDP-Dvirenose.
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Figure 31 DNA electrophoresis gels of D-fucofuranose and D-virenose constructs.
(Upper) Plasmid maps of pFUCO, pFUCOII, pVIR*II. (Lower Left) NdeI/HindIII digest of
pVIR*II. (Lower Middle) HindIII/BamHI digest of pFUCO. (Lower Right) NdeI/HindIII
digest of pFUCOII.
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Table 5 Physico-chemical characterization of metabolites of S. lividans (cosG9B3-GilN-)
strain
OH OCH3
OCH3
H3C
HO
HO

O
O

O

HO

Gilvocarcin V (39)
Rrel= 15.30 min-1; Yield: 11.0 mg/L
MW= 494 g/mol (C27H28O9)
Negative mode APCI-MS: m/z=493 [M-H] (low res)
UV maxima (from HPLC-diode array): 250 (90%), 287 (100%), 398 (35%)
Position

Gilvocarcin V (39)
δH (500 MHz)

1-OH
9.71 (1H, s)
2-H
6.95 (1H, d, J=8.5)
3-H
8.06 (1H, d, J=8.5)
7-H
7.99 (1H, d, J=2.0)
9-H
7.76 (1H, s)
10-OCH3
4.19 (1H, s)
11-H
8.48 (1H, s)
12-OCH3
4.12 (1H, s)
6.19 (1H, d, J=5.5)
1′-H
4.67 (1H, m)
2′-H
3.86 (1H, m)
3′-H
3.51 (1H, dd, J=4.2, 5.9)
4′-H
3.86 (1H, m)
5′-H
1.24 (1H, d, J=6.5)
6′-CH3
1”-H
6.94 (1H, dd, J=18.0, 11.0)
2”-He
5.50 (1H, d, J=11.0)
2”-Hz
6.14 (1H, d, J=18.0)
a)
Dimethyl sulfoxide-d6, J in Hz
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Table 6 Oligonucleotides used in Chapter 3

Primer Name
chryCMT_XbaI_
for
chryCMT_NdeI_
for
chryCMT_SpeIE
coRI_rev
chryU_SpeI_for
chryU_EcoRI_re
v
chryGT_SpeI_for
chryGT_EcoRI_r
ev
chryDE_PstI_for
chryDE_BamHI_
rev
gilU_HindIII_for
gilU_EcoRI_rev
ravDE_PstI_for
ravDE_BamHI_r
ev
gilL_NdeI_for
gilL_HindIII_rev
gilN_FRT_for

gilN_FRT_rev

gilN_ctrl_for
gilN_ctrl_rev

Oligonucleotide Sequence
5’- ATTTCTAGACCTTCCCGACGCCCCGTG-3’
5’- ATTCATATGCCTTCCCGACGCCCCGTG-3’
5’- ATTGAATTCTACTAGTGCGGCGGCG GGGTGC-3’
5’-ATACTAGTCGGAATGCCGACAACT-3’
5’-GTCGAATTCGAGGTCTCCTCGGATCG-3’
5’- ATACTAGTGCTAGCACGGCGGCGCCG TTTCC-3’
5’-ATGAATTCAGGCGGGAGCAGGCGGG -3’
5’-ATCTGCAGTTTGTCCACGCTGTTGTTT-3’
5’-TTCGGATCCAATGCCCTATGCGAT-3’
5’- ATAAGCTTGCAGTGAGGCACTC CTGTCGTC -3’
5’-ATGAATTCCGGCCTGGGTCTTTTGT CGTTC -3
5’-GTTCTGCAGTCC GCAGTGAATTCC CGG -3’
5’-TTA AGGATCCGAGATGAGTGCGCACCCA-3’
5’- ACCATATGAAAGTAGCAGTGCTCGGT-3’
5’- ACAAGCTTGACACACGTGTCCCTGGT-3’
5’CGTCAGCGGAGCAGCCGGGTGGAGTGGGGTGAGGGCATG
ATTCCGGGGATCCGTCGACC -3’
5’CCTCGTTCTCTTCTGCCGCCGCGTTCGCCCTTCGGGTCATG
TAGGCTGGAGCTGCTTC -3’
5’-CTGTTCGTGTGGGGCGGG-3’
5’-TCGCCGCCGCGGCCCGGTCCGCA -3’

Isolation of metabolites from S. lividans TK 24 (cosG9B3-GilN-)
For the isolation of substantive amounts of the major metabolite from S. lividans
TK 24 (cosG9B3-GilN-), a 5 liter fermentation of the organism in SG media was carried
out in a two stage fermentation process. In brief, a glycerol stock of S. lividans TK 24
(cosG9B3-GilN-) was thawed and 100 μL of the revived strain was plated on an M2 agar
plate supplemented with 50 μg/mL apramycin and incubated at 28 °C for 5 days. In a
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first stage growth phase, spores of this organism were inoculated into a 100 mL flask of
sterilized SG media in a 250 mL baffled flask, and this flask was incubated in an orbital
shaker for 3 days (250 RPMs, 28 °C). For the production phase, five liters of sterilized
SG media was apportioned in 500 mL amounts in 10 baffled 2 liter Erlenmeyer flasks.
This media was supplemented with 50 μg/mL apramycin and 5% (v/v) of the culture
from the growth phase flask was inoculated into each of the production phase flasks.
This fermentation was carried out for five days. The culture was collected, filtered with
celite (50 g/L fermentation), and the resulting mycelial cake was extracted twice with
acetone, dried in vacuo under reduced pressure, and the rest of the aqueous phase was
dried by lyophilization. The culture filtrate was passed over a 5 × 10 cm C18 reverse
phase silica column, washed with water, and the retained material was eluted in a
gradient of 20%, 40%, 60%, 80%, and finally 100% MeOH:H2O. The major metabolites
were mostly eluted in the 80% and 100% gradients of MeOH. The fractions containing
gilvocarcins were compiled, the solvent was dried in vacuo, and the water was removed
by lyophilization on a freeze drier.
The individual peaks were resolved via semi-preparative high-performance liquid
chromatography (HPLC) on a Sun-Fire semi-prep C18 column (19×150 mm, 5 μm) on a
Waters 1525 EF platform with a Waters 2487 dual absorbance detector UV lamp. A
gradient of 0.2% formic acid in double distilled water and acetonitrile was used (Solvent
A= 0.2% formic acid in water, solvent B=acetonitrile; 0–15 min 25% B to 100% B; 16–
24 min 100% B; 25–26 min 100% to 25% B; 27–32 min 25% B, flow rate 2.5 mL/min).
The eluted material under each peak was collected, dried in vacuo, and finally
lyophilized. Sample purity was verified via HPLC/MS analysis to assure the presence of
a single peak. The sample was further dried under nitrogen gas for 2-3 hours, and finally,
dissolved in DMSO-d6 for 1H-NMR measurements. NMR was recorded on a Varian
VNMR 500 MHz spectrometer.
PCR Redirect inactivation of gilN and conjugal transfer of cosG9B3-gilNThe disruption cassette for inactivation of gilN was amplified using a
chloramphenicol resistance template and 59-nucleotide long primers gilN_FRT_for and
gilN_FRT_rev (see Table 3.3). The boxed-in regions of the primers indicate genetic
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regions of 39 base pairs directly upstream and downstream of the gilN ATG start codon
(gilN_FRT_for) and the gilN TGA stop codon (gilN_FRT_rev), respectively, and the 20
nucleotides that are not boxed-in bind to the chloramphenicol resistance cassette. The
cassette was introduced into E. coli BW25113/pKD20, containing cosmid G9B3 (Aprresistant), which encodes all of the genes for gilvocarcin biosynthesis in Streptomyces sp.
The disrupted cosmid (cosG9B3-CHL-gilN-), containing the chloramphenicol resistance
cassette, was introduced into E. coli XL-Blue MRF’/pcp20. This E. coli strain harbors an
FLP-recombinase gene that recognizes genetic sites on both sides of the gilN-CHL
genetic locus of cosG9B3-CHL-gilN-, and it excises this genetic locus resulting in an inframe 81 base pair scar. AprR, ChlS sensitive colonies were identified by replica plating
and verified by PCR analysis using a pair of control primers that amplify a region~100
base pairs upstream and downstream of gilN, gilN_ctrl_for and gilN_ctrl_rev (see Table
3.3). While the original gilN PCR products from cosG9B3 showed products of 966 base
pairs, after FLP-mediated excision of the disruption cassette, a PCR product of ~250 bp
was obtained (Table 3.3). CosG9B3-gilL- was generated in a similar fashion. The
mutated cosmids cosG9B3-gilL- and cosG9B3-gilN- were introduced into Streptomyces
lividans TK24 by conjugation from E. coli ET12567 carrying the non-transmissible
helper plasmid pUZ8002 as described by Kieser et al. (3)
Cloning of 6-deoxy-2’-hydroxy-hexose biosynthesizing plasmids
For the generation of plasmids that could direct the biosynthesis of NDP-Dfucofuranose and NDP-D-virenose, the various genetic components of their biosyntheses
were amplified via polymerase chain reaction using cosChry1-1 and cosG9B3 as
templates (Figure 30). Pfu polymerase was used to amplify genes from template DNA
as described in chapter 2, except for gilU, which was cloned with Taq polymerase, blunt
ended, then cloned into TOPO vector. All PCR products were ligated into TOPO cloning
vector following the manufacturer’s protocols. ChryCMT was amplified from cosChry11 with two sets of forward primers and reverse primers, one pair for incorporating
XbaI/EcoRI restriction sites and one pair for incorporating NdeI/HindIII restriction sites,
for pEM4-based and pUWL201PW-based cloning, respectively. TOPO-chryCMT was
digested with XbaI/EcoRI and ligated into the same sites of pEM4 downstream of the
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ermE* promoter to give pEN1. This resulting construct was digested with SpeI/EcoRI
for ligation of chryGT to yield pEN2. For pEN3, chryGT was digested out with
SpeI/EcoRI and chryU was ligated into the same restriction sites. For vectors with an
enhanced ribosomal binding site and for expressing entire NDP-D-fucofuranose and
NDP-D-virenose biosynthetic pathways, pUWL201PW was chosen. RavDE and chryDE
were amplified independently, cloned into TOPO vector, and digested with PstI/BamHI
and ligated into a unique restriction site downstream of the ermE* promoter of
pUWL201PW to give pUWL(chryDE) or pUWL(ravDE). TOPO-chryCMT(NdeI) was
digested with NdeI/EcoRI and ligated into the same sites of pET-28a(+) to give pET28a(+)-(chryCMT). ChryU was ligated into the SpeI/EcoRI site of this vector, to yield
pET-28a(+)-(chryCMT+chryU), which was then digested with NdeI/HindIII to give a
~2.4 kb chryCMT-U band, which was then rescued and ligated into the NdeI/HindIII sites
of pUWL(ravDE) to afford pVIR*II. ChryCMT from pET-28a(+)-(chryCMT) was
digested out and ligated into the NdeI/HindIII sites of pUWL(chryDE) to give pKVIR.
Digestion of gilU with HindIII/EcoRI from TOPO-gilU and subsequent ligation of it into
pUWL(ravDE) afforded pFUCO. pFUCOII was generated by ligation of gilL cut with
NdeI/EcoRI into pFUCO in the same sites.
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CHAPTER 4: ALTERING THE GLYCOSYLATION PATTERN OF
TETRACENOMYCINS
INTRODUCTION
Tetracenomycin C (8) and elloramycin (106) are anthracycline-like polyketides
produced by Streptomyces glaucescens and Streptomyces olivaceus Tü 2353.
Tetracenomycin C was discovered by Weber et al. in 1979, and elloramycin was
discovered and its structure solved by Rohr et al. in 1985 (146-147). The cloning of the
biosynthetic gene loci for 8 and 106 by Hutchinson et al. paved the way for further
characterization of the enzymatic components for these compounds, and polyketides as a
whole (148-149) The biosynthesis of these molecules was fundamental for
understanding the role individual enzymes in polyketide synthesis and establishing
minimal gene sets for cyclization/aromatization (150-153). The biosynthesis of 8 and
106 was found to have tetracenomycin B3 as a branching point between them, in the case
of elloramycin having 8-O-rhamnosylation by ElmGT and in the case of tetracenomycin
C 8-O-methylation by TcmN (Figure 32) (154).
The minimal PKS consisting of ElmKLM installs the poly-β-ketothioester, which
is cyclized by ElmNI, J, and I to afford tetracenomycin F1 (Figure 32). ElmH installs
the quinone oxygen, and ElmG is a novel monooxygenase-dioxygenase that catalyzes the
triple hydroxylation of tetracenomycin A2 to afford tetracenomycin C (8) (155). The 4and 12a- oxygens are installed stepwise from molecular diatomic oxygen, while the 4aoxygen is installed from attack of water onto the oxirane. In the process, the aromaticity
of the D ring of tetracenomycin is broken, thereby resulting in a hypsochromic shift in the
UV spectrum from ~450 nm (e.g. red anthraquinones TCM B3 and D3) to ~412 nm (e.g.
yellow 8-DMTC, 105). In the biosynthesis of elloramycin, ElmGT glycosylates 8-O
position of 105 with L-rhamnose, and subsequent O-methylations of the 2’, 3’, and 4’-OH
positions of the L-rhamnose moiety by ElmMI, ElmMII, ElmMIII, and O-methylation of
the 4a-OH by ElmD (Figure 32)(126, 156).
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ElmGT is one of the most flexible glycosyltransferases in secondary metabolism
Cos16F4 was hypothesized to harbor a sugar flexible glycosyltransferase after it
was heterologously expressed in the mithramycin producer, S. argillaceus, and the
urdamycin producer, S. fradiae (157). When expressed in PKS-deletion mutants of both
producing strains, D-olivosyl (107), L-rhodinosyl (116), D-mycarosyl (108), and Dolivosyl-1,3-D-olivosyl (109) tetracenomycin analogues were accumulated in the
fermentations of these recombinant organisms (Figure 33) (157-158). Furthermore,
these derivatives were produced in a S. argillaceus mutant in which all four
glycosyltransferases were inactivated, thereby indicating that the glycosyltransferase
responsible for the sugar transfer was encoded on cos16F4 (157). The identification of
the 1149 nucleotide sequence for elmGT enabled new experimentations regarding
deoxysugar biosynthesis.
Salas et al. expounded upon the cosmid expression experiments of Rohr et al. by
cloning accessory plasmids that encoded deoxysugar biosynthetic genes into a single
combinatorial operon. By cloning genes from the oleandomycin biosynthetic pathway, Loleandrose biosynthetic genes were sequentially cloned into plasmid “pLN2” and
successfully co-expressed with cos16F4 to afford L-olivosyl tetracenomycin C (113) and
several congeners (e.g. 114,Figure 33) that were O-methylated by the ElmMI, ElmMII,
and ElmMIII O-methyltransferases (Figure 32) (39, 159). By deleting the oleV (2,3dehydratase) and oleW (3-ketoreductase) genes from this construct resulted in pLN2Δ or
pRHAM plasmids (e.g. NDP-L-rhamnose biosynthesis) that when co-expressed with
cos16F4 in S. lividans restored production of elloramycin A (106) (39). These initial
experiments revealed remarkable flexibility of the deoxysugar biosynthetic genes oleL
(3,5-epimerase) and oleU (4-ketoreductase) in accepting both NDP-4-keto-2,6deoxyhexose and NDP-4-keto-6-deoxyhexose intermediates. Furthermore, it proved that
deoxysugar biosynthetic genes could be cloned into a single operon for heterologous
overexpression in a foreign host. These experiments demonstrated that ElmGT had
unprecedented substrate flexibility towards foreign D- and L-configurated deoxysugar
donor substrates. Furthermore, substrate flexibility on behalf of the deoxysugar
biosynthetic enzymes revealed that it would be possible to exploit the “plug and play”
construction of pLN2 to incorporate other genes that would alter the stereochemistry of
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deoxysugars produced in vivo. Taken together, these results yielded a platform in which
the substrate flexibility of ElmGT could be interrogated and different deoxysugar
constructs could be assayed for their ability to produce novel glycosylated
tetracenomycins.
This proof of concept yielded many other deoxysugar constructs that produced
novel tetracenomycin derivatives (107-120), which were able to be characterized via
mass, UV, and various 1H, 13C, and 2D NMR spectroscopic analyses (Figure 32) (39,
160-163). Unfortunately, the antitumoral activity of many of these compounds was
worse than 106, with the exception of 118, which exhibited GI50 values in several breast
(MDA-MB-231), NSCL (A549), and colon (HT-29) cancer cell lines of below 10-5 molar
concentrations in the sulforhodamine B cytotoxicity assay (162). Very likely, the
presence of a C-3’-methyl branch on the α-L-mycarose moiety is partly responsible for
the slightly improved cytotoxicity of this derivative.
Surprisingly, accumulation of 113 in the culture broth of S. lividans
(cos16F4)/pRHAM indicated that ElmGT could accept NDP-D-glucose (30) as a donor
substrate (163). This was surprising because many glycosyltransferases involved in
polyketide biosynthesis discriminate against nondeoxygenated sugars, such as NDP-Dglucose (30). Instead, 6-deoxygenation appears to be a structural pre-requisite before
many glycosyltransferases will bind a sugar donor substrate, even though NDP-D-glucose
is present as an intermediate in many biosynthetic pathways. Interestingly, NDP-D-oliose
(35) was never transferred by ElmGT, neither when a sugar plasmid directing its
biosynthesis was introduced, nor when cos16F4 was heterologously expressed in S.
argillaceus, which produces NDP-D-oliose endogenously (158, 160). As such, 111 is the
only example in which a D-configurated sugar with an axial 4-OH has been transferred by
ElmGT; the axial 3-OH may force it to have a slight conformational change in the active
site that allows it to bind. One other “limitation” of ElmGT appeared to be its apparent
inability to transfer ketosugars; one plasmid, pRHAMΔU, which directs NDP-4-keto-Lrhamnose biosynthesis, did not result in any glycosylated tetracenomycins when it was
co-expressed with cos16F4. Recently, mutation of active site residues of ElmGT has
been shown to modulate transfer of specific deoxysugars (164).
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Figure 33 Elloramycin analogues generated by combinatorial biosynthesis.
Previously reported differentially glycosylated derivatives of 8-demethyl tetracenomycin
C (105). ElmGT demonstrates remarkable substrate flexibility to a variety of L- and Dconfigurated NDP-deoxysugar donors (107-120).
Aminosugars: their importance for glycodiversification, bioactivity, and solubility
Incorporation of aminosugars into a glycosylated antibiotic is one important
strategy for altering its bioactivity through glycodiversification. Aminosugars are
88

important for the bioactivity of many antibiotic compounds. Among the foremost of
these are the aminoglycosides, such as kanamycin and neomycin, which are broad
spectrum antibiotic agents that bind to the 30S subunit of the ribosome of bacteria. The
biosynthesis of these important antibiotics features generation of a diversity of
aminosugars and specialized glycosyltransferases that catalyze their attachment. Being
that these compounds are purely carbohydrate derived, they are highly soluble in water
and can be packaged as a salt.
Macrolides, such as methymycin (3) and erythromycin A (7), employ an
aminosugar, NDP-D-desosamine, which enables binding to the 30S subunit of the
ribosome as a mechanism of action (165). NDP-D-desosamine is a particularly intriguing
aminosugar, from the standpoint that it is 4-deoxygenated. The desosamine biosynthetic
pathway has been studied extensively by the Hung-wen Liu group, and it was
demonstrated that NDP-4-keto-6-deoxy-D-glucose (32) is the substrate for a novel PLPdependent 4-aminotransferase, DesI, which generates TDP-4-amino-4,6-dideoxy-Dglucose (121), which is then oxidatively deaminated by DesII to afford TDP-3-keto-4,6dideoxy-D-glucose (122), which undergoes PLP-dependent 3-amination by DesV to
afford TDP-3-N,N-didemethyl-D-desosamine (123) (Figure 34) (166-170).
Medermycin is a member of the benzoisochromanequinone family of polyketides,
and its only distinguishing characteristic is the C-glycosidically linked aminosugar Dangolosamine. It has activity against gram positive bacteria, and like 123, possesses a
dimethylamino functionality at 3-position, in the case of 123 3,4,6-trideoxygenation and
in the case of 124 2, 3, 6-trideoxygenation (Figure 34). The dimethylamino functionality
is important for converting the amine functionality into a tertiary amine, which is
potentially useful for the formation of a quaternary ammonium cation in solution. In the
biosyntheses of both 123 and 124, a keto group is the handle for transamination: for 123,
the 3-keto group from 2,3 dehydration by Med16, and in the case of 124, the 4-keto
group of NDP-4-keto-6-deoxy-D-glucose and the resulting 3-keto group from DesII
deamination of 121 (Figure 34).
Daunorubicin (25) and doxorubicin (26) are canonical polyketide anticancer
drugs. Central to their activity is the α-glycosidically linked L-daunosamine residue (126,
Figure 34), that is responsible for positioning these drugs within the minor groove of
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DNA (171). The L-acosamine sugar (125) of 4’-epidoxorubicin (epirubicin) affords this
drug with faster clearance, and as a result, it evinces lessened cardiotoxicity as compared
to 26. Hutchinson et al. were able to genetically engineer a 4’-epirubicin-producing
strain of S. peucetius 29050 by inactivating the host 4-ketoreductase, dnmV, and
integrating a copy of the equatorial-reducing 4-ketoreductase, avrE, into the chromosome
(171) (Figure 34). This experiment demonstrated the ubiquity of
inactivating/recombining deoxysugar biosynthetic genes to steer flexible
glycosyltransferases towards accepting alternate sugar donors.
As a result, constructs pertaining to the biosynthesis of 121-127 were previously
cloned by Madan Kharel and Tao Liu, yet the functionality of these plasmids to encode
successful aminosugar synthesizing pathways had not successfully been addressed. One
of the aims of this present work is to individually transform each of these aminosugar
plasmids into S. lividans (cos16F4) in an effort to interrogate ElmGT’s ability to transfer
sugar donor intermediates that may be accumulated in these recombinant strains
(Chapter 4 Experimental).
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RESULTS AND DISCUSSION
Reconstitution of cos16F4 8-demethyl tetracenomycin C heterologous production
Previously in the Rohr lab, S. argillaceus (MtmPKS-)/cos16F4 and S. fradiae
(UrdA-)/cos16F4 strains were generated by heterologously expressing cos16F4 in
vivo(172). However, no glycerol stock for the S. lividans (cos16F4) strain used by Salas
et al. for co-expression of “sugar plasmids” along with elm biosynthetic machinery was
available. Moreover, it was necessary to re-establish a producing strain for co-expression
experiments. The advantage of using S. lividans as a host strain for heterologous
expression of cos16F4 is that it possesses no overt deoxysugar biosynthesis of its own,
therefore, expression of cos16F4 in S. lividans results in accumulation of the aglycone, 8demethyl tetracenomycin C. Therefore, it was envisioned that cos16F4 could be
transformed efficiently via either protoplast transformation or electroporation. Because
cos16F4 is a pKC505-derived vector, it lacks the necessary oriT for conjugation with E.
coli ET12567/pUZ8002, as was used to transform the cosmids in Chapter 1 (Materials
and Methods). Therefore, protoplasts of S. lividans TK 24 were prepared and
transformed with cos16F4 DNA. Several days later, thirteen colonies expressing the
AprR were selected and plated on an M2 agar plate supplemented with apramycin. One
colony exhibited excellent growth and a dark red-orange pigmentation, and this colony
was fermented in 100 mL SG media supplemented with apramycin. After four days, this
strain was extracted with EtOAc, and the extract had a characteristic red-orange hue. To
this end, 20 μL of this methanolic extract was analyzed by HPLC/MS and a single peak
eluting at Rt=12.0 min-1, with a characteristic UV absorption of the tetracenomycins (UV
(MeOH) λmax at 212, 289, 412 nm) (Figure 35). The compound demonstrated a parent
fragmentation of 459 amu [M-H] (ESI-MS (–ve) mode, Figure 35) which was consistent
with the reported mass/UV spectra for 8-demethyl tetracenomycin C. Furthermore, the
extract exhibited strong blue fluorescence when exposed 360 nm UV light. This strain, S.
lividans (cos16F4) was saved for further transformation experiments with deoxysugar
cassettes.
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Figure 35 (Upper) HPLC Chromatogram trace of S. lividans (cos16F4)
methanolic extract, 8-demethyl tetracenomycin C (105) Rt=12.0 min-1. (Lower) ESI-MS
(low res) [459 amu, M-H] (–ve) mode of 105. Characteristic UV-vis of 8-demethyl
tetracenomycin C (105).
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Heterologous expression of aminosugar and 2’-hydroxysugar synthesizing
cassettes
Previously, constructs directing the biosynthesis of NDP-D-angolosamine and
NDP-3-N,N-didemethyl-D-desosamine were cloned using the strong constitutive ermE*
promoter of pEM4 (Chapter 2, Table 2.1; Chapter 4, Table 4.1). The desosamine
biosynthetic genes were cloned sequentially into pEM4 by Dr. Kharel, synthesizing three
cassettes that would biosynthesize 121-123 (Dr. Kharel, Unpublished Results). pDesI
contains desIII, desIV, and desI and should biosynthesize aminosugar 121; pDesII
contains desIII, desIV, desI, and desII and should biosynthesize 3-ketosugar 122; pDesIII
contains desIII, desIV, desI, desII, and desV and should synthesize didemethyl NDP-Ddesosamine. pDmnI was made by replacing the oleW 3-ketoreductase gene of pLN2 with
the daunosamine 3-aminotransferase, dnrJ, and it was anticipated to encode biosynthesis
for 125. For biosynthesis of 126, NDP-L-daunosamine, a gene complement of dnrJUV
was substituted for the oleWLU 3-ketoreductase, 3,5-epimerase, and 4-ketoreductase
genes of pLN2. The incorporation of these genes should afford 3-transamination, 3,5
epimerization, and axial 4-ketorduction to yield 126.
Upon transforming each of these constructs independently into the S. lividans
(cos16F4) strain, and analyzing methanolic extracts of the transformants, most of these
strains failed to accumulate glycosylated tetracenomycins. Most likely, ElmGT is
incapable of transferring aminosugars. As an alternative explanation, the aminosugar
plasmids may not synthesize the intended aminosugars in vivo. Surprisingly, in extracts
of S. lividans (cos16F4)/pDmnI, an additional peak with Rt= 15.7 minutes was
accumulated, in addition to 105 (Figure 36). This peak demonstrated a parent
fragmentation of 659 amu in (-ve) ESI-MS mode, which corresponds to the mass of
elloramycin A (106). No other glycosylated tetracenomycins could be identified in these
extracts when investigating the UV spectrum at 385 nm wavelength. This finding can be
explained because pDmnI also contains oleSELU, which are the gene complement of the
pRHAM plasmid that is known to produce NDP-L-rhamnose in vivo (39). OleLU
demonstrate flexibility towards both NDP-6-deoxyhexoses and NDP-2,6-deoxyhexoses.
The deletion of oleLU and replacement of these genes with dnrJUV in pDmnII
effectively eliminated this NDP-L-rhamnose pathway, as 106 was not accumulated in that
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strain. The failure to accumulate tetracenomycins with appended aminosugars is not
unusual, as there are virtually no examples of glycosyltransferases in secondary
metabolism that show flexibility towards aminosugar donors that do not already bind an
aminosugar donor as a natural substrate. Recently, in the S. venezuelae pikromycin
biosynthetic pathway, the DesVII desosaminyltransferase responsible for transferring
NDP-D-desosamine to its macrolide aglygones was found to require the co-expression of
DesVIII in order to form a catalytically active glycosyltransferase (173). Without
DesVIII, DesVII was catalytically inactive, however, when co-expressed with DesVIII
then separated, DesVII was catalytically active. The erythromycin, doxorubicin, and
tylosin biosynthetic pathways all possess candidate ORFs for such aminosugar
glycosyltransferase auxillary proteins: EryCII, DnrQ, and TylM3 (173). Very likely
aminosugar glycosyltransferases require these chaperone proteins for proper folding; the
one glycosyltransferase where this does not appear to be the case is RavGT, which can
transfer both NDP-D-fucofuranose and NDP-D-ravidosamine without an apparent
chaperone (30). To prove the functionality of these constructs, very likely they will need
to be expressed in blocked pathways from which they were expressed (e.g. pDmnI or
pDmnII in daunosamine disruption mutants of S. peucetius; pDesI, pDesII, pDesIII in
desosamine disruption mutants of S. venezuelae).
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Figure 36 HPLC chromatogram of S. lividans (cos16F4)/pDmnI extract.
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Heterologous expression of 2-hydroxysugar plasmids and ketosugar plasmids
pFUCO, pFUCOII, pVIR*II, and pKVIR were all introduced into S. lividans
(cos16F4) via protoplast transformation. Fucosylated and virenosylated tetracenomycins
were expected to be accumulated in the recombinant strains. Unfortunately, methanolic
extracts failed to reveal the presence of glycosylated tetracenomycins. Again, either the
constructs failed to synthesize the intended deoxysugars in vivo, or ElmGT was unable to
successfully accept the donor substrate. There is some evidence to support this latter
finding, because in at least two separate cases, ElmGT was unable to accept a Dconfigurated sugar that has an axially positioned 4’-OH (158, 160). When cos16F4 was
heterologously expressed in the mithramycin producer S. argillaceus, and when cos16F4
was co-expressed with a plasmid directing biosynthesis of NDP-D-oliose (35), no Doliosyl tetracenomycin C was isolated and described (158, 160). This indicates that
ElmGT has poor tolerance for D-configurated sugar donors with axially configurated 4OH groups, which applies to sugars 96 and 103. However, these constructs may not also
be functioning in vivo.
Additionally, ketosugar constructs were generated by deletion of 4-ketoreductases
from pFL942 and pLN2-derived constructs (39) (Figure 37). pKOL was generated by
deleting oleU from pLN2 and re-ligating the plasmid, and it should direct biosynthesis of
NDP-4-keto-L-olivose (Figure 37 and Figure 38) pFL952 (e.g. NDP-4-keto-L-mycarose,
Figure 37) was constructed by deleting eryBIV from pFL942 and re-ligating, and
cmmUII and oleY were removed from pMP1*UII to afford pDKOL (e.g. NDP-4-keto-Dolivose) (Figure 37).

Figure 37 Ketosugar plasmid maps generated for this work.
Genes are color-coded according to function: Pink (NDP-glucose-synthase); Blue (4,6
dehydratase); Green (2, 3-dehydratase); Yellow (3-ketoreductase); Grey (Omethyltransferase not functioning in this construct), Purple (3-C-methyltransferase); Red
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(3,5 epimerase (oleL)) or 5-epimerase (eryBVII)); Appropriate restriction sites used for
cloning are indicated.
In these latter two constructs, mtmD and mtmE are under the control of one divergent
ermE* promoter, and the other sugar genes are under the control of another divergent
ermE* promoter. Plasmid maps for all of these constructs are depicted in Figure 37.
The activities of OleS (NDP-glucose-synthase), OleE (NDP-glucose-4, 6dehydratase), OleV (2, 3-dehydratase), OleL (3, 5-epimerase), and OleW (3ketoreductase) catalyze the conversion of NDP-D-glucose to NDP-4-keto-2, 6-dideoxy-Dglucose during the biosynthesis of NDP-L-olivose (Figure 38). The 4-ketoreduction step
catalyzed by OleU represents the last step of the NDP-L-olivose biosynthetic pathway.
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Thus, the absence of oleU from pLN2 in pKOL would lead to the accumulation of NDP4-keto-L-olivose, which could be utilized by ElmGT as an alternative donor substrate
when the natural substrate (TDP-L-rhamnose) is not available. To test this hypothesis, the
pKOL plasmid was expressed in the S. lividans (cos16F4) strain.
Interestingly, expression of pKOL in S. lividans (cos16F4) resulted in the
accumulation of two major peaks with Rt (10.76 and 11.26 min., respectively), in
addition to 8-DMTC, when ethyl acetate extracts were analyzed by HPLC/MS (Figure
39). Both peaks showed UV absorption typical for a tetracenomycin-type compound.
Low resolution ESI/MS revealed a peak of 585 amu (-ve mode) pertaining to the
molecular ion of the compound and a pseudomolecular ion of the hydrated species at 603
amu (-ve mode), indicating the addition of water to the molecule. These data suggested
that this compound could be a new tetracenomycin analogue with an attached NDP-4keto-2, 6-dideoxy ketosugar. Under aqueous condition, ketosugars can easily interconvert
from the keto form to a hydrate form. The second peak possessed an m/z value of 587 in
(-) ESI mode. These mass data suggested the presence of a glycosylated tetracenomycin
in which the sugar was fully reduced. Both peaks possessed a fragmentation ion
corresponding to the 8-DMTC aglycone (m/z 457, M-H-). This strain was fermented in a
large scale fermentation (7.2 L) for isolation and spectroscopic characterization of the
metabolites. Unfortunately, expression of pFL952 and pDKOL failed to accumulate
appreciable amounts of glycosylated metabolites. Very likely, the encoded donor sugar
substrates are not recognized by ElmGT.
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Figure 39 HPLC analyses of the metabolites:
trace A, 8-demethyl-tetracenomycin C (A) (Rt. 12.98 min.) isolated from S. lividans
(cos16F4); trace B, metabolites isolated from the S. lividans (cos16F4)/pKOL mutant, 8demethyl-(4’-keto)-α -L-olivosyl-tetracenomycin C (B (Rt. 10.76 min.) and D (Rt. 12.26
min.) denote hydrated and keto forms, respectively) and 8-demethyl-α -L-olivosyltetracenomycin C (C) (Rt. 11.26 min.)
Structural Elucidation of Metabolites Accumulated by the S. lividans (cos16F4)/
pKOL strain
The structure of 8-demethyl-8-(4΄-keto)-α-L-olivosyl-tetracenomycin C (127,
Figure 40) was solved through NMR and mass spectral analyses. The (-) HR-ESI MS of
3 showed two peaks at 585.1267 amu and 603.1363 amu, which corresponded to the
molecular formula of its keto form (C28H26O14 , calcd. molecular weight 585.1317 [M-H]) and its hydrate from (C28H26O14, calcd. molecular weight 603.1423 amu [M-H-]),
respectively. 1H NMR data of 127 revealed 2 singlets for two aromatic protons (δ 7.94
and δ 7.66) and two methoxy signals corresponding to the 3-OCH3 (δ 3.81) and 9-OCH3
(δ 3.97) of 8-DMTC, respectively (1H and 13CNMR table in Table 4.3). The anomeric
proton of the sugar appeared as a broad singlet (δ 6.16) which suggested its α
configuration. A pair of protons at δ 2.13 and δ 2.24 corresponded to the C-2′ methylene
protons. A 4΄-H signal was not observed, indicating the presence of keto/hydrated-keto
group. The splitting of the 3΄-H (dd, J= 12.0, 6.5 Hz) at δ 4.68 indicated a large diaxial
coupling with 2΄-Ha and an axial-equatorial coupling with 2′-He. The 5΄-H appeared as a
quartet (J= 6.5 Hz) at δ 4.39, which indicated coupling with 6΄-CH3. The 1H, 1H-COSY
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exhibited two spin systems for the sugar moiety, one stretching from 1΄-H to 3΄-H, and
the other stretching from 5΄-H to 6΄-CH3, which strongly indicates the presence of a
ketone/hydrated ketone at C-4΄ (Figure 40). The 13C showed a carbonyl signal at δ
207.4, which indicates that 127 is present predominantly in the ketosugar form when
measured in Methanol-d4. The HMBC demonstrated correlations between 6’-CH3
protons and both 5’-C and 4’-carbonyl, which indicated that the ketone was present at 4’position (Figure 40). These data suggested the structure of 127 as 8-demethyl-8-(4΄keto)-α-L-olivosyl-tetracenomycin C.
Compound 114 was eluted at the identical retention time when co-injected with
standard 8-demethyl-8-α-L-olivosyl-tetracenomycin. The identity of 114 as 8-demethyl8-α-L-olivosyl-tetracenomycin was further confirmed through the comparison of 1H
NMR data with published 1H NMR data.
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H-1H-COSY (▬), and selected HMBC (→) correlations of 8-Demethyl-8-(4'-keto)-α-Lolivosyl-tetracenomycin C (127).
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The presence of 127 was quite interesting, because ElmGT has never been shown
to carry a ketosugar before. As such, isolation and characterization of 127 represents the
first successful attempt to overcome ElmGT’s inflexibility towards a ketosugar. As a
result, it seems plausible that ElmGT demonstrates at least some substrate flexibility to
this L-configurated ketosugar, because of its close stereoelectronic similarity to NDP-Lrhamnose. It is possible that ElmGT binds the hydrated form of NDP-4-keto-L-olivose,
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which would present three hydroxyl groups to ElmGT, much like NDP-L-rhamnose also
possesses three hydroxyl groups that may be recognized. However, it is also surprising
that ElmGT was unable to accept the NDP-4-keto-D-olivose, NDP-4-keto-L-rhamnose,
and NDP-4-keto-L-mycarose sugars (39). NDP-L-mycarose was previously shown to be
a poor substrate for ElmGT (only ~10% of all tetracenomycins in the S. lividans
(cos16F4)/pFL942 strain were L-mycarosylated tetracenomycins) (162).
Production of 114 along with 127 by S. lividans (cos16F4)/pKOL was surprising.
It is speculated that a pathway-independent ketoreductase of S. lividans TK 24 might be
responsible for the conversion of NDP-4-keto-L-olivose to NDP-L-olivose, and the latter
is probably utilized by ElmGT as an alternate substrate to yield 114. Pathway
independent reductions have been reported previously in the literature. Earlier in the
pikromycin biosynthetic pathway, a D-quinovosyl macrolide was accumulated instead of
the anticipated 4-keto-6-deoxy-D-glucosyl analogue when desI was inactivated in
Streptomyces venezuelae (168). To search for possible sugar ketoreductases in
Streptomyces lividans TK 24 that could be responsible for reduction of NDP-4-keto-Lolivose, thus possibly explaining the presence of 114, the amino acid sequence for OleU
was compared to encoded proteins in the Streptomyces lividans genome using the protein
BLAST public database. One such candidate was indicated in the search, SSPG_00655
(30% sequence identity/42% sequence similarity). This candidate has a domain that
shows similarity to RfbD, which is a 4-ketohexulose reductase responsible for equatorial
4-ketoreduction of NDP-4’-keto-L-rhamnose in the NDP-L-rhamnose pathway. This
enzyme may be responsible for the 4-ketoreduction witnessed in 114.
Biological activity of 127 towards Streptomyces prasinus
To evaluate the biological activity of 127, 1 mg mL-1 methanolic solutions of 127
and 106 were prepared. 106 was included as a positive control. Streptomyces prasinus
NRRL B-2712 was chosen as a test organism, because it was the most sensitive gram
positive organism tested against 106 (146). Disc diffusion assays were performed in
triplicate as previously described (146), and both 106 and 127 demonstrated activity
against S. prasinus. However, 127 (mean zone of inhibition 12±2 mm diameter)
demonstrated less antibacterial activity than 106 (mean zone of inhibition 24±2 mm
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diameter). This is not surprising, as many tetracenomycin derivatives with substitutions
in the 8-O-glycoside moiety exhibit lower antibacterial activity and antitumoral activity
than 106, which demonstrates that the 8-O-permethylated L-rhamnose moiety is
important for the biological activity of elloramycin.
Glycosyltransfer of ketosugars is a rare phenomenon; expanding the catalogue of
known substrates for ElmGT
ElmGT represents one of the most flexible glycosyltransferases with respect to its
ability to accommodate a large number of sugar donor substrates as compared to
glycosyltransferases in other secondary metabolite biosynthetic pathways. ElmGT
reportedly utilizes various NDP-D-sugars: D-olivose, D-mycarose, D-diolivose, Damicetose, D-boivinose, D-digitoxose, and D-glucose. ElmGT also accepts a number of
NDP-L-sugars: L-rhamnose, L-rhodinose, L-digitoxose, L-olivose, L-amicetose, L-mycarose
and 4-deacetyl-L-chromose B. However, ElmGT has not been previously shown to
accommodate NDP-ketosugars. In this context, production of 127 through the expression
of pKOL in S. lividans (cos16F4) was interesting, especially, as earlier efforts to
glycosylate 8-DMTC with NDP-4-keto-L-rhamnose were unsuccessful (Rodriguez, et al.,
2000).
Despite the many glycosyltransferases discovered, those which can attach
ketosugars to their acceptor co-substrates are relatively scarce. MtmGIV (and possibly
MtmGIII) from the mithramycin pathway has/have been shown to handle NDP-4-keto-Dolivose and NDP-4-keto-D-mycarose to generate novel premithramycin and mithramycin
analogues in Streptomyces argillaceus strains in which mtmC (3-C-methyltransferase)
and mtmTIII (4-ketoreductase) genes were disrupted (Remsing, et al., 2002). EryBV
from the erythromycin pathway has been shown to accommodate NDP-4-keto-Lmycarose (Salah-Bey, et al., 1998). Similarly, BgtfA from the balhimycin pathway is
capable of utilizing NDP-4-keto-L-vancosamine as a natural sugar donor substrate (Pelzer
S - Sussmuth, et al.). The unprecedented flexibility of ElmGT towards NDP-4-keto-Lolivose reported in this communication is particularly encouraging for further studies
towards understanding the structural role of ElmGT in binding deoxysugar substrates.
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SUMMARY
In summary, cos16F4 was used to heterologously express 8-demethyltetracenomycin C and the glycosyltransferase ElmGT. Various “sugar plasmids” were coexpressed with resulted in recombinant strains, and co-expression of plasmid pKOL,
which biosynthesizes NDP-4-keto-L-olivose resulted in accumulation of the new
tetracenomycin analogue 8-demethyl-8-(4'-keto)-α-L-olivosyl-tetracenomycin C. This
analogue was structurally elucidated through HR-ESI mass, 1H-NMR, 13C-NMR, 1H,1HCOSY, and HMBC NMR spectroscopy. It was determined to have roughly 50% of the
antimicrobial activity of elloramycin A towards Streptomyces prasinus.
EXPERIMENTAL
Bacterial Strains and Culture Conditions
Escherichia coli XL1 blue (Invitrogen) was used as a host for routine cloning
experiments and was grown on LB agar or in LB broth at 37 °C. S. lividans TK24 and
derivative strains were grown on M2 agar or in YEME liquid medium at 28 °C for 3 days
for preparation of protoplasts following the previously reported protocol (3). When
antibiotic selection of recombinant strains was required, 25 μg/mL apramycin, 25 μg/mL
thiostrepton, or 100 μg/mL of ampicillin were used. Protoplast transformation was carried
out to introduce the cosmid cos16F4 into Streptomyces lividans TK 24 following the
standard protocol (3, 174). An apramycin resistant colony was selected for the
production of 8-demethyl-tetracenomycin and was used as host for the expression of a
newly generated deoxysugar biosynthetic construct(s).
Bioactivity conditions against Streptomyces prasinus NRRL B-2712 were carried
out as previously described (146). In brief, spores of Streptomyces prasinus were grown
on plates (0.4% yeast extract, 1.0% malt extract, 0.4% glucose, 2.0% agar). The strain
was grown for 50 hours until the plate was well-sporulated, then the spores were
collected, diluted in sterile water, and adjusted to OD 1.3 (560 nm). 0.5 mL of the spore
suspension was plated on each of 3 plates, and methanolic test solutions were prepared at
a concentration of 1 mg/mL. 6 mm filter discs were prepared from Wattman filter paper
using a hole punch, were sterilized in a 50 mL centrifuge tube, soaked in the antibiotic
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solution, allowed to dry in a laminar flow hood for 30 minutes, then grown in the
presence of S. prasinus. Zones of inhibition were measured in triplicate and averaged.

Generation of plasmids directing the biosynthesis of ketosugars,
aminosugars, and 2-hydroxysugars
The 4-ketoreductase gene (oleU) was removed from plasmid pLN2 (Rodriguez, et
al., 2002). NheI and SpeI were used to digest pLN2, thereby releasing the oleU fragment.
DNA gel electrophoresis was carried out to remove the oleU gene and the resulting
fragment (~14kb) was rescued and re-ligated to generate pKOL. In this construct, all of
the sugar genes are under strong ermE* promotion. The plasmid map for this construct is
depicted in Figure 37. This plasmid was introduced into the S. lividans (cos16F4) strain
through protoplast transformation. Plasmid pFL952 was prepared as described
previously (134). In brief, plasmid pFL942 (directs biosynthesis of NDP-L-mycarose),
was digested with SpeI/NheI, thus releasing the eryBIV 4-ketoreductase. The ~14kb
plasmid was rescued, self-ligated using T4 DNA Ligase, and then transformed into XLI
Blue E. coli for amplification of the construct.
Plasmids pVIR*II, pFUCOII, pFUCO, and pKVIR were prepared as discussed in
Chapter 2, Materials and Methods. Plasmids pRavI, pDmnI, pDmnII, pDesI, pDesII,
and pDesIII were prepared by Dr. Madan Kharel (Personal Communication). Plasmid
pTLAG was cloned by Dr. Tao Liu (Dissertation).
Table 7 Plasmids used in Chapter 4

Plasmid Name
Cos16F4

pLN2

pFL942

Relevant Characteristics
AprR. Directs biosynthesis
of 8-DMTC (105) in
Streptomyces. Encodes
ElmGT, pKC505-derived
cosmid.
AmpR, TsrR. OleVWSELUY
under ermE* promotion.
NDP-L-olivose.
AmpR, TsrR. OleV,
MtmDE, EryBII, BIII, BIV,
BVII under divergent
104

Reference
(149)

(135)

(134)

pMP*UII

pRavI

pDmnI

pDmnII

pDesI

pDesII

pDesIII

pTLAG2

pKOL

pFL952

pFUCO

ermE* promotion. NDP-Lmycarose.
AmpR, TsrR. OleVW,
cmmUII, OleY, MtmDE,
under divergent ermE*
promotion. NDP-Lmycarose.
AmpR, TsrR. RavDE, NMT,
AMT, IM under ermE*
promotion. NDP-Dravidosamine
AmpR, TsrR. OleSEVLU
DnrJ under ermE*
promotion. NDP-Lacosamine
AmpR, TsrR. OleSEV,
DnrJUV under ermE*
promotion. NDP-Ldaunosamine
AmpR, TsrR. DesIII, DesIV,
DesI under ermE*
promotion. NDP-4-amino6-deoxy-D-glucose (121)
AmpR, TsrR. DesIII, DesIV,
DesI, DesII under ermE*
promotion. NDP-3-keto4,6-dideoxy-D-glucose
(122).
AmpR, TsrR. DesIII, DesIV,
DesI, DesII, DesV under
ermE* promotion. NDP-3N,N-didemethyl-Ddesosamine (123).
AmpR, TsrR. Med20, 18,
17, 16, 15, 14 under ermE*
promotion. NDP-Dangolosamine
AmpR, TsrR. OleVWSELY
under ermE* promotion.
NDP-4-keto-L-olivose.
AmpR, TsrR. OleV,
MtmDE, EryBII, BIII, BIV,
BVII under divergent ermE*
promotion. NDP-4-keto-Lmycarose.
AmpR, TsrR. gilU, ravDE
105

(160)

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication.

Tau Liu, Dissertation.

This work.

(134)

This work.

cloned under ermE* in
pUWL201PW. Intended to
produce NDP-D-fucose.
AmpR, TsrR. gilLU, ravDE, This work.
cloned under ermE* in
pUWL201PW. Intended to
produce NDP-Dfucofuranose.
AmpR, TsrR. chryCMT,
This work.
chryDE cloned under
ermE* in pUWL201PW.
Intended to produce NDP4-keto-D-virenose.
AmpR, TsrR. chryCMT,
This work.
chryU, ravDE cloned under
ermE* in pUWL201PW.
Intended to produce NDP-Dvirenose.

pFUCOII

pKVIR

pVIR*II

Table 8 Bacterial strains used in Chapter 4
Strain Name
S. lividans TK24 (cos16F4)
§

Relevant Characteristics
Harbors cos16F4. Produces
105.

Reference
(149)

S. lividans (cos16F4)/pRav1 § co-expressed with pRavI.
Produces 105.
S. lividans
§ co-expressed with pDmnI.
(cos16F4)/pDmnI
Produces 105 and 106.
S. lividans
§ co-expressed with pDmnI.
(cos16F4)/pDmnII
Produces 105.
S. lividans (cos16F4)/pDesI § co-expressed with pDesI.
Produces 105.
S. lividans
§ co-expressed with pDesII.
(cos16F4)/pDesII
Produces 105.
S. lividans
§ co-expressed with
(cos16F4)/pDesIII
pDesIII. Produces 105.
S. lividans
§ co-expressed with
(cos16F4)/pTLAG2
pTLAG2. Produces 105.
S. lividans
§ co-expressed with
(cos16F4)/pFUCO
pFUCO. Produces 105.
S. lividans
§ co-expressed with
(cos16F4)/pFUCOII
pFUCOII. Produces 105.
S. lividans
§ co-expressed with
(cos16F4)/pVIR*II
pVIR*II. Produces 105.

This work.

106

This work.
This work.
This work.
This work.
This work.
This work.
This work.
This work.
This work.

S. lividans
§ co-expressed with
(cos16F4)/pKVIR
pKVIR. Produces 105.
S. lividans (cos16F4)/pKOL § co-expressed with pKOL.
Produces 105, 114, 127.
S. lividans
§ co-expressed with
(cos16F4)/pDKOL
pDKOL. Produces 105.
S. lividans
§ co-expressed with
(cos16F4)/pFL952
pFL952. Produces 105.

This work.
This work.
This work.
This work.

Table 9 Physicochemical characterization and NMR data of 8-Demethyl-8-(4'-keto)-α-Lolivosyl-tetracenomycin C (127).
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Rrel= 10.76 min-1; Yield: 2.0 mg/L
MW= 586 g/mol (C28H26O14)
Negative mode APCI-MS: m/z=585 [M-H] (low res), m/z=603 (hydrate); (-) HR-ESI
MS (keto form calc. 585.1317 amu, found 585.1267 amu [M-H-]; hydrate form calc.
603.1423, found 603.1363 amu [M+18])
UV maxima (from HPLC-diode array): 210 (60%), 286 (100%), 409 (20%)
NMR Data (d4-methanol)
Position

1
2
3
3-OCH3
4
4-OH
4a
4a-OH
5
5a
6
6a
7
8

8-Demethyl-8-(4'-keto)-α-L-olivosyl-tetracenomycin C (127)a
δC (125 MHz)

δH (500 MHz)

193.0
100.8
176.1
57.8
70.7
85.9
194.8
141.5
122.1
129.6
112.4
155.4

5.62 (s)
3.81 (s)
4.88 (d, 1.5)
7.91 (s)
7.55 (s)
-
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9
9-OCH3
9-CO
10
10-CH3
10a
11
11-OH
11a
12
12a
12a-OH
1′
2′

130.9
53.4
169.5
139.5
21.3
122.6
167.8
110.6
198.2
84.6
96.4
37.3

3′
3′-OH
4′
4′-OH
5′
6′

70.6
207.4
72.5
14.3

3.97 (s)
2.79 (s)
6.16 (s)
2.24 (ddd, 15.0, 12.0, 3.0, Ha),
2.13 (dd, 15.0, 6.5, He)
4.68 (dd, 12.0, 6.5)
4.39 (q, 6.5)
1.12 (keto, d, 6.5)
1.16 (hydrate, d, 6.5)

Isolation of tetracenomycins from recombinant S. lividans (cos16F4) strains
S. lividans (cos16F4)/pKOL was grown on M2 agar medium at 28 °C
supplemented with thiostrepton and apramycin for 5 days. For small scale production of
tetracenomycins, an agar chunk of bacterial spores was inoculated in 250 mL Erlenmeyer
flasks containing 100 mL of Soytone-Glucose (SG) medium supplemented with
antibiotics for 4-5 days. 25 mL of the culture was extracted with ethyl acetate and the
organic layer was dried in vacuo. Extracts were then redissolved in methanol and were
subjected to HPLC/MS analyses on a MicroMass ZQ 2000 (Waters) instrument equipped
with HPLC (Waters alliance 2695 model) and photodiode array detector (Waters 2996).
A Sun-Fire semi-prepC18 column (19 × 250 mm, 5 μm) and Symmetry C18 (4.6 x 250
mm, 5 μm) analytical column were used for semi-preparative and analytical scale
separations, respectively. A gradient of acetonitrile and 0.1% formic acid in water was
used to separate compounds as reported previously (See Chapter 3, Materials and
Methods).
For larger scale production of glycosylated tetracenomycins, 7.2 L of SG medium
and allocated into 800 mL portions in 9 baffled 2 L Erlenmeyer flasks. The production
media was supplemented with antibiotics and inoculated with freshly prepared spores
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from M2 agar plates of the recombinant strains. Fermentation was carried out for 5 days
at 28 °C in an orbital shaker. The culture was harvested, mixed with celite (50 g/L
fermentation broth), and then filtered. The mycelial cake was discarded, and the culture
broth was passed through Amberlite® XAD16 resin (column dimensions 80 cm x 4 cm).
The column was washed with 100% distilled water, and crude tetracenomycins were
obtained by elution with 2 L of methanol. The solvent was dried in vacuo. This extract
was separated via silica gel column chromatography using 200 mL gradients of
dichloromethane and methanol from 0-100% of methanol, increasing in 5% each step.
Fractions containing tetracenomycins were pooled, dried in vacuo, and further purified
using semi-preparative HPLC as described previously (Chapter 3, Materials and
Methods). Using this protocol, 14.4 mg and 12.2 mg of compounds 127 and 114 were
isolated, respectively. (-) High resolution ESI spectra of pure compounds were recorded
at the University of Wisconsin Biotechnology Center. NMR spectra were recorded on a
Varian VNMR 500 MHz spectrometer using deuterated methanol as solvent.
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CHAPTER 5: ALTERING THE GLYCOSYLATION PATTERN OF
MITHRAMYCINS
INTRODUCTION
Biological activity of mithramycin
The aureolic acid antibiotic mithramycin (70) has been well-studied by various
groups for the tremendous potential it exhibits as an antineoplastic, Alzheimer’s, and
Parkinson’s drug (79, 83-84, 86, 90-91, 93). As an anticancer agent, it has been used to
treat Paget’s bone disease, bone-related malignancies, and testicular carcinoma (88). It
binds to the minor groove of GC-rich DNA, especially in proto-oncogenes c-src and cmyc, and as such, it is a de facto inhibitor of Sp1-dependent pathways (87, 89, 91, 94).
Overexpression of Sp1 has been implicated in Alzheimer’s disease and colon, breast, and
pancreatic cancers.

Mithramycin binds as a homodimer in head to tail fashion, that is
2+

coordinated by a Mg cation (87). Structurally, mithramycin consists of a tricyclic core
and possesses a dihydroxy-methoxy-oxo-pentyl side chain at 3-position, which is
responsible for interaction with the phosphate backbone (86). The disaccharide
consisting of D-olivose, D-olivose is important for binding to DNA, perhaps by stacking
on top of the dimer aromatic core (86). The trisaccharide is also essential, because the Dmycarose moiety is positioned in the floor of the minor groove of DNA, and it provides
stabilization of the MTM-Mg2+dimer complex by virtue of hydrogen bonding with both
strands of DNA(98). Mithramycin, however, is contraindicated due to severe hepatic,
renal, and gastrointestinal cytotoxicities (86).
Mithramycin has also found use as part of a multi-drug therapy with bevacizumab
in down-regulating VEGF (vascular epithelial growth factor) (111). Mithramycin itself
has been independently confirmed to decrease c-myc/c-src expression in cancer cell lines,
inhibiting Sp1 from binding to these promoters (70 inhibits c-src promotion in a
luciferase-reporter assay to about 30% of the expression of a control sample not treated
with 70) (86). As such, mithramycin has been increasingly employed in multi-drug
therapies to target cancers that are refractory to treatment with a single chemotherapeutic.
Mithramycin’s Sp1-dependent inhibition effectively blocks all downstream cell signaling
pathways that depend on Sp1-promoted upregulation, and this may work in tandem with
other compounds that target some other aspect of cancer cell/Alzheimer’s proliferation,
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for example VEGF or beta amyloid precursor protein, for example (86-87, 90-91, 93,
111).
Despite its tremendous potential as a cancer therapeutic, mithramycin and the
other first generation aureolic acids suffer from severe drawbacks. Because these
molecules are biosynthesized naturally, they have not been optimized for binding to
mammalian targets, such as protooncogenes, and as such, these drugs exhibit detrimental
effects in healthy somatic cells and cancer cells alike. Due to the severe cytotoxic side
effects of 70, combinatorial biosynthetic methods have been employed in the Rohr and
Salas labs to generate novel mithramycin analogues with better drug properties: lessened
cytotoxicity or higher potency (e.g. IC50). These alterations have focused on derivatizing
the polyketide aglycone and substitutions in the saccharide pattern. These “second
generation” combinatorial mithramycin/premithramycin analogues have revealed
tremendous insights into the biosynthesis and of 70. Furthermore, the isolation of several
analogues has revealed unanticipated substrate flexibility displayed by the enzymatic
machinery, and some of these analogues possess enhanced potency and reduced
cytotoxicity as compared to mithramycin.
Pathway engineering studies to alter the mithramycin/premithramycin polyketide
skeleton
The Rohr and Salas labs have previously conducted several inactivations of genes
responsible for modification of the polyketide. Inactivations of mtmMI and mtmMII
revealed the functions of these encoded proteins as the 4-O-methyltransferase that installs
the methoxy group onto 4-demethylpremithramycinone (27), and the 7-Cmethyltransferase responsible for installing the 7-C-methyl sidechain of 70 (23). The
accumulation of 7-demethylmithramycin (82) in the S. argillaceus (mtmMII-) strain
revealed that all of the downstream biosynthetic enzymes could process the 7-desmethyl
substrates, however, this compound failed to exhibit any in vivo cytotoxicity, indicating
the importance of the 7-C-methyl group for binding to DNA (Figure 41) (86).
Disruption of mtmOI and mtmOIII did not result in disruption of mithramycin
biosynthesis, however, disruption of mtmOII led to production of premithramycinone G
(87, Figure 41) (24). This improperly cyclized molecule reveals important implications
for MtmOII’s role in early mithramycin biosynthesis, either by installing a ketone to
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allow for fourth ring cyclization and/or installation of the 2-oxygen of 70. Inactivation of
mtmOIV resulted in the accumulation of premithramycin B (80), a tetracyclic
premithramycin that features the intact trisaccharide (D-olivose, D-oliose, D-mycarose) at
2-position and the disaccharide at 6-position (D-olivose, D-olivose) (Figure 41) (95, 103).
Elucidation of the structure of 80 lead to the elaboration of MtmOIV being a highly
specific Baeyer-Villiger monooxygenase (BVMO) responsible for oxidative cleavage of
the fourth ring to afford the canonical tricyclic mithramycin scaffold (95, 103, 109, 175).
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Figure 41 Premithramycin and mithramycin-type compounds
from inactivating genes responsible for altering the polyketide-derived portion of
mithramycin.
MtmOIV is unique in that it is a BVMO for which the substrate is known. The fact that
MtmOIV only recognizes a fully glycosylated premithramycin B molecule indicates that
this rigid structural specificity is an intrinsic means by which the mtm pathway avoids
wasteful and promiscuous generation of less active mithramycins with fewer sugars (95,
103, 109, 175). However, this same rigidity also prevents MtmOIV from turning over
novel premithramycin substrates that may bear unusual or foreign deoxysugars.
The inactivation of the mtmW gene resulted in novel mithramycins with
unexpectedly shorter side chains, thereby revealing its role in the 3-sidechain
ketoreduction step of the β-diketone intermediate (Figure 13). The accumulated products
were called mithramycin SK (for shortened ketone) (128), demycarosyl-mithramycin SK,
mithramycin SDK (shortened diketone) (129) , and mithramycin SA (130) (shortened
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acid) (Figure 42) (89, 97). The anticipated product was the mithramycin β-diketone
compound (81), however, because this possesses a highly reactive β-diketone motif,
subsequent carbon migration rearrangements occur. If water attacks the 2”-ketone, a
hydrate can form. A retro-aldol reaction results in subsequent deprotonation of one of the
hydroxyl protons that can restore the ketone, and result in severance of the 2”-3” carboncarbon bond, which affords mithramycin SA (130). Or, if water abstracts a proton from
the 3”-hydroxy, carbon migration can result in shifting of the 4”-acyl group to the 2”position (Figure 42). From this species, water either attacks the aldehyde directly,
resulting in elimination of formic acid, which affords mithramycin SK (128), or water
abstracts a proton from 2”-hydroxyl, which results in elimination of formaldehyde, and
formation of mithramycin SDK (129) (Figure 42). Feeding experiments with [1-13C]acetate and [1,2-13C2]-acetate confirmed that the 3”-carbon is excised during this
rearrangement (97).
The antitumoral activities of 128-130 were evaluated in 60 cell line panel by
using the NCI sulforhodamine B cytotoxicity assay. Mithramycin SA 130 demonstrated
very weak binding to Salmon testes DNA and exhibited weak in vivo cytotoxicity, due in
large part to the fact that its 3-side chain is much too short to interact specifically with the
phosphate backbone of DNA (86-87). Mithramycin SK 128, however, demonstrated
1500-fold less cytotoxicity than mithramycin, and furthermore, it demonstrated up to 90
times higher activity than mithramycin in squamous, melanoma, leukemia, and CNS
cancer lines (86-88). Furthermore, mithramycin SK was able to inhibit polyploidy in
actively dividing cancer cells (112). Mithramycin SDK 129, however, severely inhibits
Sp1-
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Figure 42 Spontaneous rearrangements of Mithramycin SK (128), mithramycin SDK
(129) and mithramycin SA (130).
Mechanisms for rearrangements of 3-pentyl side chain of mithramycin β-diketone to
form mithramycin SK (128), mithramycin SDK (129), and mithramycin SA (130).
Structures of metabolites from mtmW-disrupted strain S. argillaceus M7W1 with
shortened side chains in blue.
dependent pathway transcription, up to 90% at a 100 nM concentration in a luciferasebased reporter assay (as compared to 40% for 70 and 60% for 128) (89). The IC50 for
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129 was up to 2-fold lower than for 70 and 128 (87). Astonishingly, when orthotopic
ovarian tumor xenografts were introduced into a mouse model, then treated with 400
μg/kg/day of 70, 128, or 129, median survival in the 129 treated group was 80 days (as
compared to 55 for the control group without mithramycin treatment), yet 4 of the 10
mice treated with 129 survived past 100 days tumor free (87, 89). These studies cemented
mithramycin SDK as the best-in-class aureolic acid derivative with most potential for
further clinical trials.
Altering the glycosylation pattern of premithramycins/mithramycins through
“flooding” of the pathway with nucleoside-diphosphate-activated deoxysugars and
inactivation experiments
As discussed in Chapter 4, glycodiversification is a powerful strategy for altering
the structure and activity of a particular drug. The successful implementation of this
strategy requires the accumulaton of nucleoside-diphosphate-activated deoxysugars that
are not normally produced in the strain and the successful interrogation of a donorflexible glycosyltransferase. The Salas group demonstrated the effectiveness of
interrogating the substrate-flexible ElmGT with a variety of plasmid-borne NDPdeoxysugars. In Chapter 4, the successful generation and structure elucidation of a new
ketosugar-bearing tetracenomycin (127) illustrated this approach in vivo.
The mithramycin biosynthetic pathway features five glycosyltransfer events and
four glycosyltransferases, therefore inactivation experiments of various deoxysugar
biosynthetic genes and glycosyltransferases were undertaken (98-99). Inactivation of
mtmGI, mtmGII, mtmGIII, and mtmGIV and feeding of 4A-deolivosyl-premithramycin B
to the mtmGI-deleted mutant established the unambiguous order of glycosylation events
leading to 70 (96, 100, 105) (Figure 13). While inactivation of several of the deoxysugar
biosynthetic genes (e.g. mtmV, mtmU, mtmC, mtmDE) resulted in accumulation of early
pathway intermediates premithramycinone or premithramycin A1, inactivation of
mtmTIII and mtmC revealed an unanticipated accumulation of premithramycins and
mithramycins with alterations to the saccharidal moieties (88, 98-99) (Figure 43). These
molecules revealed substrate flexibility on the part of MtmGIV and/or MtmGIII towards
accepting ketosugars.
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As a further extension of their work, the Salas lab envisioned that transformation
of S. argillaceus with various sugar plasmids could result in mithramycin molecules with
substitutions in the saccharide chain.
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Figure 43 Structures of mithramycin-type compounds resulting from S. argillaceus
mtmTIII- and mtmC- (83-86) inactivations.
Mithramycins resulting from overexpression of NDP-L-digitoxose plasmid in S.
argillaceus.
Overexpression of several of these resulted in novel mithramycins that were active or
slightly less active than 70 in the cancer cell lines tested (111). When plasmid pLNBIV
(encodes NDP-L-digitoxose biosynthesis) was introduced into S. argillaceus via
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protoplast transformation, four new mithramycins were identified (131-134) with
substitutions in the saccharide pattern (112). Two of these compounds were the result of
“jamming” of glycosyltransferases, 133 and 134. From a biosynthetic perspective, these
compounds were interesting and revealed unexpected flexibility by the
glycosyltransferases. Very likely, jamming of MtmGIV/MtmGIII results in accumulation
of 133 and jamming of MtmGII results in accumulation of 134. 133 indicated an
acceptor flexibility of mtmGIV and possibly acceptor/donor flexibility of MtmGIII to
transfer NDP-D-mycarose to premithramycin A1. 132 was unique from all mithramycins
generated by these experiments, because it was the only compound to feature an L-sugar
(NDP-L-digitoxose), yet a simple ring flip to the 4C1 conformer likely accounts for its
acceptance by MtmGIII (the 4C1 conformer of NDP-L-digitoxose possesses the same
stereochemistry at 3- and 4-position as NDP-D-oliose, the natural substrate of MtmGIII).
All compounds exhibited unanticipated substrate specificity on behalf of MtmOIV, but
compound 131 demonstrated much improved bioactivity over 70 in many of the cancer
cell lines tested by the NCI (112). In ER+ MCF-7 breast cancer cells, mithramycin
induced 37.8% apoptosis, whereas 131 induced 64.8% apoptosis. In ER- MDA-231
cells, mithramycin only induced 2.6% apoptosis; however, 131 induced an amazing
63.6% apoptosis. 131 is essentially an isostere of mithramycin, possessing the same
stereochemistry of the E sugar (NDP-D-digitoxose vs. NDP-D-mycarose), yet it lacks the
3-C-methyl branch. Because the D-mycarose moiety sits in the floor of GC-rich minor
grooves and forms hydrogen bonds with both strands of DNA, the methyl group may
cause steric interference (98). Apparently, the D-digitoxose substitution greatly enhances
the activity of 131 as compared to mithramycin, yet, in both ER+ and ER- breast cell
cancer lines, it possessed the highest level of biological activity compared to the other
glycorandomized mithramycins produced in these studies. ER- breast cell cancer
desparately requires novel treatments to overcome its considerable chemoresistance
(112). This validates the approach of glycodiversification towards optimizing the ligand
binding of mithramycin-type compounds.

MtmOIV is the Baeyer-Villiger Monooxygenase (BVMO) that catalyzes fourth ring
scission in biosynthesis of mithramycin
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MtmOIV catalyzes the key oxidative cleavage of mithramycin biosynthesis that
results in generation of an active tricyclic compound(95, 103, 109, 175). MtmOIV and
its sister enzyme from chromomycin A3 biosynthesis, CmmOIV, have both been
crystallized and their active site residues determined through mutagenesis experiments
(176) (Figure 44). Some of these mutants, such as MtmOIV-R204A feature mutations in
key residues, such as arginine 204, that are responsible for limiting MtmOIV’s tolerance
to premithramycin substrates. In this case, arginine 204 is considered to be a key
gatekeeper residue that allows for the stabilization of the trisaccharide chain of
premithramycin B in the enzymatic active site. Mutation of arginine 204 to alanine
achieved a significant reduction of the Km of MtmOIV-R204A with respect to its affinity
for premithramycin B, while retaining a comparable kcat to the wildtype enzyme. As
such, MtmOIV reduces bound FAD to FADH via NADPH, after which diatomic oxygen
binds to form the key peroxyflavin species (Figure 44). The peroxyflavin species attacks
the 1-position carbonyl, forming the Criegee intermediate, oxygen inserts into the carboncarbon bond, and the lactone collapses to form mithramycin DK (81). Substrate flexible
MtmOIV mutants will be useful for future combinatorial generation of mithramycins, and
part of the aim of this work is to generate strains and characterize suitable
premithramycins for such an approach.
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RESULTS AND DISCUSSION
Despite the considerable advances that have been made to understand the
biosynthesis and generate novel derivatives of mithramycin, new interrogations of
biosynthetic machinery involving uninvestigated deoxysugar donor substrates and
recombinations of sugar plasmids with restricted mutants of S. argillaceus remain to be
tested. The work of the Salas group in heterologous expression of NDP-deoxysugar
cassettes served as the impetus and inspiration for envisaging new mithramycin scaffolds.
Based on what is already known about the substrate flexibility of the mtm GTs, several
novel strains were prepared and preliminary investigation of the compounds accumulated
in these novel strains was undertaken.
In preliminary screening of recombinant strains for the presence of additional
mithramycin-type/premithramycin compounds, methanolic extracts of recombinant
strains were compared to extacts of the parent wild-type or restricted S. argillaceus strain.
Additional peaks were visualized via a UV photodiode array detector on a Waters HPLCMS as discussed in Chapter 3. Premithramycin-type compounds are clearly distinctive
based on their tetracyclic ring system, and as such, they possess a characteristic UV
spectrum with absorption maxima at 230 nm, 280 nm, 329 nm, and 424 nm.
Mithramycins, with a tricyclic chromophore and 3-aliphatic side chain, were clearly
identified with absorption maxima at 230, 278, 317, and 411 nm (111). In this case, the
hypsochromic shift from 329 nm to 317 nm from the MtmOIV-catalyzed opening of the
fourth ring is particularly diagnostic for distinguishing premithramycin and mithramycintype compounds.
The generation of a novel fermentation method towards demycarosyl-3D-β-Ddigitoxosyl mithramycin and generation and structure elucidation of demycarosyl-3D-βD-digitoxosyl

mithramycin SK were achieved using a different methodology different

from that of the EntreChemTM biotech company (personal communication, Dr. Rohr), and
our lab’s methodology is being drafted into a manuscript for submission soon.
Generation of S. argillaceus wildtype strains overexpressing NDP-activated Lsugars
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Several strains were reported by Salas et al. to produce novel premithramycintype compounds, but were not further investigated. As such, the production spectrum of
these strains could serve as a useful point of reference for evaluating the production of
other deoxysugar plasmid-containing Streptomyces argillaceus strains. Streptomyces
argillaceus was independently transformed with pLN2 (NDP-L-olivose), pLNBIV (NDPL-digitoxose),

and pRHAM (NDP-L-rhamnose) to afford strains S. argillaceus

(pLNBIV), S. argillaceus (pLN2), and S. argillaceus (pRHAM), respectively. As
reported previously, extracts of S. argillaceus (pRHAM) accumulated only mithramycin,
premithramycin A1, and a small amount of an unknown compound (111). This
compound demonstrated a mass of 557 amu in (-)APCI-MS mode [M-H], which could
correspond to 14 mass units higher than premithramycin A1. This compound could
correspond to a D-mycarose-substituted premithramycin A1, or more likely,
premithramycin A1’ with the 7-C-methyl group. S. argillaceus (pLN2) produced
mithramycin and two premithramycin type compounds with a mass each of 674 amu [MH] in APCI (-ve) mode. As reported previously, these could correspond to two novel
premithramycins with disaccharides corresponding to D-olivose-1,3-L-olivose and Lolivose-1,3-L-olivose (111). What is clear from the overexpression of NDP-activated Lsugars in S. argillaceus is that they result in “jamming” of the glycosyltransferases, and
the accumulation of these premithramycin-type compounds. This is not unexpected,
because the mtm GTs normally bind D-configurated sugars, and in only a handful of cases
have glycosyltransferases from secondary metabolism been shown to accommodate both
D- and L-configurated

sugars: GilGT (NDP-L-rhamnose, NDP-D-olivose, NDP-D-

fucofuranose), ElmGT (many sugars, see Chapter 4), and UrdGT2 (NDP-L-rhodinose
and NDP-D-rhodinose) (177). Furthermore, much of this jamming seems to occur with
regards to MtmGIII.
In extracts of S. argillaceus (pLNBIV), ten metabolites in addition to
mithramycin (70) were accumulated (Figure 45). Four of these are known to be
mithramycins described previously (131-134), and as such, were able to be assigned
according to retention time, UV spectrum, and mass analyses. In addition, six
premithramycin type compounds were accumulated. Three of these were identified based
on identical retention time with standard compounds and mass analyses as
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premithramycin A1 (76), premithramycin A1’, and premithramycinone. However, three
of these compounds are unknown and exhibit atypical UV-Vis absorption spectra for
premithramycin type compounds. These three compounds exhibit a sharp absorption
maximum at 406 nm. From this experiment, it was apparent that mithramycin was still
the major metabolite in the production spectrum, and extract from S. argillaceus
(pLNBIV) was essential to developing a robust HPLC semi-preparative separation
program. Also, the three unidentified premithramycins may be good candidates for
pathway engineering. This could be achieved by inserting a copy of a mutagenized
mtmOIV gene (e.g. R204A) into the chromosome of S. argillaceus (pLNBIV).
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Figure 45 HPLC traces of metabolites of S. argillaceus (pLNBIV).
Trace A represents extracts from S. argillaceus wildtype, which produces mithramycin
(70). Trace B represents extracts from S. argillaceus (pLNBIV), which produces 70
along with novel mithramycins with substitution in the saccharide chains (131-134,
Figure 44), premithramycin A1 (76), * represents the 7-C-methyl derivative of 76,
premithramycin A1’. 27 is premithramycinone and § indicates premithramycin-type
metabolites with atypical UV (a sharp UV absorption maximum at ~406 nm).
Expression of aminosugar and 2’-hydroxysugar plasmids in S.argillaceus wildtype
Deoxysugars directing the biosynthesis of various aminosugars (see Chapter 4)
were introduced into S. argillaceus wildtype. Most of these deoxysugar plasmids failed
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to alter mithramycin biosynthesis, however, the S. argillaceus (pDesIII) (NDP-N,Ndidemethyl-D-desosamine) strain accumulated premithramycin A1 and an additional
premithramycin-type compound that was not investigated. Additionally, the S.
argillaceus (pDmnI) strain accumulated premithramycinone and premithramycin A1,
which may result from accumulation of NDP-L-rhamnose jamming MtmGIII, as in the S.
argillaceus (pRHAM) strain (Figure 46). Furthermore, an additional premithramycin
was accumulated with Rt=21.3 min-1.

H3C
O
HO
H2N

ONDP

Figure 46 HPLC chromatogram of the metabolites from S. argillaceus (pDmnI) strain.
This strain accumulates one unknown (yellow star) premithramycin in addition to
mithramycin, premithramycin A1, and premithramycinone. The structure of NDP-Lacosamine is indicated as a reference for what the plasmid should biosynthesize.
The 2’-hydroxysugar plasmids pVIR*II, pEN3, pFUCO, and pFUCOII were all
introduced into S. argillaceus wildtype via protoplast transformation. It was envisioned
that these plasmids should redirect mithramycin biosynthesis to incorporate 2’hydroxylated sugars. In the case of pVIR*II or pEN3, it was envisioned that either NDP4-keto-D-virenose or NDP-D-virenose would be surrogate substrates for MtmGIV and
would be incorporated at sugar E position. In the case of pFUCO or pFUCOII, it was
envisaged that NDP-D-fucopyranose or NDP-D-fucofuranose would be accumulated in
the strain and incorporated into one of the saccharide chains (e.g. perhaps sugar D
position, substituting NDP-D-fucose for NDP-D-oliose). Or, alternatively, some
collaboration between plasmid-borne enzymes and endogenous sugar tailoring machinery
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could result, or perhaps even jamming of the glycosyltransferases, as is witnessed in 133
and 134 in the case of S. argillaceus (pLNBIV). Expression of pFUCO and pFUCOII
failed to result in new glycosylated mithramycins/premithramycins. However, pVIR*II
and pEN3 both successfully generated the same production pattern, indicating that likely
the C-methyltransferase chryCMT at least is functional in these strains, and possibly the
virenosyl 4-ketoreductase chryU, as well. In these strains, S. argillaceus (pEN3) and S.
argillaceus (pVIR*II), one new mithramycin was accumulated as a minor compound, and
3 premithramycins were accumulated. The premithramycins correspond to
premithramycin A1, premithramycinone, and an unknown tetrasaccharidal
premithramycin with a mass of 977 amu [M-H] in (-) APCI-MS mode, perhaps
corresponding to a tetrasaccharidal premithramycin with an NDP-D-virenose moiety in E
position (Figure 47). The accumulation of premithramycin A1, as seen in other
recombinant strains, indicates that NDP-D-virenose or one of its encoded intermediates
jams MtmGIII and that perhaps 2’-hydroxysugars are poor substrates for mtm pathway
GTs. The mithramycin-type compound in these strains evinces a mass of 1099 amu in (-)
APCI-MS mode, which could be expected for a compound 16 mass units larger than
mithramycin. Such an addition could be accounted for by the presence of an additional
oxygen substituent, which would be expected if an NDP-D-virenose or its 4’-epimer were
incorporated at E position. This plasmid was also introduced into S. argillaceus M7W1
strain to generate S. argillaceus M7W1 (pVIR*II), which was not further investigated.
Both strains are promising for further structure elucidation studies and possibly for
structure activity relationship (SAR) studies.
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Figure 47 HPLC chromatogram of the metabolites from NDP-D-virenose expressing
strains.
(Upper Trace) extracts of S.argillaceus (pVIR*II) and (Lower Trace) S. argillaceus
(CMT+U). Strains both accumulate premithramycin A1, premithramycinone, a
mithramycin-type compound Rt= 15.5 min-1(1099 amu, [M-H] (-) APCI-MS), and a
premithramycin type compound Rt=19.5 min-1 (977 amu, [M-H] (-) APCI-MS).NDP-Dvirenose included as reference. Red stars are mithramycin-type compounds, gold stars
are premithramycin-type compounds.
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Generation of Streptomyces argillaceus (pKOL)
Given that MtmGIV has a demonstrated capacity for accepting ketosugar donor
substrates (98), it was envisioned that transformation of S. argillaceus wildtype with
plasmid pKOL would possibly result in flooding the pathway with NDP-4-keto-L-olivose
and its attachment in E position (see Chapter 4). Extracts of the resulting strain S.
argillaceus (pKOL) revealed production of a new mithramycin-type compound with
Rt=16.1 min-1 as the major product, in addition to a few minor premithramycin-type
compounds (Figure 48). This mithramycin demonstrated a mass of 1069 amu [M-H] in
(-) APCI-MS mode, which indicates a loss of 14 mass units from mithramycin. This
mass did not correspond with any type of ketosugar-containing compound as was
expected, as the anticipated keto/hydrate pseudomolecular ions were not present. Most
likely, this 14 amu difference corresponds to the difference of a C-methyl group. As a
result, it appeared as though there was a substitution of the D-mycarose moiety with an
unmethylated 2,6-dideoxysugar. Comparison with extract for S. argillaceus (pLNBIV)
indicated the identical retention time with 131, and interestingly, the mithramycins from
the pLNBIV mutant that resulted from “jamming” of the glycosyltransferases were
absent in the pKOL-harboring strain.
Accumulation of 131 in extract of S. argillaceus (pKOL) was unexpected, but it
can be explained by collaboration of plasmid-borne biosynthetic machinery with
endogenous host enzymes. pKOL produces many intermediates that are also used by
mtm pathway enzymes, which may be accepted by host tailoring genes and the
glycosyltransferases. In the normal biosynthesis of mithramycin, the genes are expressed
at a rate that maintains a balanced enzymatic flux, which results in the efficient
biosynthesis of mithramycin. When pKOL is expressed in vivo, this enzymatic flux is
imbalanced by the manifestation of foreign enzymes, which presently flood the pathway
with NDP-activated deoxysugar donors and may divert it into unforeseen directions. The
accumulation of some of these donor sugar substrates may effectively deceive the
endogenous glycosyltransferases, which results in the accumulation of side products.
With respect to the in vivo expression of pKOL, it is remarkable that none of the other
mithramycins that “jammed” the glycosyltransferases in the pLNBIV overexpression are
present. As such, it can be asserted that the lack of the plasmid-borne 4-ketoreductase is
126

responsible for removing the bottleneck that jammed the glycosyltransferases in previous
experimentation. In the case of pLN2 overexpression, only premithramycins were
obtained in addition to 70, which indicates that the NDP-L-olivose is mostly accumulated
in this strain and cannot be processed further than the disaccharide. Furthermore, the 4ketoreductase gene eryBIV in pLNBIV must lead to the predominant accumulation of
NDP-L-digitoxose, which can be transferred into the sugar D position by MtmGIII, but
only as the 4C1 ring-flipped conformer, which is similar to NDP-D-oliose with regards to
stereochemistry (Figure 49). The D-digitoxose in E position likely results from
accumulation of NDP-4-keto-2,6-dideoxyglucose, which is produced by oleSEVW in
pKOL, which is then processed by one of two routes: 1) acceptance by MtmGIV and
attached in E position, followed by MtmTIII-facilitated tautomerisation of the 3-OH to
axial configuration, and finally 4-ketoreduction; or 2) MtmTIII tautomerisation/4ketoreduction and glycosyltransfer of NDP-D-digitoxose (Figure 49).
From a pharmacognosy perspective, the selective accumulation of 131 in a yield
of ~5-6 mg per liter as the primary metabolite is a major boon, considering that the Ddigitoxose substitution in E position has been shown to have significant antitumoral
improvement over mithramycin, especially in ER- breast cancer cell lines. The complex
production pattern of S. argillaceus (pLNBIV) and the hassle of separation have
prohibited the further development of this compound. Therefore, this experiment
demonstrates a more effective route towards isolation of 131 via an improved
fermentation method of a genetically manipulated strain of Streptomyces argillaceus.
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Figure 48 HPLC chromatogram trace of metabolites from S. argillaceus (pKOL) strain.
The main compound accumulated is demycarosyl-3D-β-D-digitoxosyl mithramycin (131).
NDP-4-keto-L-olivose structure indicated as a reference for the sugar that pKOL
biosynthesizes.
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Generation of Streptomyces argillaceus M7W1/pKOL strain and identification of
metabolites

Having established an improved fermentation method for the production of 131 in
S. argillaceus (pKOL), a recombination experiment was envisioned in which a restricted
mutant of S. argillaceus could be transformed with pKOL to achieve novel
mithramycin(s) with a modified polyketide framework and a sugar substitution. For this
experiment, S. argillaceus M7W1, which features a chromosomal disruption of the mtmW
gene resulting in mithramycins with shorter aliphatic side chains (128-130), was used as a
transformation host. The resulting recombinant strain, S. argillaceus M7W1/pKOL was
fermented for 5 days and methanolic extracts were visualized via HPLC/MS. As
predicted, several new peaks corresponding to mithramycin-type compounds were
visualized (Figure 50). Premithramycin A1 and premithramycinone were accumulated.
Known metabolites mithramycins SK and SDK were recognized based on their UV-Vis
spectrum, comparison of retention time with standard compound (mithramycin SK
Rt=17.1 min-1 and mithramycin SDK Rt=19.2 min-1), and mass in (-) APCI-MS mode
(1053 amu for mithramycin SK and 1051 amu for mithramycin SDK). One other
mithramycin-type compounds was recognized as demycarosyl-mithramycin SK based on
its mass in (-) APCI-MS mode (910 amu). Two new compounds that were not identified
in extracts of S. argillaceus M7W1 demonstrated mithramycin-type UV absorption and
possessed Rt=Δ-0.6 min-1 as compared to the corresponding mithramycin SK and SDK
(Figure 50). These compounds demonstrated masses that were 14 amu less than their
mithramycin SK and SDK counterparts, indicating a substitution of an unmethylated 2,6dideoxysugar at E position (1039 amu for 135 and 1037 amu for 136, [M-H] (-) APCIMS). This indicated that the molecular weight for 135 was 1040 amu and for 136 was
1038 amu, which suggested that these new compounds might pertain to demycarosyl-3Dβ-D-digitoxosyl mithramycin SK (135) and SDK (136) (Figure 51).
135 and 136 combine two of the most advantageous structural features as
determined by previous SAR studies of mithramycin analogues (89, 97, 111-112). Such
heterologous expression experiments using restricted mutants have been performed
before, namely transformation of sugar plasmids into a strain blocked in biosynthesis of
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NDP-D-oliose (111), however, this marks the first successful attempt at combining two
beneficial bioisosteres in a single mithramycin molecule: a shortened 3-aliphatic side
chain with a sugar substitution.

Figure 50 HPLC chromatogram of metabolites from S. argillaceus M7W1/pKOL strain.
135 and 136 correspond to new metabolites generated in this strain. § indicates
demycarosyl-mithramycin SK normally produced in S. argillaceus M7W1.
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Figure 51 (Upper) Suggested structures of new mithramycin-type compounds
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Isolation and structure elucidation of demycarosyl-3D-β-D-digitoxosyl mithramycin
SK

A 10.0 liter fermentation of S. argillaceus M7W1/pKOL was carried out in a two
step process and for five days (See Experimental Section). To prevent the accumulation
of mithramycin SA-related metabolites, the pH of the production medium (10.0 liters of
liquid R5A medium, see Bacterial Strains and Culture Conditions) was adjusted to
6.95. After the third day, twenty-five milliliters of sample was extracted with twenty-five
milliliters of ethyl acetate acidified with 50 microliters of formic acid, concentrated, and
injected for HPLC-MS analysis. The fermentation was allowed to continue for an
additional twenty-four hours if premithramycins were present in the production spectrum,
likely due to the flooding of the mithramycin pathway with NDP-deoxysugar substrates
that had not yet been processed by MTM glycosyltransferases. The fermentation was
stopped after five days before the accumulation of mithramycin SA-metabolites.
The culture was acidified to pH 5.5 and extracted three times with an equal
volume of ethyl acetate, then was concentrated. The resulting yellow-brown extract was
fractionated over a reverse phase C18 silica column and the mithramycin compounds were
purified via reverse phase HPLC. From this, 22 milligrams of 135 were able to be
purified, while the other mithramycin components were produced in insufficient yields or
too poorly separated to allow for structural elucidation.
The structure of the new mithramycin analogue was determined through HR-ESI
mass spectral and 1D- and 2D-NMR spectroscopic methods, including 1H-NMR, 13CNMR, 1H-1H-gCOSY, 1H-13C-HSQC, and HMBC methods. Further comparison with
published literature concerning the sugar signals of 131(112) was corroborated with the
HSQC and HMBC correlations. The low resolution APCI (-ve mode) mass spectral
analysis indicated an [M-H] peak of 1039.4 amu for 135, while the APCI (+ mode)
indicated a parent peak of 1063.2 amu corresponding to [M+Na]. The HR-ESI mass
spectral analysis indicated a found mass of 1039.4432 amu corresponding to a [M-H]
peak and 1063.4337 amu corresponding to [M+Na], which established the molecular
weight of the new mithramycin to be 1040.4 amu and the formula to be C50H72O23. This
revealed a difference of 14 amu between this compound and mithramycin SK, which
could correspond to a difference of a single methylene group.
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The 1H-NMR and 13C-NMR showed the characteristic signals of the tricyclic
mithramycin polyketide skeleton (see NMR table in Experimental). Two aromatic
protons were observed as singlets (δH 6.87 and δH 6.69) as 5-H and 10-H, respectively,
while the 2-H signal (δH 4.89, δC 78.0) appeared as a doublet with a large axial splitting
shifted downfield due to the neighboring 1-CO moiety. The 4ax and 4eq signals appeared
as doublet of doublets (4-Hax at δH 3.25 (dd 16, 12 Hz), and 4eq at δH 3.00 (dd 16, 3)) with
a large germinal splitting and a,a or a,e couplings, respectively, with the 3-H proton (δH
3.50 dddd 16, 12, 4, 1; δC 41.5). The 7-CH3 was evident based on a signal at δC 9.3 in the
C spectrum and δH 2.47 singlet in the 1H spectrum, indicating it to be the intact aromatic
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methyl group characteristic of mithramycins. The position of 7-CH3 was confirmed
based on HMBC correlations of the methyl protons with the 6-C and 8-C carbons (Figure
52). Nine aromatic signals were detectable in the 13C spectrum, while the 9-C was too
small to observe. This essentially left the problem of elucidating the structure of the new
mithramycin to alterations in the C-3 side chain and delineating the nature of the
saccharidal chains.
The C-3 side chain of the new mithramycin was found to differ considerably from
mithramycin due to the 1H and 13C signals. The 1’-OCH3 was found as a singlet (δH3.83,
δC 59.7), while the 2’-H proton was shifted downfield in the 1H spectrum (δH 4.85, δC
80.2) as a doublet with a two Hertz coupling. An additional acetoxy methyl singlet was
found downfield at δH 2.49, which indicated an alpha ketone group. Most importantly, an
HMBC correlation between the δH 2.49 4’-H methyl protons and the C-3 carbonyl
(δ211.0) established the proximity of the 3’-CO and 4’-CH3 groups. HMBC correlations
between the 2’-H and 3-C, 1’-methoxy, and 4’-C carbons further evidenced the presence
of a shortened ketone side chain.
The 13C spectrum indicated five anomeric signals (δ97.9, δ99.5, δ98.5, δ100.1,
δ101.9) and five deoxysugar methyl groups (δ17.8, δ19.0, δ19.4, δ19.4, δ19.7), while the
3E-CH3 of D-mycarose was missing. The 1H-13C-HSQC revealed five aliphatic
methylene carbons (δ37.9, δ41.6, δ38.5, δ33.3, and δ40.2), the sum total of which
identified the characteristic presence of five 2,6-dideoxysugar moieties. The 1H-1HgCOSY revealed five deoxysugar spin systems stretching from 1H-6H. Furthermore,
five anomeric signals presented in the 1H spectrum (δ4.96, δ5.06, δ5.44, δ5.57, δ5.66)
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with a large diaxial coupling and an a,e splitting, indicating them to be D-configured 2,6
dideoxysugars as per Klyne’s rule (36). The 13C and 1H upheld the presence of the 6-OD-olivose-1,3-D-olivose

disaccharide, while the C sugar was likewise determined to be a

2-O-connected D-olivose based on HMBC correlations between the 1C proton and 2-C
and 2-H and 1C anomeric carbon. The HMBC spectrum correlated the 1D anomeric
proton to the 3C carbon, while the presence of a characteristic broad doublet δH 4.10
(three Hertz coupling) indicated the 4D proton to be equatorial, which confirmed the
presence of D-oliose at the D-sugar position. The E sugar was found to be missing the
3E-CH3 signal from the 13C spectrum and the missing methyl singlet from the 1H
spectrum, while the 1H-1H-gCOSY indicated a spin system for this sugar stretching from
1E-6E. It was confirmed to be a β-D-digitoxose sugar, due to the presence of an
equatorial 3E proton at δH 4.46 (broad d, 3 Hz) and shifted signals for the 2E (δC 40.2), 3E
(δC 69.1), 4E carbons (δC 72.1). The couplings of the 2-axial proton (δH 2.01 ddd 13, 10,
3 Hz), the 4E proton (δH 3.63 dd 9, 3 Hz), and the COSY-correlation between 2Eeq, 2Eax,
and 4E with the 3E proton established the D-digitoxose stereochemistry. Altogether, the
structure of 135 was confirmed to correspond to the new compound, demycarosyl-3D-βD-digitoxosyl

mithramycin SK.
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Figure 52 1H-1H-COSY (▬), and selected HMBC (→) correlations for demycarosyl-3Dβ-D-digitoxosyl-mithramycin SK.
Generation of Streptomyces argillaceus M7W1/pKAM
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As a further extension of the hypothesis that ketosugar plasmids may be
potentially useful for producing differentially glycosylated analogues of mithramycin
without untoward “jamming” of the glycosyltransferases, an NDP-L-cinerulose
biosynthesizing plasmid was constructed from the NDP-L-rhodinose plasmid, pLNRHO,
by deleting the 4-ketoreductase gene, urdZ3, resulting in plasmid pKAM. It was
envisioned that such a plasmid might direct biosynthesis of NDP-4-keto-2,3,6-trideoxyD-glucose,

which might then be reduced by an mtm pathway 4-ketoreductase to NDP-D-

amicetose, which has then been shown to be transferred by MtmGI very efficiently into A
position (Figure 52). Previously, Salas et al. isolated a novel mithramycin when pFL844
was expressed in S. argillaceus wildtype with a D-amicetose replacing the A and B
disaccharide (Figure 52).
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135

If the endogenous mtm sugar ketoreductases can collaborate efficiently with pKAMborne machinery, then overexpression of pKAM in the S. argillaceus M7W1 strain
should result in the shortened chain derivatives of dideolivosyl-3A-β-D-amicetosylmithramycin. Surprisingly, extracts of S. argillaceus M7W1/pKAM contained no new
peaks corresponding to mithramycins and only minor amounts of mithramycin SK.
Instead, four peaks corresponding to premithramycins in excellent yield were
accumulated. Two of these peaks corresponded to premithramycin A1 and
premithramycinone, yet two others corresponded to unknown premithramycins with one
sugar and four sugars, respectively (Figure 53). The monoglycosylated premithramycin
evinced a molecular weight of 528 amu, as determined by (-) APCI-MS. This
corresponds to 16 mass units less than premithramycin A1, which likely indicates a 2,3,6trideoxygenated sugar at C position. This could correspond either to a D- or Lconfigurated amicetose sugar, which has never been characterized as being attached at Cposition before. From a biosynthetic perspective, such an attachment is unproductive,
because this sugar lacks the 3-OH handle which is necessary to establish the next
glycosidic bond. The premithramycin with four sugars demonstrated a mass of 928 amu,
as determined by (-) APCI-MS, which corresponds to a premithramycin with possibly
trisaccharide and monosaccharide chains, respectively. The mass suggests that one or
possibly two trideoxygenated sugars are incorporated onto this molecule, which given the
sugar’s lack of a 3-OH, would necessarily restrict their glycosylation to the A and E sugar
positions. Given that the amicetosyl-substituted mithramycin is efficiently turned over by
MtmOIV, this premithramycin compound likely has a sugar attached in either E or A
position that interfere with its turnover by MtmOIV. This compound may be an excellent
candidate for interrogating the substrate flexibility mutant MtmOIV oxygenases, given
that it possesses a fully intact trisaccharide chain. Furthermore, the production spectrum
of this recombinant strain is not complex, and the yield of these compounds appears to be
quite reasonable, which are encouraging for further structure elucidation and pathway
engineering experiments.
The absence of the dideolivosyl-3A-β-D-amicetosyl-mithramycin derivatives with
shortened side chains was surprising. Quite possibly, MtmGI demonstrates flexibility to
NDP-L-cinerulose or one of the pKAM-encoded pathway intermediates, and
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glycosylation of this sugar at A position results in a molecule which MtmOIV cannot
recognize. The presence of a monosaccharidal premithramycin was also surprising, as
this sugar has not been reported at C position before; yet, in previous combinatorial
biosynthesis experiments involving amicetose sugars, those pathways progressed
efficiently towards fully-formed mithramycins. Therefore, this compound may not have
been detected in those other strains. Some jamming of glycosyltransferases by NDP-Lcinerulose may be responsible for the accumulation of this latter compound. As a result,
it is hypothesized that transformation of pFL844 into S. argillaceus M7W1 would very
likely result in accumulation of these shortened chain dideolivosyl-3A-β-D-amicetosylmithramycin derivatives.

Figure 54 HPLC chromatogram of metabolites from S. argillaceus M7W1/pKAM.
This plasmid reprograms the biosynthesis to generate two novel premithramycins with
attached trideoxygenated sugars. Monosaccharide premithramycin, 526 amu (-)APCIMS, Rt=21.3 min-1. Premithramycin with four sugars, 928 amu (-) APCI-MS, Rt=18.0
min-1.
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SUMMARY
In summary, Chapter 5 has described some preliminary microbiology work
towards glycodiversification of the mithramycin scaffold by interrogating the mtm
pathway glycosyltransferases with “deoxysugar plasmids” that encode novel deoxysugars
not previously transformed into Streptomyces argillaceus. Through this work, several
new recombinant strains with markedly altered production patterns have been produced,
and the metabolites from these strains have been preliminarily characterized via UV-vis,
APCI-MS mass, and retention time analyses. A couple premithramycin compounds with
four sugars have been identified, which could be isolated, structurally characterized, then
used as substrates for interrogating mutant MtmOIV oxygenases. Or, perhaps, an in vivo
approach employing an integrative vector, such as pSET152, with a cloned copy of such
an MtmOIV (e.g. MtmOIV-R204A) under ermE* promotion could be integrated into the
chromosome of such a strain.
Additionally, the promising antitumoral mithramycin compound 131 was
produced selectively in fermentations of S.argillaceus (pKOL), which overexpresses the
NDP-4-keto-L-olivose pathway. The flooding of this pathway with NDP-activated sugar
donors results in accumulation of NDP-4-keto-2,6-dideoxy-D-glucose, which is then
transferred to E position as a D-digitoxose. As a further extension of this work, the
mtmW-disrupted mutant, S. argillaceus M7W1, was used as a transformation host for
pKOL, which lead to the elaboration of two shortened-chain mithramycins, 135 and 136.
The structure of 135 was confirmed via HR-ESI mass spectral and 1D- and 2D- NMR
spectroscopic methods as demycarosyl-3D-β-D-mithramycin SK, which may exhibit
exciting new biological activity. The presence of two rationally designed and potentially
pharmaceutically advantageous bioisosteres is unprecedented for a mithramycin
molecule, and this also reflects on the substantial power of combinatorial biosynthesis to
achieve improved analogues of complex natural products.
Furthermore, as Chapters 4 and 5 have demonstrated, the flooding of sugar
biosynthetic pathways with ketosugars provides a new approach towards the
glycodiversification of polyketide molecules. Because there are so few examples of
glycosyltransferases in nature that can transfer a ketosugar, such interrogations are
largely serendipitous and unexploited. In Chapter 4, ElmGT was found to have an
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unusual capacity to transfer NDP-4-keto-L-olivose to its aglycone, which revealed an
unanticipated flexibility towards an NDP-ketosugar. In Chapter 5, by utilizing the same
sugar cassette, the S. argillaceus mithramycin biosynthetic pathway was interrogated in
the same fashion. Although MtmGIV has been demonstrated to attach NDP-Dketosugars to its acceptor substrate(s), no such ketosugar-decorated polyketide was
detected. Instead, the selective accumulation of 131 was achieved, which revealed that
by pooling NDP-4-keto-D-olivose and NDP-4-keto-L-olivose, glycosyltransferase
jamming was effectively circumvented (as exhibited by the absence of other mithramycin
congeners or the appreciable accumulation of premithramycins in the production
spectrum.) Just as important, the NDP-4-keto-L-olivose did not appear to serve as a
substrate for any of the other glycosyltransferases, and in theory, it may play an important
role in inhibiting MtmC to allow for the accumulation of NDP-4-keto-D-digitoxose.
Therefore, in S. argillaceus, the flooding of the MTM pathway with NDP-4-keto-Dolivose is a necessary pre-requisite to steer the pathway towards production of NDP-4keto-D-digitoxose, which is likely accepted in the active site of ketoreductase MtmTIII in
the absence of its C-3 methylated substrate. Furthermore, because the D-digitoxose
substitution is sufficiently tolerated by MtmOIV to allow for opening of the fourth ring,
this strategy could be repeated in the S. argillaceus M7W1 strain to achieve the shortened
ketone side chain.
EXPERIMENTAL

Table 10 Plasmids used in Chapter 5
Plasmid Name
pLN2

pRHAM

pMP*UII

pDmnI

Relevant Characteristics
AmpR, TsrR. OleVWSELUY
under ermE* promotion.
NDP-L-olivose.
AmpR, TsrR. OleVWSE
under ermE* promotion.
NDP-L-rhamnose.
AmpR, TsrR. OleVW,
cmmUII, OleY, MtmDE,
under divergent ermE*
promotion. NDP-D-oliose.
AmpR, TsrR. OleSEVLU
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Reference
(135)

(134)

(160)

Madan Kharel, Personal

pDmnII

pDesI

pDesII

pDesIII

pKOL

pFUCO

pFUCOII

pVIR*II

pEN3

pKAM

DnrJ under ermE*
promotion. NDP-Lacosamine
AmpR, TsrR. OleSEV,
DnrJUV under ermE*
promotion. NDP-Ldaunosamine
AmpR, TsrR. DesIII, DesIV,
DesI under ermE*
promotion. NDP-4-amino6-deoxy-D-glucose (121)
AmpR, TsrR. DesIII, DesIV,
DesI, DesII under ermE*
promotion. NDP-3-keto4,6-dideoxy-D-glucose
(122).
AmpR, TsrR. DesIII, DesIV,
DesI, DesII, DesV under
ermE* promotion. NDP-3N,N-didemethyl-Ddesosamine (123).
AmpR, TsrR. OleVWSELY
under ermE* promotion.
NDP-4-keto-L-olivose.
AmpR, TsrR. gilU, ravDE
cloned under ermE* in
pUWL201PW. Intended to
produce NDP-D-fucose.
AmpR, TsrR. gilLU, ravDE,
cloned under ermE* in
pUWL201PW. Intended to
produce NDP-Dfucofuranose.
AmpR, TsrR. chryCMT,
chryU, ravDE cloned under
ermE* in pUWL201PW.
Intended to produce NDP-Dvirenose.
AmpR, TsrR. chryCMT,
chryU placed under ermE*
in pEM4. Intended to
produce NDP-D-virenose in
strain that produces 32.
AmpR, TsrR. OleVWSELY ,
urdQ under ermE*
promotion. Produces NDP140

Communication

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication

Madan Kharel, Personal
Communication.

This work.

This work.

This work.

This work.

This work.

This work.

L-cinerulose.

AmpR, TsrR. OleVWSELY ,
urdQ,urdZ3 under ermE*
promotion. Produces NDPL-rhodinose

pLNRHO

This work. (39)

Table 11 Bacterial strains used in Chapter 5
Strain Name
Streptomyces argillaceus §
Streptomyces argillaceus
M7W1 †
Streptomyces argillaceus
(pLN2)
Streptomyces argillaceus
(pRHAM)
Streptomyces argillaceus
(pLNBIV)
Streptomyces argillaceus
(pDmnI)
Streptomyces argillaceus
(pDmnII)
Streptomyces argillaceus
(pDesI)
Streptomyces argillaceus
(pDesIII)
Streptomyces argillaceus
(pFUCO)
Streptomyces argillaceus
(pFUCOII)
Streptomyces argillaceus
(pEN3)

Streptomyces argillaceus
(pVIR*II)

Streptomyces argillaceus

Relevant Characteristics
Produces mithramycin (70).
Wildtype strain.
Produces mithramycins
SK/SDK/SA (128-130).
mtmW-disrupted strain.
§ expressing pLN2.
Produces 2 preMTMs and
70.
§ expressing pRHAM.
Produces 76 and 70.
§ expressing pLNBIV.
131-134, 76, 27, 70, and 3
unknown pre-MTMs.
§ expressing pDmnI.
Produces 70, 76, 27, and
unknown preMTM.
§ expressing pDmnII.
Produces 70.
§ expressing pDesI.
Produces 70.
§ expressing pDesIII.
Produces 70 and unknown
preMTM.
§ expressing pDesIII.
Produces 70.
§ expressing pDesIII.
Produces 70.
§ expressing pEN3.
Produces 70, 76, 27. 2
unknown preMTMs and
unknown MTM
§ expressing pVIR*II.
Produces 70, 76, 27. 2
unknown preMTMs and
unknown MTM.
† expressing pVIR*II.
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Reference
(108)
(89, 97)

(111)

(111)
(112)

This work.

This work.
This work.
This work.

This work.
This work.
This work

This work

This work.

M7W1/(pVIR*II)
Streptomyces argillaceus
(pKOL)

Uninvestigated.
§ expressing pKOL.
Produces 70, 76, 27, 131,
and two unknown
preMTMs.

Streptomyces argillaceus
M7W1/(pKOL)

† expressing pKOL.
Produces 128, 129, 76, 27,
135, 136.
† expressing pKAM.
Produces 76 and 27 and 2
unknown preMTMs

Streptomyces argillaceus
M7W1/(pKAM)
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This work.

This work.

This work.

Table 12 Physicochemical and NMR Data for Demycarosyl-3D-β-D-digitoxosyl
mithramycin SK (135).
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Rrel= 16.62 min-1; Yield: 2.2 mg/L
MW= 1040.4 g/mol (C50H72O23)
Negative mode APCI-MS: m/z=1039.4 [M-H, 100%]; APCI-MS (+ mode): 1063.2
[M+Na, 40%]. (-) HR-ESI MS ([M-H] calc. 1039.4359 amu, found 1039.4432 amu. (+)
HR-ESI MS [M+Na] calc. 1063.4362 amu, found 1063.4337 amu.)
UV maxima (from HPLC-diode array): UV (from HPLC-diode array): λmax 211 (85%),
278 (100%), 317 (15%), 332 (13%), 413 (18%)
NMR Data (pyridine- d5)

Position

1
2
3
4ax
4eq
4a
5
6
7
7-CH3
8
8a
9
9a
10
10a
1’
1’-OCH3
2’

Demycarosyl-3D-β-D-digitoxosyl mithramycin
SK (135)
δC (125 MHz)

δH (500 MHz, J in Hz)

n.o.*
78.0
41.5
28.3

4.89 d (11)
3.50 dddd (16, 12, 4, 1)
3.25 dd (16, 12)
3.00 dd (13, 3)
6.87 s
2.47 s
6.69 s
4.62 dd (3,2)
3.83 s
4.85 d (2)

136.6
100.4
160.3
111.9
9.3
160.6
109.2
n.o.*
109.5
117.6
137.7
81.1
59.7
80.2
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3’
4’
5’
1A
2Aax
2Aeq
3A
4A
5A
6A
1B
2Bax
2Beq
3B
4B
5B
6B
1C
2Cax
2Ceq
3C
4C
5C
6C
1D
2Dax
2Deq
3D
4D
5D
6D
1E
2Eax
2Eeq
3E
4E
5E
6E

211.0
27.5
97.9
37.9
79.0
76.1
74.0
19.4
99.5
41.6
73.5
78.6
73.6
19.0
101.9
38.5
81.3
74.7
72.0
19.7
100.1
33.3
77.2
73.3
73.9
19.4
98.6
40.2
69.1
72.1
71.1
17.8

2.49 s
5.66 dd (10, 2)
2.20-2.25 (overlap)
2.74 td (12, 5)
3.55 t (9, overlap)
3.60 m
4.19 dq (9, 6.5)
1.69 d (6.5)
5.06 dd (10, 2)
2.20-2.25 (overlap)
2.65 ddd (12, 5, 4)
4.17 (overlap)
3.89 t (10)
3.63 dq (10, 5)
1.53 d (6.5)
5.44 dd (10, 2)
2.10-2.15 (overlap)
2.60-2.65 (overlap)
3.94 ddd (12, 10, 6)
3.46 dd (9, 6.5)
4.26 dq (9, 6.5)
1.60 d (6.5)
4.96 dd (10, 2)
2.20-2.30 (overlap)
2.20-2.30 (overlap)
4.00 ddd (12, 6, 3)
4.10 br d (3)
3.75 dq (6.5, 3)
1.61 d (6.5)
5.57 dd (10, 2)
2.01 ddd (13, 10, 3)
2.35-2.45 (complex)
4.46 br d (3)
3.63 dd (9, 3)
4.42 dq (9, 6.5)
1.60 (6.5)

Bacterial Strains and Culture Conditions
Escherichia coli XL1 blue (Invitrogen) was used as a host for routine cloning
experiments and was grown on LB agar or in LB broth at 37°C. Streptomyces
argillaceus or Streptomyces argillaceus M7W1 recombinant strains were grown on R5A
agar: sucrose, 100 g/liter; K2SO4, 0.25 g/liter; MgCl2 · 6H2O, 10.12 g/liter; glucose, 10
g/liter; Casamino Acids, 0.1 g/liter; yeast extract (Difco), 5 g/liter; and MOPS, 21 g/liter,
R5 trace elements, 2 mL/liter. For preparation of protoplasts, spores of S. argillaceus or
S. argillaceus M7W1 were inoculated into 100 mL YEME liquid medium in a 250 mL
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baffled Erlenmeyer flask at 28 °C for 3 days for preparation of protoplasts following the
previously reported protocol (3). When antibiotic selection of recombinant strains was
required, 25 μg/mL apramycin, 25 μg/mL thiostrepton, or 100 μg/mL of ampicillin were
used. Protoplast transformation was carried out to introduce the various sugar plasmids
into Streptomyces argillaceus or Streptomyces argillaceus M7W1 following the standard
protocol (3, 174).

Generation of plasmids directing the biosynthesis of ketosugars,
aminosugars, and 2-hydroxysugars
The 4-ketoreductase gene (urdZ3) was removed from plasmid pLNRHO (39).
NheI and SpeI were used to digest pLNRHO, thereby releasing the urdZ3 fragment. DNA
gel electrophoresis was carried out to remove the urdZ3 gene and the resulting fragment
(~14kb) was rescued and re-ligated to generate pKAM. In this construct, all of the sugar
genes are under strong ermE* promotion. pKOL was generated in a similar manner (see
Chapter 4, Materials and Methods).
Plasmids pVIR*II, pFUCOII, pFUCO, and pEN3 were prepared as discussed in
Chapter 2, Materials and Methods. Plasmids pDmnI, pDmnII, pDesI, pDesII, and
pDesIII were prepared by Dr. Madan Kharel (Personal Communication). pLN2,
pRHAM, and pLNBIV were all prepared previously by Salas et al. (39). All plasmids
were transformed into S. argillaceus or S. argillaceus M7W1 via protoplast
transformation.

Isolation of mithramycins from recombinant S. argillaceus M7W1/ (pKOL)
strains
One aprR/tsrR transformant corresponding to Streptomyces argillaceus
M7W1/(pKOL) was plated on R5A agar plates supplemented with 25 μg/mL apramycin
and thiostrepton at 28 °C for 5 days. For small scale production of mithramycins, an agar
chunk of bacterial spores was inoculated in 250 mL Erlenmeyer flasks containing 100
mL of R5A medium supplemented with antibiotics for 4-5 days. 25 mL of the culture
was extracted with ethyl acetate and 0.1% formic acid, and the organic layer was dried in
vacuo. Extracts were then redissolved in methanol and were subjected to HPLC/MS
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analyses on a MicroMass ZQ 2000 (Waters) instrument equipped with HPLC (Waters
alliance 2695 model) and photodiode array detector (Waters 2996). A Semi-Prep
Symmetry C18 column (7.8×300 mm, 5 μm) and Symmetry C18 (4.6x250 mm, 5 μm)
analytical column were used for semi-preparative and analytical scale separations,
respectively. A gradient of acetonitrile and 0.1% formic acid in water was used to
separate compounds as reported previously (105). (Solvent A= 0.1% formic acid in
water, solvent B=acetonitrile; 0–20 min 25% B to 70% B; 20-22 min 70%% B to 90% B;
22–24 min 90% to 100% B; 24–26 min 100% B; 26-28 min 100% B to 25% B; 28-30
min 25% B, flow rate 0.5 mL/min).
For larger scale production of glycosylated mithramycins, spores of Streptomyces
argillaceus M7W1/(pKOL) were grown in eight 100 mL trypticase soy broth (TSB)
cultures supplemented with apramycin and thiostreptone at 28 °C for 30 hours. In the
production phase, 10.0 L of R5A liquid medium was allocated into 100 mL portions in
100 baffled 250 mL Erlenmeyer flasks and the pH adjusted to 6.95 to promote the
generation of mithramycins with SK and SDK side chains. 4% (v/v) of the TSB cultures
was used to inoculate each flask, which was supplemented with antibiotics. Fermentation
was carried out for 3-5 days at 28°C in an orbital shaker. After the third day, 25 mL of
culture was extracted with ethyl acetate, dried, and then checked via HPLC/MS analysis
to determine the production of mithramycin-type compounds. If premithramycins were
detected, fermentation was continued for another 24 hours. As a result of the flooding of
the pathway with NDP-deosyxugar intermediates, additional time was required to allow
for all glycosyltransfer events and MtmOIV to process premithramycin-type compounds
to active mithramycins. After detection of mithramycin-type compounds via HPLC/MS,
the culture was harvested (to avoid decomposition of metabolites to mithramycin SA),
mixed with celite (50 g/L fermentation broth), and then filtered. The mycelial cake was
extracted with 400 milliliters of methanol and sonicated for thirty minutes. The culture
was acidified to pH 5.5 with concentrated HCl and extracted three times with 2 L of ethyl
acetate. The solvent was dried in vacuo. The extracts were resuspended in ddH2O,
poured over a reverse phase C18 silica column (column dimensions 5.0 cm x 13 cm)
under vacuum (1-5 mbar). The column was washed with 1 liter of 10:90 acetonitrile:
ddH2O. Three hundred milliliter fractions were taken, increasing the acetonitrile partition
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by 10% each step from 0%-100%. 135 and 136 were found primarily in the 30%, 40%,
50%, and 60% acetonitrile fractions. The 30%, 40%, and 50% acetonitrile fractions were
combined, dried in vacuo, finally being lyophilized to remove water. This extract was
dissolved in methanol, centrifuged, and the supernatant filtered for reverse phase HPLC
chromatography. The individual peaks were resolved via semi-preparative highperformance liquid chromatography (HPLC) on a Symmetry semi-prep C18 column
(7.8×300 mm, 5 μm) on a Waters 1525 EF platform with a Waters 2487 dual absorbance
detector UV lamp. A gradient of 0.2% formic acid in double distilled water and
acetonitrile was used (Solvent A= 0.2% formic acid in water, solvent B=acetonitrile; 0–
20 min 25% B to 70% B; 20-22 min 70%% B to 90% B; 22–24 min 90% to 100% B; 24–
29 min 100% B; 29-31 min 100% B to 25% B; 31-34.5 min 25% B, flow rate 2.5
mL/min). The eluted material under each peak was collected, dried in vacuo, diluted
with double distilled water (10 mL), and finally lyophilized. Sample purity was verified
via HPLC/MS analysis to assure the presence of a single peak. Using this protocol, 22
mg of 135 was isolated. HR-ESI mass spectral analyses were conducted by the Biotech
Department at the University of Wisconsin, and NMR measurements were conducted on
a 500 MHz Varian VNMR instrument using deuterated pyridine as solvent.
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Figure 55 1H-NMR data for demycarosyl-3D-β-D-digitoxosyl mithramycin SK recorded
at 500 MHz.
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Figure 56 13C-NMR data for demycarosyl-3D-β-D-digitoxosyl mithramycin SK recorded
at 125 MHz.
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Picked up prospective graduate student at airport for interview with the
program.
Attended pot luck to answer questions for prospective graduate students
about the department.
Indirectly assisted summer student/rotation students with questions,
helped with protocols in the lab, and generated enthusiasm for drug
discovery division.
Assisted with the graduate school’s open house and fielded questions of
interviewing students.

PEER REVIEWED PUBLICATIONS:
First co-author paper/First author
1) Nybo SE, Shaaban K, Scott D, Rohr J.

Generation of A New Mithramycin

Analogue by Incorporating Two Beneficial Bioisosteres through Combinatorial
Biosynthesis. In preparation.
2) Nybo SE, Shaaban K, Kharel MK, Salas JA, Méndez C, Sutardjo H, and Rohr
J**. Ketoolivosyl-tetracenomycin C: A new ketosugar-bearing tetracenomycin
generated by combinatorial biosynthesis in a recombinant Streptomyces strain.
Submitted, Oct. 2011.
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3) Kharel MK*, Nybo SE*, Shepherd MD*, and Rohr J**.

Cloning and

characterization of the ravidomycin and chrysomycin biosynthetic gene clusters.
Chembiochem. 2010 Mar 1;11(4):523-32.
4) Nybo SE, Shepherd MD, Bosserman MA, and Rohr J**. Genetic manipulation of
Streptomyces sp. Curr Protoc Microbiol. 2010 Nov;Chapter 10:Unit 10E.3.
Co-author manuscript
5) Kharel MK., Shepherd MD, Nybo SE, Smith ML, Bosserman MA, Rohr J**.
Isolation of streptomyces species from soil. Curr Protoc Microbiol. 2010 Nov;
Chapter 10:Unit 10E.4
6) Madan K. Kharel, Nybo SE, Pahari P, Shaaban KA, Shepherd MD, Tibrewal N,
and Rohr J**. Angucyclines: Biosynthesis, Mode-of-Action, Synthesis, and New
Natural Products. Nat. Prod. Report. In preparation.
*These authors contributed equally to this work.
** Primary Investigator.
MEETINGS
1) Kharel, Madan K., S. Eric Nybo, Micah D. Shepherd, Jurgen Rohr**. “Genetic
Investigation of Chrysomycin and Ravidomycin Biosynthesis.” Abstracts, 39th
Central Regional Meeting of the American Chemical Society, Covington, KY,
United States, May 20-23 (2007), CRM-257.
2) Clements, Joseph S., Eva Csuhai, Gerald L. Seebach, S. Eric Nybo, Zackary R.
Edens.

“Anthrapyridone syntheses:

Electronic effects, part II.” Abstracts of

papers, 227th ACS National Meeting, Anaheim, CA, United States, March 28April 1 (2004), CHED-796.
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